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Amyloidogenic neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s 
disease (PD) are an important health issue. However, the underlying molecular mechanisms of the 
disease-related protein aggregates, that are present in humans, are only understood partially. I have 
used and developed biophysical methods to study the structural and biological properties of 
individual aggregates of Amyloid β peptide and α-Synuclein, proteins whose aggregation is 
associated with the development of Alzheimer’s and Parkinson’s disease respectively.  
I expanded the single aggregate visualisation through enhancement (SAVE) technique, which 
is a method based on the fluorescent dye Thioflavin T (ThT) that reversibly bind to the aggregates 
and whose fluorescence increases upon binding. I firstly explored the use of other dyes for these 
experiments and found that a ThT dimer has higher affinity to α-Synuclein aggregates in vitro. I 
then applied the SAVE method to the cerebral spinal fluid (CSF) of a cohort of AD patients and 
control CSF and observed no clear difference in aggregate number. However, these experiments 
provided insights into how antibodies bind the aggregates in human CSF. I could show, that despite 
altering the Ca2+ influx into both cells and vesicles, the antibody did not measurably affect the 
aggregate structure.  
To study the size specific effects of the Amyloid β 42 (Aβ42) peptide in more detail, I used 
and optimised gradient ultracentrifugation combined with single aggregate imaging to study the 
structural properties of the isolated aggregates. This aggregation kinetic independent method 
allowed me to compare the properties of fluorescently labelled and unlabelled Aβ42 and 
characterize the size dependent properties of aggregates in a single experiment. Since I could 
measure the relative concentration of different size aggregates it was also possible to compare the 
properties of single aggregates of different sizes. I then used biological assays to examine the ability 
of aggregates to permeabilise membranes resulting in the entry of calcium ions, and their ability to 
induce TNFα production in microglia cells. Both processes are thought to play key roles in the 
development of AD. I found that small soluble oligomers are most potent at inducing Ca2+ influx, 
whereas longer protofilaments are the most potent inducers of TNFα production. My results 
suggest that the mechanism by which aggregates damage cells changes as aggregation proceeds, as 
longer aggregates with different structures are formed. Protofilaments with a diameter of 1 nm or 
less have a structure that could make them particularly potent at causing the signalling of toll-like 
receptors, providing a molecular basis for their ability to induce TNFα production. 
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Amyloidogenic neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s 
disease (PD) are an important health issue. However, the underlying molecular mechanisms of the 
disease-related protein aggregates, that are present in humans, are only understood partially. I have 
used and developed biophysical methods to study the structural and biological properties of 
individual aggregates of Amyloid β peptide and α-Synuclein, proteins whose aggregation is 
associated with the development of Alzheimer’s and Parkinson’s disease respectively.  
I expanded the single aggregate visualisation through enhancement (SAVE) technique, which 
is a method based on the fluorescent dye Thioflavin T (ThT) that reversibly bind to the aggregates 
and whose fluorescence increases upon binding. I firstly explored the use of other dyes for these 
experiments and found that a ThT dimer has higher affinity to α-Synuclein aggregates in vitro. I 
then applied the SAVE method to the cerebral spinal fluid (CSF) of a cohort of AD patients and 
control CSF and observed no clear difference in aggregate number. However, these experiments 
provided insights into how antibodies bind the aggregates in human CSF. I could show, that despite 
altering the Ca2+ influx into both cells and vesicles, the antibody did not measurably affect the 
aggregate structure.  
To study the size specific effects of the Amyloid β 42 (Aβ42) peptide in more detail, I used 
and optimised gradient ultracentrifugation combined with single aggregate imaging to study the 
structural properties of the isolated aggregates. This aggregation kinetic independent method 
allowed me to compare the properties of fluorescently labelled and unlabelled Aβ42 and 
characterize the size dependent properties of aggregates in a single experiment. Since I could 
measure the relative concentration of different size aggregates it was also possible to compare the 
properties of single aggregates of different sizes. I then used biological assays to examine the ability 
of aggregates to permeabilise membranes resulting in the entry of calcium ions, and their ability to 
induce TNFα production in microglia cells. Both processes are thought to play key roles in the 
development of AD. I found that small soluble oligomers are most potent at inducing Ca2+ influx, 
whereas longer protofilaments are the most potent inducers of TNFα production. My results 
suggest that the mechanism by which aggregates damage cells changes as aggregation proceeds, as 
longer aggregates with different structures are formed. Protofilaments with a diameter of 1 nm or 
less have a structure that could make them particularly potent at causing the signalling of toll-like 
receptors, providing a molecular basis for their ability to induce TNFα production.  
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1  Introduction 
An ever-ageing population has led to a great increase in neurodegenerative 
diseases such as Alzheimer’s disease and other dementias, Parkinson’s disease and 
others. These diseases have in common that they all adversely affect some part of the 
central nervous system, hence the term neurodegenerative diseases. Importantly in the 
last decade all these diseases have become much more common. This is accounted for 
by an increase in life expectancy, with age being the main risk factor for most of these 
neurodegenerative diseases. This obviously excludes hereditary disease as their risk 
factor is usually genetic and the onset is earlier than in sporadic cases of the diseases.  
The WHO estimates worldwide, around 50 million people have dementia, with 
nearly 60 % living in low- and middle-income countries and nearly 10 million new 
cases every year. The total number of people with dementia is projected to reach 82 
million in 2030 and 152 million in 2050 [1]. 
This poses a significant economic burden as these diseases require intensive 
nursing and care for often extended periods of time. Especially the memory 
impairment can not only be devastating for the patient but also for family and friends. 
In the case of PD, the nursing and care prospects are similar. Where PD is not 
associated with memory impairment the severe impairment in physical abilities calls 
for close supervision and help by the nursing staff.  
Clinically the diagnosis in both cases is difficult and definitive only later in the 
progression of the disease which further complicates possible treatments. Often a 
definitive diagnosis of the specific clinical subtype of the disease can only be given post 
mortem. All these factors make the sporadic neurodegenerative diseases an ever-
increasing problem in the population. This asks for better treatment and accurate 
diagnosis. Especially as many of the neurodegenerative diseases have very similar early 
clinical symptoms such as mild cognitive impairment, caused by various diseases 
similarly. To distinguish and recognise these symptoms and causes very early on and 
tailor treatment accordingly is as important as finding drugs that possible slow down, 
halt or even reverse progression of the disease.  
The number one risk factor for non-hereditary forms of AD and PD is age. There 





trauma to the head in FTD or APO4 overexpression/ duplication in AD, but none 
of them can account for as much of cases other than age. The consequences, the wide 
spread and a generic main risk factor warrants the need for better treatment and 






1.1 Neurodegenerative Diseases and Amyloid Aggregation 
One of the first accounts of AD and its underlying cause was the finding of 
amyloid plaques by Alois Alzheimer, a German physician, in 1907 [2]. He followed a 
patient with dementia and unique clinical symptoms and described the plaques he 
found on the post mortem stained brain slices [2]. The first description of Parkinson’s 
disease was already in 1817 by James Parkinson in great detail with the identification 
of the Lewy-Bodies in 1912 by Fritz Heinrich Lewy who found these aggregates in 
some brain regions outside the substantia nigra [3,4]. 
With AD and PD first described over a century ago [2,3], it took over 75 years to 
identify the main proteinaceous components of the deposits found in these diseases: 
in 1985, the peptide amyloid-β (Aβ) was identified as main component of the 
extracellular plaques found in AD [5] and shortly thereafter neurofibrillary tangles 
(NFTs) were shown to primarily consist of the microtubule associated protein tau [6-9]. 
Subsequently, α-synuclein (αS) was identified as main component of Lewy bodies 
typically present in PD brains by Maria Spillantini and co-workers [10].  
Figure 1  Histological and molecular representations of amyloid aggregates reproduced and 
modified from [11] (A) Light microscopic picture of Aβ plaques (blue) and neurofibrillary tau lesions 
(brown) in the cerebral cortex in AD. (B) Electron micrograph of a paired helical tau filament from 
AD. The cross-over spacing is ~80 nm. Paired helical filaments form the majority of tau filaments, 
with straight filaments being in the minority. [Reproduced from [12]] (C) Steric-zipper crystal 
structure of the hexapeptide VQIVYK (residues 306 to 311) from the core of tau filaments, which 
is required for aggregation. Two β-sheets are shown (gray and blue), with the β-strands being 
parallel within each sheet, and antiparallel between sheets (…). (D) Light microscopic picture of 
Lewy bodies and Lewy neurites made of α-synuclein (brown) in the substantia nigra in PD. 
[Reproduced from Spillantini et al. [10] 
Histological sections of typical amyloid deposits of αS called Lewy bodies, of tau 
called neurofibrillary tangles and Aβ called amyloid plaques are shown in (Figure 1). 
The respective fibrillar accumulations are stained in dark blue or brown in all cases. 
They are all in the µm range ‘growing’ into substantial sizes from their monomeric 





These plaques and tangles contain aggregated protein. That means that a big 
number of monomer units are aggregated into large structures held together by 
hydrophobic interactions of their polypeptide chains. These aggregates usually consist 
of extended beta-sheet secondary structure elements in repetitive form, commonly in 
the shape of long fibrils. These beta-sheet structures where the ones Alois Alzheimer 
could stain and observe as they extend to µm dimensions.  
The β-sheet aggregates have since been found to be a common occurrence in 
neurodegenerative diseases which exhibit progressive neuronal cell loss and the protein 
aggregates are present in the effected and surrounding brain areas. [4,13-15]. The presence 
of amyloid aggregates has been linked to more than just AD and PD since [16]. Protein 
aggregation has also been described as a general property of the polypeptide chain [17,18]. 
Amyloid aggregates typically consist of non-native protein with the unfolding or 
misfolding event as the start of the aggregation process. This unfolded state does not 
have the native configuration of the protein and is then able to self-interact. This state 
can be a misfolded native protein as e.g. in the case of PrP or it can be an unfolded 
non-native polypeptide product as e.g. in the case of Aβ. The process requires 
unfolding, which is facilitated in intrinsically disorder proteins such as αS and others, 
as they explore more conformations on their folding landscape and are hence more 
prone to aggregation. The aggregates then grow through monomer addition, once a 
nucleus is present. Further secondary processes can lead to the formation of additional 
nuclei. These processes could be secondary nucleation and fragmentation. Both 
processes have been included in mathematical models which could fit available data 
more accurately than a simple nucleation elongation process. [19–21] Fibril fragmentation, 
as the name suggests, is the process of fibrils breaking apart and form more fibrils 
which can then grow and fragment further. Secondary nucleation is the templated 
growth on a fibril acting as a nucleus which can provide additional surface for the 
aggregation. Both processes could potentially lead to an exponential increase in fibril 
mass which could facilitate disease spreading and progression.  
For many of amyloid forming proteins the cellular function is not known. But 
there is also a lack of understanding of the precise molecular mechanisms underlying 
these diseases. I will introduce some modern techniques that have been used previously 
and are used in this dissertation to put the following results and techniques into context 





disorders, including AD, I will not discuss the properties and molecular nature of the 
tau protein. The work in this thesis is focused on Aβ and αS and hence, the focus will 






1.2 Biophysical Techniques to Study Protein Aggregates 
I will give an overview over the use of advanced biophysical techniques to study 
protein aggregation with a focus on αS and Aß. Most recent in vitro studies have used 
recombinant or solid phase synthesised proteins that were incubated under conditions 
favouring aggregation [22,23,32,24–31]. Even though the in vivo fibrils are morphologically 
indistinguishable from the ones in vitro [33,34] their biological states could still differ and 
this has only been shown for fibrils. The aggregation reaction varies greatly between 
proteins and conditions. However, it is commonly separated in three phases: a lag 
phase in which no or very little fibril formation is observed, the elongation phase in 
which the fibrils grow and the final plateau phase in which the reaction reaches an 
equilibrium with no observable changes [35]. Of particular interest is the lag and 
elongation phase as in these two phases most of the crucial molecular processes take 
place. The formation of aggregation nuclei happens in the lag phase while in the 
elongation phase a multitude of mechanistically different elongation processes can 
happen which will be discussed in more detail later. 
In protein purification insolubility would often be described as a negative trait, 
nonetheless in the case of amyloid proteins this might have helped to describe the 
amyloid fibrils first, of all the occurring protein aggregate forms [36,37]. In recent years 
much evidence suggests that the more soluble aggregates are more toxic [38–46]. These 
are highly heterogeneous, rare and transient in nature, and so are difficult to study.  
This is why many modern techniques have been developed and adapted to study these 
early soluble aggregates.  
1.2.1 Bulk techniques 
One of the most common techniques to observe in vitro fibril-formation is the use 
of the molecular rotor dye thioflavin-T (ThT) [47]. The fluorescence quantum yield 
drastically increases upon binding to beta-sheet rich protein structures which are a 
main feature of amyloid fibrils [48]. The increase in fluorescence which correlates with 
the presence of amyloid fibrils can either be measured continuously with the dye 
present (e.g.in a plate-reader) or at given time point with the aggregation occurring in 
absence of the dye (e.g. in a conventional fluorimeter). This distinction is important as 
it allows to control for interference of the dye with the aggregation reaction. These 
methods are easily implemented and used routinely to control aggregation reactions of 





reactions has led to insights into the kinetics of the process. The main rate limiting 
steps were determined from kinetic data through the models and determine the 
contribution of primary nucleation, elongation, secondary nucleation and fibril 
fragmentation [49-51]. 
The fluorescence from the aggregation is only measured for the ensemble of the 
system which is the main limitation of these techniques. We cannot observe individual 
species with these methods, but moreover we might not detect species that are 
important for the disease progression as they might not contain sufficient beta-sheet 
content to effectively bind ThT. This is where new dyes have been developed and 
tested to detect a wider range of aggregates [52,53]. 
To get insight into the actual size of the species present, other techniques such as 
dynamic light scattering (DLS) and analytical ultracentrifugation (AUC) can be used. 
DLS uses the light scattering properties of small insoluble particles to infer a size 
distribution and is commonly used in protein aggregation studies(Figure 2) [54]. Again, 
DLS is an ensemble method, which means for any given measurement it will only give 
an average size of the aggregates. It has a resolution limit of about 1 nm with a bias 
towards larger species, which scatter the light better [54].  
Figure 2  Commonly used bulk techniques to characterise protein aggregation. (A) ThT 
fluorescence trace measured in bulk with a fluorimeter or a plate reader with increased fluorescence 
due to the aggregation of αS (B) Size distributions of monomeric, oligomeric and fibrillar 
populations of αS, measured by DLS (C) CD traces of CD traces of αS monomers (blue trace), 
oligomers (red trace) and fibrils (green trace). The figure has been reproduced from Kundel et al. [37] 
Structural information about the protein backbone can be measured with circular 
dichroism (CD). Amino acid secondary and tertiary structure elements rotate the 
polarisation of light differentially in their absence or presence. Hence, CD can give 
information about the average structural composition of the aggregates. This is 
particularly useful as aggregates undergo a structural transition from an unfolded state 
via possible intermediate or native conformations to amyloid fibrils which can all have 





1.2.2 Fluorescence based single-molecule techniques 
The protein aggregation process is highly heterogeneous, which demands for 
techniques to characterise individual aggregates such as the highly heterogeneous 
oligomers all the way to fibrils. Single molecule fluorescence methodologies have 
therefore revealed much about the non-homogeneous processes in protein 
aggregation. In fluorescence microscopy, even with a fluorophore attached to the 
protein of interest, it is still important to achieve a high signal-to-noise ratio to visualise 
single molecules. This can either be achieved by increasing the signal, which is often 
limited by the available fluorophores. The second method is to reduce the background 
by reducing the excitation volume. The two most common techniques this is achieved 
are: confocal microscopy and total internal reflection fluorescence (TIRF) microscopy. 
Figure 3  Schematic of the working principle of a confocal microscope for smFRET and 
TCCD. In a confocal microscope the excitation light is focused onto the back aperture of a high 
numerical aperture lens to form a diffraction limited spot to excite the fluorophores. The emission 
light is then filtered from the excitation light and focused onto an APD. For TCCD a second 
excitation wavelength is overlapped with the first one. The microfluidic channel is shown 
schematically. The details of the filters and dichroic mirrors are given in chapter 3.2. 
Confocal microscopy uses a collimated laser beam that is focused by a high 
numerical aperture lens to a diffraction limited spot to excite the fluorophore. The 
fluorescence of the excited fluorophores is then focused and collected on a highly 





Figure 4  TIRF setup for smFRET and SAVE measurements. The TIRF microscope uses the 
principle of the total internal reflection by angling the incident laser beam to excite a very thin layer 
in the sample. The excitation light gets filtered and focused on an emCCD camera for detection. 
The details of all the filters and dichroic mirrors are given in chapter 3.2 
In TIRF microscopy the incident laser beam is angled so the majority of the 
excitation light is reflected and only an evanescent wave excites only a very thin layer 
(~150-200 nm) in the sample just above the cover slide. 
Confocal microscopy was first used to study protein aggregation with two colour 
coincidence detection (TCCD). In TCCD two wavelength confocal volumes overlap 
and their appropriate emissions are both measured with independent ADPs. Whenever 
a dye traverses the confocal volume they generate a burst of fluorescence. Monomeric 
dye labelled proteins give rise to a single burst in one channel whereas aggregated 
proteins will give a signal in both channels (Figure 5 C). This allowes us to distinguish 
monomeric protein from aggregates and the intensity of the fluorescence bursts gives 
some information about the size of the aggregates. The first protein studied with this 
technique was a equimolar mixture of differentially dye-labelled SH3 domain of 





This principle can be extended and modified multiple ways. In the scanning for 
intensely fluorescent targets (SIFT) [57,58], the two overlapped beams are moved 
through the sample to detect species. The use of a microfluidic channel improves the 
sampling rate over measuring only species crossing the confocal excitation volume due 
to diffusion (Figure 5 A) [59]. Furthermore, instead of the coincident fluorescence 
signal, the Förster resonance energy transfer (FRET) can be measured with the same 
principle. This can be achieved by using a fluorescence donor and acceptor pair and 
excitation in only the donor channel. This can be used to determine the relative mean 
distance between the fluorophores, giving some insights into the monomer density 
within an aggregate [40,60,61].  
Figure 5.  TCCD and smFRET for the ultrasensitive detection of protein aggregates (A) The 
schematic of the microfluidic channel with 100 µm in width and 25 µm in height is shown.(B) In 
TCCD, two colour excitation is used to excite molecules transiting the confocal volume. Only 
those which contain both dyes give rise to coincident bursts. (C) In FRET based measurements, 
only one wavelength of light is used to excite the molecules. In molecules in which the two dyes 
are close enough for FRET to occur (yellow star), there is a simultaneous burst in both channels.  
Although surface effects are removed in these solution-based techniques the data 
interpretation has limitations, as the structures are inferred from a burst of 
fluorescence. Structures exceeding the size of the confocal and aggregates not passing 
through the excitation volume completely can cause further problems in data analysis. 
Finally, due to the sub-nanomolar concentrations required to achieve single-molecule 
sensitivity, some species may dissociate upon dilution. However, development of 
microfluidic devices that allow rapid mixing before measuring can remedy this problem 





A confocal microscope setup as the one described can also be used for 
fluorescence correlation spectroscopy (FCS) [62,63]. FCS measures the temporal 
fluctuations of multiple fluorophores in the confocal volume which allows to infer 
concentrations and diffusion coefficients of the species. As it relies on multiple 
fluorophores in the confocal volume it can be difficult to deconvolute mixtures 
without defined populations.  
TIRF microscopy is usually a surface-based method. It uses the phenomenon of 
total internal reflection that occurs when a plane of light travelling through a 
transparent medium of a given refractive index is incident upon a dielectric interface 
with another medium of a lower refractive index at an angle greater than the critical 
angle. This results in an “evanescent wave” penetrating a small distance into the 
medium and decaying exponentially. In the case of objective based TIRF [64], collimated 
laser light from a high numerical aperture objective lens is reflected from the bottom 
of a glass coverslip containing aqueous solution, and the evanescent wave is used to 
excite a wide field typically <200 nm into the sample (Figure 4). In contrast to 
epifluorescence microscopy this partial excitation leads to a greatly increased signal to 
noise. The resulting fluorescence is, in both cases, collected by the same objective, 
filtered and focused onto an electron-multiplying charge-coupled device (emCCD) or 
an equivalent scientific complementary metal-oxide-semiconductor (sCMOS) camera. 
As surface based widefield technique TIRF microscopy can overcome some of 
the limitations posed by the confocal techniques described. It can be used to directly 
observe fluorescently labelled amyloid aggregates on a glass slide. The physical 
structure and size can be visualised due to the diffraction limit with a resolution of 
approximately 250 nm depending on the wavelength. Under very controlled conditions 
the photobleaching properties of fluorescent dyes can be used to estimate the numbers 
of subunits which decreases stepwise. With increasing sizes these estimation get less 
precise as too many dye molecules are present and the individual steps are not visible 
anymore, which can be avoided by sub-stoichiometric labelling [65]. 
With the diffraction limit capping the achievable resolution in wide field 
microscopy to around 250 nm another problem is posed in the study of amyloid 
aggregates. As transitions between monomers to nuclei to soluble oligomers to 
protofilaments and to small fibrils can all happen below an aggregate size of 250 nm 





Optical super-resolution methods [66-68] have enabled the identification of 
structures as small as 5 nm [69]. The most commonly used approaches to achieve these 
results are Photoactivated localisation microscopy (PALM) [66], stimulated emission 
depletion (STED) [68] and stochastic optical reconstruction microscopy (STORM) [67]. 
STED is implemented on a scanning confocal microscope which limits the 
illumination of the sample to a region smaller than the diffraction limit. STORM works 
by separating the signal of single fluorophores spatially and temporal (stochastic 
switching and readout). The individual fluorescence localisation can then be fitted to 
2D Gaussian functions to determine their centre which allows for improved 
resolution. This switching can be achieved through various principles. In STORM the 
fluorescent dyes are stochastically photoswitching between dark and fluorescent states. 
PALM achieves the stochastic separation of the fluorophores through 
photoswitchable fluorescent proteins (usually switched to a longer wavelength through 
irradiation with ultraviolet light) to separate fluorescence from single emitters in 
time [66]. Methods such as point accumulation for imaging in nanoscale topography 
(PAINT) [70] and uniform PAINT (uPAINT) [71] use fluorescent probes that 
temporarily bind to surfaces or binding partners. This has been adapted in DNA-
PAINT [72,73]. Transient binding is achieved by interaction of short strands of DNA 
designed to fit the residence times required at the desired conditions. The PAINT 
principle has also been used in sPAINT [74] a technique designed to super-resolve the 
surface hydrophobicity of e.g. amyloid fibrils with the binding of the dye nile red. Nile 
red does not only transiently bind to the surfaces, allowing super resolution, but 
simultaneously shifting wavelength depending on the hydrophobicity of the 
environment, allowing for hydrophobicity maps on the nanoscale. 
1.2.3 Lable free techniques 
I will discuss approaches that do not require the attachment of an organic 
fluorophores to the protein of interest, hence label free. The covalent attachment can 
be difficult to achieve or alter properties of the protein or label. The labelling sites 
could be limited by the commonly used chemical attachment on primaty amines or 
sulfhydryl groups on the amino acid sidechains. If neither none of these functional 
groups are or too many, a 1:1 molar labelling can be difficult to achieve. Mutations or 
alternative stop-codon usage respectively can circumvent this limitation but in both 





attachment of fluorophores can affect the kinetics of protein aggregation, or structures 
of the fibrils [75].  
Label free techniques can use mechanisms to facilitate structural insight via the 
use of completley non-fluorescent methods, such as AFM, NMR or EM, that use 
integral properties of the proteins to make them visible.  Another approach is to use 
indirect labelling strategies such as the use of antibodies, nanobodies or aptamers that 
carry the fluorescent label and specifically bind to the target structures. The 
fluorophore can also be the probe itself as in the case of extrinsically fluorescent dyes 
such as ThT, pFTAA and Bis-ANS or nile red in SR applications [74,76]. One method is 
to use ThT coupled with TIRF microscopy to detect protein aggregates directly. This 
means this can and has been used to observer aggregates in biofluids such as 
cerebrospinal fluids. [77] I will discuss this in more detail in chapter 4.  
1.2.4 Other techniques 
To overcome some of the shortfalls of ensemble techniques, surface-based 
methods have also been used to characterise the aggregation process. Quartz crystal 
microbalance (QCM) sensors are able to determine mass variation per unit area by 
measuring the change in frequency of a resonating quartz crystal. This method is 
sensitive enough to report on the change in mass of surface-attached fibrils and has 
enabled very precise measurements of the influence of solution conditions on αS fibril 
elongation to be obtained [78].  
The advances in super resolution light microscopy allow imaging resolutions of 
greater than 20 nm to be achieved. However, higher resolution structures can be 
necessary and useful which require more resolving power. Transmission electron 
microscopy (TEM) is commonly used to determine the structures of aggregates at 
higher resolution. A highly focused electron beam is used to image specimen to 
resolutions as high as 0.2 nm. The sample preparation is complex which limits its 
applications. Some of these sample preparation issues have been solved cryo- elctron 
microscopy (cryo-EM) in which the samples are not chemically fixed but rapidly 
cooled, so they are fixed in amorphous ice. The developers of this technique have 
recently been awarded the Nobel prize in Chemistry [79,80]. To resolve molecular 
structures, it is necessary to reconstruct many different projections of the identical 
protein which requires a very high sample purity, which is a challenge for highly 





oligomers of αS [81], tau filaments extracted from a human AD brain sample [82], poly-
glutamine expanded huntingtin fibrils from cultured neurons [33], and Aβ fibrils [83] were 
solved. 
Atomic force microscopy (AFM) as a non-fluorescent surface-based technique 
allows the mapping of surface topography and Youngs modulus of molecules. AFM 
uses a tip on a cantilever to raster scan a surface [84]. The reflection of a laser beam off 
the tip reports the displacement of the tip, allowing vertical resolutions of the surface 
of less than 1 nm with lower vertical resolution. Despite the high resolution and the 
advantage of being label free, AFM is still a surface-based technique, with the problems 
that come with this. For example findings can be perturbed by differing fibril growth 
rates on the surface or different binding propensities to the surface [85]. 
Both AFM and EM have the advantage that the proteins can be detected in the 
absence of proteins. They are both sensitive to surface effects which may alter 
findings [85]; this could stem for example from changed fibril growth rates on the 






1.3 Alzheimer’s disease and the visualisation of amyloid beta aggregates 
The following paragraph is an excerpt from a review I co-authored and was 
published [37].  
The presence of extracellular plaques composed of the Aβ peptide is a 
pathological hallmark of AD [5]. Aβ is formed and released into the extracellular space 
through the cleavage of the amyloid precursor protein (APP) [86]. This cleavage can be 
performed by several proteases such as ADAM 10, BACE 1, α- and γ-secretase, leading 
to the formation of various N- and C-terminal isoforms of Aβ [87,88]. When the 
expression and degradation of Aβ is controlled there is evidence suggesting that the 
peptide has several important and possibly neuroprotective functions, such as 
regulating synapse activity [89]. However, when the homeostatic balance of Aβ 
production is disturbed the aggregation of the peptide plays a key role in 
neurodegeneration [90-92]. As a result, much effort has been dedicated to characterising 
aggregated Aβ species. It is not clear precisely which factors lead to the loss of the 
normal balance, however the ratio of the most abundant cleavage products Aβ1-40 
and Aβ1-42 has been implicated to be important to AD pathogenesis, adding greater 
complexity to the oligomer formation process [93]. 
Due to the high aggregation propensity of Aβ, it can be challenging to obtain a 
homogeneous monomeric sample, as the molarities required for many ensemble 
methods are high enough to trigger aggregation. This makes studying the kinetics of 
aggregation troublesome, since there may already be seeds present which can 
complicate the reaction. Despite this, a variety of soluble aggregates have been studied, 
but most have not been characterised beyond the use of SDS-PAGE and antibody 
reactivity [94]. Beyond this, various structural and functional details have been obtained 
for water-soluble, non-fibrillar Aβ assemblies [94]. Structures that have been described 
include protofibrils [95,96], Aβ-derived diffusible ligands [97,98], globulomers [99], 
spheroids [100,101], disulphide cross-linked Aβ [29], cell-derived SDS-stable low n-
oligomers [102,103], Aβ*56 [104] and a brain-derived SDS-stable Aβ-dimer [29,94]. They all 
have in common distinctly different biological effects compared with mature fibrils, 
although some of them contain cross β-sheet structures, such as the protofibrils [95,96]. 
The most commonly used techniques to characterise Aβ aggregates are AFM and 





by various aggregates, such as elongated amyloid fibrils and small, globular 
oligomers [105-108]. These approaches have been used to study all species throughout the 
aggregation process, as well as comparing the structure of aggregates produced by 
mutant variants [109,110]. AFM studies showed that not only the morphology of 
aggregates changed throughout the aggregation process, but the Young’s modulus (a 
measure of stiffness) also increased, suggesting an internal structural 
rearrangement [111]. Furthermore, Aβ fibrils have been resolved at the atomic level with 
X-ray crystallography and solid state-NMR including variations in clinical subtypes of 
AD [112-114]. Structures of the cross β-sheet amyloid state are reviewed in great detail by 
Eisenberg and Jucker [115]. A complete de novo 42 amino acid atomic model of Aβ fibrils 
has also recently been solved via cryo-EM [116].  
Fluorescently labelled Aβ peptide variants are readily available as solid-phase 
synthesis allows the efficient site-specific conjugation of single fluorescent tags to the 
Aβ peptides. This has facilitated the use of highly sensitive single-molecule methods 
to study the properties of individual Aβ aggregates, especially oligomers. The 
application of single-molecule methods to study early aggregates has provided insights 
into the size distributions and effects of very early aggregates [117-119]. Narayan and 
colleagues found that Aβ oligomers initiated neuronal damage on astrocytes [120] and 
were sequestered by an extracellular chaperone [118]. They described the oligomers as 
mostly below 10-mers in monomer units, and using TCCD it was possible to study 
these at levels much closer to their physiological concentrations compared to other 
techniques [118]. Furthermore, these fluorescent methods have been used to show how 
oligomers preferentially interact with cell membranes relative to monomers [121]. 
Subsequently, Flagmeier et al. used an ultrasensitive membrane disruption assay to 
show that Aβ42 oligomers but not monomers or fibrils are able to disrupt lipid vesicles 
at picomolar concentrations [92]. 
Aggregate analysis via TCCD and confocal photobleaching trajectory analysis [117] 
are limited by acquisition times and instrumental dead times. Whilst the timescale of in 
vitro aggregation of the majority of amyloidogenic proteins is sufficiently slow to take 
full advantage of these techniques, the temporal resolution can be a limiting factor for 
the ability to detect early aggregation events of proteins with fast aggregation kinetics, 
such as Aβ42. To overcome this limitation, microfluidic strategies have been used, 





increase the rate of detection, and therefore increase the time-resolution of the 
methods [60].  
TCCD measurements of co-oligomer formation between Aβ40 and Aβ42 helped 
generate a thermodynamic model of the peptides’ aggregation propensities [122]. It 
should be noted that the ability to size aggregates from TCCD and smFRET 
measurements is limited due to several factors such as the inhomogeneity of the 
confocal volume and fluorescence quenching at high label densities. Improvements to 
the former have been suggested by Murphy et al. through the use of Bayesian 
Inference [123], which led to the data analysis on population sizes and intramolecular 
distance being more robust than simple threshold-based analysis, especially in more 
complex datasets.  
Super-resolution techniques have been used to probe the seeding capacity of Aβ 
aggregates in addition to the morphology of aggregates in CSF [124,125]. By seeding 
fluorescently labelled Aβ40 with brain- and CSF-derived Aβ from AD and control 
patients it has been shown, using dSTORM, that seeding capacities and elongation 
rates were dependent on aggregate size [126].  
In order to perform label free imaging in vivo, there has been a surge in the 
development of fluorescence imaging probes with similar properties as ThT and 
Thioflavin S (ThS). Notably the class of oligothiophenes has been used to image Aβ 
aggregates in their pre-fibrillar and fibrillar state both in vitro and in vivo (Figure 6) [127-129]. 
Interestingly, these dyes show different spectral footprints for the different amyloid 
topologies of Aβ and tau [130]. Similarly, the hydrophobicity reporter dye nile red has 
been used to spectrally super-resolve local hydrophobicity propensities of amyloid 





Figure 6  High resolution fluorescence images and emission spectra of pFTAA bound to 
pathogenic hallmarks in AD. (A,B) Fluorescence images showing an overview of the interaction 
between Aβ deposits (green), NFTs, and dystrophic neurites (yellow and red). (C) Emission spectra 
of pFTAA bound to Aβ aggregates (green spectrum) or NFTs (red spectrum). (D,E) High 
resolution fluorescence images showing the details of the distribution between Aβ deposits (green), 
NFTs, and dystrophic neurites (yellow and red). Selected Aβ deposits and NFTs are highlighted 
(green and red arrows, respectively) to indicate striking spatial co-localisation. Scale bar = 50 μm 
(A), 20 μm (B) and 10 μm (D and E). Figure adapted from Aslund et al. [128] and reproduced from 
Kundel at al [37] . 
 
A different approach in understanding the molecular mechanisms of aggregation, 
and hence oligomer formation, is through the combination of high quality kinetic data 
and kinetic modelling. This work on Aβ has been pioneered by the Knowles and Linse 
groups. High purity recombinant monomeric Aβ42 has led to robust aggregation 
kinetics which has enabled the use of global fitting models to get insight into molecular 
mechanisms of the underlying processes [131-133]. 
An online modelling platform has been made available to investigate the effect of 
interactions of Aβ with, for example chaperones [134] or antibodies [135] and to model 
molecular mechanisms for other amyloid proteins [132]. This has shown that Aβ42 
aggregation is strongly dominated by secondary nucleation, and hence the presence of 
seeds has an autocatalytic effect on the aggregation process [19]. However, care needs 





effects may be compounded by cellular components, for example fibril seeding on the 
membrane.  
The application of the above mentioned advanced biophysical methods has led to 
insights into the molecular mechanisms underlying Aβ aggregation and has given us 
insights into some structural features of the resulting soluble aggregates and amyloid 
fibrils. One of the main challenges is to link these molecular mechanisms and structural 
features to the resulting neurological effects and finally to the clinical manifestation of 
the disease. The prolonged time-course of the disease and the low Aβ concentration 
in the extracellular space are of particular interest. In vitro, Aβ aggregation time-courses 
are usually studied over hours at concentrations that are orders of magnitudes higher 
of what is found in the CSF [136]. Furthermore, the interactions and interplay between 
different Aβ peptide isoforms and with other amyloid forming proteins have not been 
conclusively explored. The application of the techniques described, could allow the 
investigation of the aggregates at the atomic and molecular level and help understand 





1.4 α-Synuclein oligomers in Parkinsons disease  
αS was one of the first described intrinsically disordered proteins [137]. It was 
identified as the major component of Lewy bodies found in PD and other 
synucleinopathies and has been associated with amyloid plaques in AD [137,138]. A 
further link between the disease and αS comes from the autosomal dominant forms of 
the disease which show duplications and triplications of the SNCA gene encoding for 
αS [139,140]. A third confirmation comes from the single residue missense mutations in 
αS in the early onset forms of PD [141-146]. 
Structurally αS consists of three main regions: the positively charged N-terminal 
region (residues 1-60), the central hydrophobic domain (61-95) also called non-amyloid 
β-component (NAC) and the acidic C-terminal end (96-140). The N-terminus contains 
a apolipoprotein-like helical sequence that drives the alpha-helix acquisition upon 
binding to membranes [147,148]. The NAC region is responsible for the aggregation of αS 
and the formation of the beta-sheet during fibril formation [149,150]. The proline rich, 
negatively charged and acidic C-terminus facilitates protein solubility and has no 
known secondary structure elements [151]. αS is highly dynamic as it is able to transition 
between different secondary structures depending on its interaction partners [152]. 
The localisation of mutations in non-sporadic PD cases are all found in the N-
terminal region of the protein just flanking the NAC region [153]. It indicates that the 
mutations modulate the conformational landscape of αS which has been shown both 
in vitro and in vivo [31,154-158]. Especially the A30P mutation proved useful as αS, with this 
mutation, forms a population of trapped oligomers that led to the hypothesis that 
oligomers are responsible for toxicity in PD [31]. 
Testing this hypothesis, the generation of a large number of oligomers was 
required. Methods to achieve this included incubating concentrated αS solutions on 
ice [159], incubating at 37C [81,160] and the combination of the incubation with size 
exclusion [161,162] or diafiltration steps [163] respectively. Even though a recent study 
managed to purify and characterise kinetically-trapped oligomeric species and 
characterise them using fluorescence, CD, AFM, DLS and cryo-EM, they did not go 
on to form fibrils [81]. With the oligomers trapped in an energy well for alternative 
aggregation/ folding of αS they might not represent the complete picture of 





oligomers differ however and can go on to form fibrils [167-169]. Many additives and 
conditions have been used to generate various forms of oligomers and have been 
extensively reviewed recently [170]. While amyloid fibrils in vivo are similar to the end 
point in in vitro [33,34], there is no structural information on the oligomers present in the 
brain as of now. It is conceivable with the same final structure that the formation 
happens via a common intermediate, but this needs to be confirmed.  
Figure 7  TEM images of oligomers. (A) Annular oligomers described for the first time by 
Lashuel et al. [159] formed by dissolving lyophilised αS in PBS at a concentration ranging from 300-
700 µM and incubating on ice for 30-60 min. Oligomers were then filtered through 0.22 µm filters 
and separated from monomers by gel filtration. Scale bar is 50 nm. (B) Spherical oligomers as 
observed by Ehrnhoefer et al. [166]. 100 µM αS was incubated in the presence of N-epigallocatechin 
gallate (1:10) and incubated in TBS buffer on a rotary shaker (conditions favouring aggregation) at 
37°C. Oligomers were separated from monomers and other aggregates by gel filtration. Scale bar 
is 100 nm. The figure is adopted Kundel et al. [37] 
Crosslinking has been used to capture the rare and transient αS oligomers in 
vitro [171,172]. Their size has been characterised but as they are crosslinked and therefore 
trapped it is not clear if they go on to form fibrils and hence how well they represent 
the oligomers in the brain. The use of native mass spectrometry has allowed to 
investigate the size of oligomers and showed different conformational states of 
monomers and dimers [173,174]. Drift-time analysis showed the presence in sizes from 
dimers to hexamers, giving insight into their topology [175]. However, these methods 
require the aggregates to be dissolved in specific buffers which could perturb their 
structures and are limited in characterising larger oligomers [174-176]. 
The use of fluorescence methods has been extensively used to monitor 
intermolecular interactins in αS. Structure-based non-covalent fluorescent probes have 
been developed and used to specifically detect oligomers, pre-fibrillar species and 
fibrils [177,178] and will be discussed in more detail in chapter 4. Similarly, nile red is a 
non-covalent structure-based fluorescent probe. This was used in sPAINT to look at 





that the oligomers have a higher surface hydrophobicity than the fibrils, which could 
be a mechanism of toxicity.  
Fluorophores can also be conjugated directly to the protein using maleimide 
chemistry on cysteine residues inserted by site-specific mutagenesis [179-181]. Great care 
has to be taken to not interfere with the aggregate formation or oligomer structure of 
the protein through the incorporation of the fluorophores. The covalent attachment 
of the fluorescent probes to the monomers opens up a variety of methods to study the 
aggregate formation. FCS, as described above, allows to estimate the size distribution 
and the concentration of oligomers from their diffusion coefficients giving some 
insight into early aggregate formation [180]. 
Single-molecule techniques are of particular power for heterogeneous mixtures as 
observed with rare αS oligomers. The first technique applied to study αS was 
SIFT [58,182-184]. SIFT assigns the bursts of higher fluorescence to oligomers, while being 
able to measure them individually. This is refined in the analysis of photobleaching 
steps in sub-stochiometric labelled αS. This was done on a TIRF setup as to allow for 
continuous imaging [65]. Accurate identification of individual photobleaching steps in a 
single aggregate is usually limited to about ten fluorophores. The study identified a 
purified oligomer of 31 monomer however. This result has to be seen within the 
limitations of the technique. The method is biased for the detection of brighter species 
and the analysis assumed one size of oligomer, which may not have been the case.  
In depth single-molecule studies using TCCD and smFRET were made possible 
through the introduction of a cysteine at position 90, just flanking the fibril-forming 
region [40,60,61]. The single-molecule measurements revealed two oligomeric populations, 
masked in ensemble methods. The two populations exhibited different ‘compactness’ 
as measured by FRET, different resistance to proteinase-K degradation and different 
stability in low ionic strength buffers [60]. The same techniques were then used to study 
the subtle structural differences between the oligomers generated by various mutant 
forms of αS and the wild type form [61,185]. Furthermore, studying the aggregation 
kinetics on single-molecule levels at different concentrations allowed to infere a kinetic 
model of the conversion rates of the two different types of oligomers [186]. 
Observing oligomers in human biofluids is helping understand structural 





even in vivo. Most efforts so far used antibodies in vivo as their application is well 
established and compatible with many imaging techniques [187,188]. Further techniques 
like complementation assays or proximity ligations assays [189-193] or confocal 
microscopy methods [194,195] have been used to study αS self-interaction.  




2 Aims of this thesis 
This dissertation has two main parts. The first part will focus on the possible 
applications of extrinsically fluorescent dyes to study protein aggregates in situ. This 
will focus on the application of new dyes in the use of the SAVE method focusing on 
aS and PD. We will answer some technical question to explore the possibility of the 
described methods as a possible biomarker.  
I will then present results how a combination of techniques has allowed us to 
transfer the said method to AD patient samples and get insight about the structure of 
the neurotoxic aggregate in human CSF. Furthermore, I will show what implications 
these findings have on the development of antibodies and why some of them could 
have failed in clinical trials. 
Secondly, I will present a novel, modified approach on how to isolate various 
oligomeric species of Aβ42 and their distinct structural properties in a cross-sectional 
manner. More importantly this new approach helped us to understand in more detail 
some biological implications of the species occurring throughout the aggregation 
reaction.  




3 Material and Methods 
3.1 Biochemical Methods 
Preparation of αS Aggregates 
αS aliquots were kindly provided by Beata Blaszczyk and Ewa Klimont. Either the 
wild-type or A90C variant (for labelled αS) of monomeric αS was purified from 
Escherichia coli as described previously [196,197]. For A90C, the single cysteine was labelled 
with maleimide-modified Alexa Fluor 647 (AF647) as previously reported [198]. The 
excess dye was removed by passing the labelled protein through a P10 desalting 
column containing Sephadex G25 matrix (GE Healthcare). The protein was 
concentrated using Amicon Ultra Centricons (Millipore), divided into aliquots, before 
being flash-frozen in liquid nitrogen and stored at -80oC. Each aliquot was only thawed 
once prior to use. For the aggregation reactions, a 70 μM solution of wild-type αS in 
25 mM Tris buffer (pH 7.4) and 0.1M NaCl (with 0.01% NaN3 to prevent bacterial 
growth during the experiments) was incubated in the dark at 37oC, with constant 
agitation at 200 rpm for 22h prior to the experiment.  
Preparation and purification of recombinant Aβ42 for Single Vesicle 
experiments 
The recombinant protein was kindly provided by Dr. Patrick Flagmeier. The 
recombinant Aβ42 (M1-42) peptide (MDAEFRHDSGYEVHHQKLVFF 
AEDVGSNKGAIIGLMVGGVVIA), here called Aβ42, was expressed in the 
Escherichia coli BL21 Gold (DE3) strain and purified as described previously with slight 
modifications [131,199]. Solutions of monomeric recombinant Aβ42 were prepared by 
dissolving the lyophilised Aβ42 peptide in 6 M Gu HCl then purified by using a 
Superdex 75 10/300 GL column (GE Healthcare Bio-Sciences AB SE-751 84 Uppsala, 
Sweden). The center of the elution peak was collected, and the peptide concentration 
was determined from the absorbance of the integrated peak area using ε280 = 1490 L 
mol-1cm−1. 
Measurement of aggregation kinetics of Aβ42 
For kinetic experiments the Aβ42 monomer was diluted with buffer to the desired 
concentration and supplemented with 20 μM ThT. All samples were prepared in low-
binding Eppendorf tubes (Eppendorf AG, Hamburg, Germany) on ice. Each sample 
was then pipetted into multiple wells of a 96-well half-area, low-binding polyethylene 




glycol coating plate (Corning 3881, Kennebuck ME, USA) with a clear bottom, at 80 
μL per well. The 96-well plate was placed in a plate reader (Fluostar Omega, Fluostar 
Optima, or Fluostar Galaxy; BMG Labtech, Ortenberg, Germany) and incubated at 
37°C under quiescent conditions using the bottom reading mode (440-nm excitation 
filter, 480-nm emission filter). For each new preparation of protein, the aggregation 
kinetics were checked by performing reactions at different concentrations of Aβ42. 
Conditions for Aβ42 aggregation 
Aliquots of monomeric Aβ42 were diluted with buffer to a concentration of 2 μM 
in low-binding Eppendorf tubes on ice. Individual samples were then pipetted into 
multiple wells of a 96-well half-area plate (Corning 3881, Kennebuck ME, USA) and 
the plate was placed into an incubator at 37 °C, under quiescent conditions. Aliquots 
for measurements of Ca2+ influx were then taken at the desired times after the plate 
was placed in the incubator. 
HiLyteTM 647 Fluor and HiLyteTM 488 Aβ42 peptide purification and 
aggregation 
Aβ labelled N-terminally with HiLyte™ Fluor 647 and HiLyte™ Fluor 488 were 
purchased from AnaSpec (#AS-64161 and #AS-60479-01). Solutions of monomeric 
protein were prepared by dissolving the protein in 10mM NaOH at high concentration 
and then purified using a Bio-Sep 2000 HPLC column (Phenomenex) in SSPE buffer 
(Thermo Fischer, #15591043). Peak fractions were collected, and the peptide 
concentration was determined using the absorbance of the fluorescent label with an 
extinction coefficient of 250,000 M-1cm-1 for HiLyte™ Fluor 647 and 70,000 M-1cm-1 
for HiLyte™ Fluor 488. Monomeric fractions were frozen immediately after 
preparation and kept at -80°C until use. 
Aliquots of monomeric Aβ were diluted to an equimolar concentration of 2 µM 
of HiLyte™ Fluor 647 Aβ42 and HiLyte™ Fluor 488 Aβ42 in low-binding Eppendorf 
tubes and incubated at 37°C, under quiescent conditions.  
Sucrose Ultracentrifugation 
The aggregated peptide was loaded on a step gradient of 10-50 % sucrose in SSPE 
buffer at pH 7.4 in increments of 10 % sucrose with a total volume of 2 ml. All samples 
were centrifuged for 15 h, 41 000 g and 20°C and the fractions were collected 
immediately and stored on ice until use and stored no longer than one day. The 




collection was done by piercing the centrifugation tubes orthogonally in 400 µl 
fractions and the remaining pellet was resuspended in 100 µl buffer. 
Dot Blot 
Synthetic Aβ42 was aggregated for 3 h at 37°C under non-shaking conditions at 
2 μM monomer concentration. 2 μl of sample at different protein dilutions were 
spotted onto nitrocellulose membrane slowly. After drying the membrane it was 
blocked by soaking in 5% BSA in TBS-T (20 mM Tris-HCL pH 7.5, 150 mM NaCl, 
0.05% Tween 20) for 0.5-1 h at room temperature. It was then incubated with the 
primary antibody at 1 μg/ml for 30 min at room temperature. After washing 3 x 5 min 
with TBS-T the blot was incubated with the secondary antibody conjugated to Alexa-
647 for 30 min at room temperature in the dark. Subsequently the blot was washed 
three times with TBS-T (15 min x 1, 5 min x 2), then once with TBS (5 min) in the 
dark. The blot was then imaged in a Typhoon gel imager at the according wavelengths.  
Dye Solutions 
ThT (Sigma-Aldrich), DiThT-PEG2 (Custom Synthesis, Peakdale Molecular) and 
DCVJ (Anaspec) stock solution was prepared in Dimethylsulfoxide (DMSO) (Sigma-
Aldrich) diluted into pre-filtered (0.02 μm filter, Whatman, GE Healthcare) phosphate 
buffered saline (PBS) (Sigma-Aldrich) to a final concentration of ~100 μM. Its exact 
concentration was determined spectroscopically using the following extinction 
coefficients: ThT 36,000 M-1 cm-1 at 412 nm; DiThT 45,800 M-1 cm-1  at 410 nm; DCVJ 
42,000 M-1 cm-1 at 460 nm (measured). For BTA-1 (Anaspec) and NR (Anaspec) the 
stock solutions were prepared weighing out the solid into DMSO. Solutions were all 
filtered (0.02 μm filter, Whatman, GE Healthcare) prior to use and not used longer 
than one day. Borosilicate glass coverslips (VWR International) were cleaned in an 
Argon plasma for 1 hour and prepared for coating with a 20mm x 20 mm Frame-Seal 
slide chamber (Bio-Rad). The coverslips were coated with 0.01% Poly-(L)-Lysine 
Solution (PLK) (Sigma-Aldrich) for at least 30 minutes. The PLK solution was 
aliquoted and stored at 80°C as storage at 4°C lead to an increase in false positives in 
the negative controls. The PLK-coated surfaces were washed three times with PBS 
before the sample was applied. Each sample was left on the coverslip for 10 min prior 
to imaging to ensure absorption of the species on the surface.  




3.2 Fluoresence Imaging and Instrumentation 
Total Internal Reflection Imaging 
The samples were imaged using a home-built total internal reflection fluorescence 
(TIRF) microscope limiting the detectable fluorescence signal to within 200 nm from 
the coverslip. For imaging of ThT, DiThT, BTA-1 and DCVJ a 405 nm Laser (LBX-
LD, Oxxius Laser Boxx, Laser 2000) was passed through a FF01-417/60-25 (Semrock) 
excitation filter to remove any stray light, passed through a quarter wave plate to 
circularly polarise the beam and expanded using a collimated Galilean beam expander. 
All other lasers and according filters and dichroic mirrors are described in Table 1. The 
aligned beam was directed parallel to the optical axis at the edge of a TIRF objective 
(APO N 60X TIRF, Olympus) mounted on an inverted Olympus IX-73 microscope 
(Olympus). Fluorescence was collected by the same objective, separated from the 
returning TIR beam by a dichroic Di01-405/488/532/635 dichroic mirror (Semrock), 
and passed through an appropriate filter for ThT, DiThT-PEG2 and DCVJ: BLP01-
488R-25, (Laser 2000) and for BTA-1: FF01-434/17-25 (Semrock). The images were 
recorded on an EMCCD camera (Evolve 512 Delta, Photometrics) operating in frame 
transfer mode (EMGain of 4.4 e-/ADU and 250 ADU/photon). Each pixel was 207 
nm in length. The distance between the 9 images measured in each grid was set to 350 
μm, and was automated (bean-shell script, Mircomanager) to prevent user bias. Images 
were recorded continuously for 100 frames with 50 ms exposure.  
Table 1  Overview over all used filters and dichroic mirrors. If not stated otherwise all filters and 
dichroic mirrors have been purchased from SEMROCK. *) Has been purchased from THORLABS.  
Laser-
Line 
405 nm 488 nm 532 nm 647 nm 
Excitation 
Filter 







Di02 R532 25x36 
(Dichroic D1) 
N/A 
Emission Filter BLP01-488R-25  FF01-587 BP  LP02-647RU-25 





Confocal smFRET measurement 
The instrumentation and measurement techniques used in this study have been 
described in great detail previously [56,200]. A schematic of the confocal setup used is 




shown in Figure 3. For all measurements using pFTAA the dye was used at 30 nM 
final concentration and only the events in the blue channel were observed. 
DNA-PAINT Imaging 
Glass coverslips (0.13 mm thickness, round, 50 mm diameter) were cleaned using 
an argon plasma (PDC-002, Harrick Plasma) for 1 h. Then, a multiwell chamber 
coverslip (CultureWell CWCS-50R-1.0, 50 channels) was cut in half and affixed to the 
glass coverslip. The slide was incubated with aspartic acid (Sigma, 1 mg/mL) for 1 h 
and washed once with Tris buffer (0.02 μm filtered, Anotop25, Whatman); 5.0 mM 
tris(hydroxymethyl)aminomethane (Tris), 1 mM EDTA, 10 mM MgCl2, pH 8). 
Samples were incubated on the slide for 5 min, before the liquid was removed and 
replaced with Tris buffer containing aptamer, imaging strand and/or ThT/pFTAA. 
The slides were then transferred to the microscope stage and coupled to the objective 
using refractive index-matched immersion oil (refractive index n = 1.518, Olympus, 
UK). If imaging for longer than 2 h, another clean coverslip was then layered on top 
of the multiwell chamber to prevent evaporation.  
Preparation of aptamer and fluorophores 
The aptamers and fluorophores were kindly provided by Dr. Horrocks. All DNA 
strands were diluted in Tris buffer. The docking and imaging strand sequences were 
the same as those used previously [201]. The docking strand-conjugated aptamer 
(ATDBio, GCCTGTGGTGTTGGGGCGGGTGCGTTATACATCTA) was used at 
a final concentration of 100 nM. The DNA imaging strand (ATDBio, 
CCAGATGTAT-Cy3b) was also dissolved in Tris buffer and used at a final 
concentration of 1 nM. The ThT solution was prepared as described and further 
diluted to 5 μM in Tris buffer and mixed with the abovementioned two DNA solutions 
for imaging.  
Super resolution imaging of cells 
To prepare cells for imaging they were first washed with phosphate buffered saline 
(PBS) before being fixed with paraformaldehyde (4% w/v) for 15 min at room 
temperature. The cells were rinsed three times with PBS before being incubated for 
1 h at room temperature in PBS containing 0.5% triton X-100 with 10% goat serum. 
The aptamer and imaging strand was then diluted to 100 nM and 5 nM respectively in 




PBS + 10% goat serum. The cells were incubated with the aptamer solution overnight 
at 4ºC before imaging. Near-TIRF illumination was used to illuminate the cells.  
Instrumentation 
A home-built total internal reflection fluorescence (TIRF) microscope was used 
for imaging. The principal layout is equivalent to what is shown in , hence it is not 
sketched again. The output from two lasers operating at 405 nm (Oxxius Laser-Boxx, 
Oxxius) and 561 nm (Cobalt Jive, Cobalt) were aligned to the optical axis of a 1.49 
N.A., 60x TIRF objective (UPLSAPO, 60XO TIRF, Olympus) mounted on an 
inverted Ti-E Eclipse microscope (Nikon, Japan). The microscope was fitted with a 
perfect focus system (PFS) which auto-corrects the z-stage drift during a prolonged 
period of imaging. The laser power was attenuated by neutral density filters before the 
beam was passed through a quarter-wave plate (to circularly polarise the laser beam), 
a beam expander and their respective excitation filters (FF01-417/60-25 for 405 nm 
and FF01-561/14-25 for 561 nm, Semrock). The lasers were combined by a dichroic 
mirror (FF458-Di02-25x36, Semrock) and passed through the back port of the 
microscope and focussed in the sample by the objective. The laser power at the 
objective was 1.13 mW and 10.07 mW for the 405 nm and 561 nm lasers respectively. 
Fluorescence was collected by the objective and separated from the excitation light by 
a dichroic mirror (Di01-R405/488/561/635, Semrock), and passed through 
appropriate filters (BLP01-488R-25 for ThT and LP02-568RS-25 for Cy3B, Semrock). 
The fluorescence was then passed through a 2.5x beam expander and recorded on an 
EMCCD camera (Evolve 512, Photometrics) operating in frame transfer mode 
(EMGain of 11.5 e-1/ADU and 250 ADU/photon). Each pixel corresponded to a 
length of 131.5 nm. Images were taken in a grid by an automated script (Micro-
Manager) to prevent user bias. Exposure times were kept constant at 50 ms; at least 
4000 frames were acquired for super-resolution images, 100 frames were acquired for 
diffraction limited images. (The principal layout is equivalent to , hence it is not shown 
again). 
3.3 Data Analysis 
3.3.1 TIRF and Super Resolution Image analysis 
Data analysis was performed using a custom written ThT analysis plugin for the 
GDCS SMLM plugin (Alex Herbert, SUSSEX UNIVERSITY) in ImageJ 




(http://imagej.nih./goc/ij) kindly developed and provided by Mathieu Palayret. The 
individual image stacks are intensity averaged over 100 frames and the background 
level is determined by a quick residuals least trimmed square estimator. The signal gets 
fitted to a Gaussian 2D point spread function by the GDCM SMLM Peak Fit plugin. 
The signal-to-background threshold for all signals was kept consistent throughout the 
dataset after initial judgment. Furthermore, the intensity histograms and signal to 
background histograms were used to check for consistency. False positive correction 
of detected spots was done manually after each experiment with only the dye or only 
the PLK coated surface respectively. Photon emission was calculated with 
(Equation 1). All graphs have been plotted and fitted with Origin Pro 9 except the 
lognormal fit of the histograms was performed with custom written code in Matlab.  
Figure 8  Workflow of the data analysis for the TIRF imaging. The RAW image stack of 50-100 
individual exposures is intensity averaged for better signal to noise. The resulting image is the used 
to identify maxima which are the aggregates we subsequently count and compare with respect to 
their intensities. The resulting control image is used to check thresholds for each batch of 
experiments to account for variability in the experiment. 
In Figure 8 it is schematically shown how the data is processed. The recorded 
stacks of multiple exposures of the same field of view are intensity averaged. The 
resulting image is cropped and then analysed further. The find maxima function of 
ImageJ is used to identify all ThT-positive spots with a noise level set for the entire 
experiment but varied between conditions to account e.g. for dye background. The 
signal to noise correction is done locally in the adjacent pixels of the peak which 
accounts for uneven field illumination. All identified aggregates are then overlaid with 
a circle to visually control for accurate fitting. The peak intensities are used to generate 
the histograms and the number of peaks is used to compare the sensitivity of the dyes 
or the number of aggregates respectively. 







Equation 1  Calculation to determine the emitted photons for image analysis 




Table 2  Values for calculation of Photons for SAVE experiments. G is the analogue gain 
(electrons per analogue-to-digital-unit (ADU), τ is the exposure time, QE is the quantum efficiency, 
M is the EMCCD multiplication and γD is the dark count rate per pixel (Hz/pixel) 
Pixel Size (nm)  207 *) 
G (e-/ADU)  4.4 
τ (s-1)   0.5 
QE  0.96 
M  150 
γD (Hz/Pixel)  500 
*) the pixel size changed to 237 nm after change of the microscope body for later experiments. 
For the two-colour coincidence analysis fitting of the signal was done as described 
above. The procedure runs for both channels and if spots in the two different channels 
are within 400 nm of each other they are colocalised. Chance coincidence which means 
having two of the fluorescently labelled species randomly occupying the same region 
is calculated by rotating one averaged channel 90° and translating it a third of the image 
size in order that any spots in the centre of the image are not accidentally found to be 
coincident. Chance coincidence is particular problematic for high densities and 
concentrations were adjusted accordingly to keep this effect minimal. 
Coincidence is calculated with Equation 2 by selecting one channel as base 
channel and calculate how many of the spots in the base channel are colocalised to the 
other channel as a fraction of all spots. This is corrected by the chance spots which are 
the colocalised spots when one of the channels is rotated by 90 degrees.  
𝐶𝑜𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 =  
𝑐𝑜𝑙𝑜𝑐𝑎𝑙𝑖𝑠𝑒𝑑 𝑠𝑝𝑜𝑡𝑠 − 𝑐ℎ𝑎𝑛𝑐𝑒 𝑠𝑝𝑜𝑡𝑠
𝑡𝑜𝑡𝑎𝑙 𝑠𝑝𝑜𝑡𝑠 − 𝑐ℎ𝑎𝑛𝑐𝑒 𝑠𝑝𝑜𝑡𝑠
 
Equation 2  Calculation to determine the coincidence for the colocalisation analysis 
 
3.3.2 smFRET data analysis 
The smFRET data is analysed using a custom written application developed by 
Mathew H. Horrocks [202]. 
For the data analysis all intensity data of the APDs was transferred into IgorPro. 
The thresholds for both channels were adjusted for each set of experiments based on 
the background signal of the monomer solutions and the buffer solutions. To show 
the threshold was in the linear range for the monomer concentrations expected I 




plotted the monomer brightness and the number of detected events as a function of 
threshold and monomer concentration (Figure 9). 
To control for consistent recording the number of detected events were plotted 
against time throughout the experiment to control for any possible channel blockages, 
varying flow rates. The monomer brightness was compared throughout and the 
alignment was checked frequently through the use of dual-labelled DNA samples.  
Figure 9  Threshold testing as a function of monomer concentration to determine the correct 
working dilutions. (A) Detected bursts in the donor channel above threshold of monomeric 488 
dye as function of threshold and concentration (B) equivalent experiment with monomeric 647 
dye. (C) Detected FRET bursts in the acceptor channel for (C) 488 dye and (D) 647 dye. The plots 
confirm that the selected thresholds are in the linear regime and the concentrations are suitable to 
distinguish the aggregates form monomeric bursts. 
For the in depth analysis the FRET efficiency was plotted against the apparent 
oligomer size and depending on the requirements various other parameters were 
extracted such as e.g. FRET- and Intensity- Histograms of aggregates, fraction of 
aggregates and aggregate counts. The details of these steps have been 
described [40,200,203].  




3.4 Other techniques 
3.4.1 Vesicle Assay 
The Vesicle Assay was performed by Dr. Suman De with the help of Dr. Patrick 
Flagmeier as described in [92].  
Vesicles are prepared by mixing 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine 16:0-18:1 PC (Avanti Polar Lipids) and 1-oleoyl-2-[12-
biotinyl(aminododecanoyl)]-sn-glycero-3-phosphocholine 18:1-12:0 Biotin PC (Avanti 
Polar Lipids) at 100:1 ratio. The solvent was then removed under vacuum in a 
desiccator overnight and the lipids were then rehydrated in HEPES buffer (pH 6.5) 
with 100 µM Cal-520 (Stratech). Five freeze-and-thaw cycles were performed using dry 
ice and a water bath, followed by 10 times extrusion (Avanti Polar Lipids) with a 
membrane of 200 nm cut off to improve the homogeneity of the vesicle size and 
lamellarity distribution. To separate non-incorporated dye molecules from the vesicles, 
size-exclusion chromatography was performed. Then the purified vesicles tethered to 
PLL-PEG coated borosilicate glass coverslides using a biotin-neutravidin-biotin 
linkage and incubated in Ca2+ containing (1.26 Mm) Leibovitz's L-15 solution 
(Thermo-fischer). The frame-seal incubation chambers affixed (Biorad) coverslides 
were placed on the instrument described below. Thereafter the sample, diluted to a 
concentration of twice the targeted value, was added to the coverslide and incubated 
for ~10 min and same field of views are imaged. Next, ionomycin (Cambridge 
Bioscience Ltd), an ionophore for Ca2+, was added and incubated for 5 min and 
subsequently images of Ca2+ saturated single vesicles in the same fields of view were 
acquired once more. Importantly, we made sure that the coverslides were not moved 
during the experiment so that exact same vesicles can be imaged in different 
conditions, which can be analysed to calculate sample induced Ca2+ influx 
quantitatively. For each field of view 50 images were taken with an exposure time of 
50 ms each. The recorded images were analysed using ImageJ (National institute of 
Health) to determine the fluorescence intensity of each spot under the three different 
conditions, namely blank (Fblank), in the presence of an aggregation mixture (Fsample), and 
after the addition of ionomycin (FIonomycin). Spot detection was implemented using ‘find 
maxima’ and intensity of the spots are calculated by considering 5 pixel diameter by 
centering brightest pixel of the spot. Then the particular sample induced relative Ca2+ 
influx into a vesicle was calculated using Equation 3. 










Equation 3  Calculation of Ca2+ influx based on the fluorescence changes detected. 
The average degree and standard deviation of Ca2+ influx was calculated by averaging 
the Ca2+ influx into individual vesicle from 16 field of views. 
3.4.2 Inflammatory Response Measurement and Cell Culture 
The TNFα levels were kindly measured by Dr. Craig Hughes. The BV2 cell lines 
were derived from immortalised murine neonatal microglia. They were grown in 
Dulbecco’s Modified Eagle’s (DMEM) supplemented with 10% foetal bovine serum 
and 1% L-Glutamine (Life Technologies) and incu-bated at 37 °C in a humidified 
atmosphere of 5% CO2 and 95% air, until approximately 1.6 x 106 cell/ml. For long 
duration experiments the buffer was exchanged every 24 hours. Elisa assays. To 
determine cumulative TNF-α production, supernatants were obtained after incubation 
with the Amyloid aggregate fractions over viable time frames and stored at −80°C until 
analysed. TNFα levels were analysed using the Duoset® enzyme-linked 
immunosorbent assay (ELISA) development system (R&DSystems, Abingdon, 
Oxfordshire, UK). 
3.4.3 Atomic Force Microscopy  
The AFM was performed by Dr. Simone Ruggeri. The AFM was done on bare 
mica (TedPella Inc., USA) substrates. The mica surface was cleaved for each sample 
and an aliquot of 10 µl of the sample solution was deposited on the positively 
functionalised surface. The droplet was incubated for 5 minutes, then rinsed by 1 ml 
of Milli-Q water and dried by the gentle stream of nitrogen gas. The preparation was 
carried out at room temperature. AFM maps were realised at least with a resolution of 
1024x1024 pixels by means of a JPK nanowizard2 system (Germany), operating in 
tapping mode and equipped with a silicon tip (μmasch, 2 Nm-1) with a nominal radius 
<10 nm. Images flattening and single aggregate statistical analysis was performed by 
SPIP (Image Metrology, Denmark) software [204].  
  




4  Studying Amyloid Aggregates in human CSF 
4.1 Introduction 
The development of new drugs is strongly coupled to two factors: firstly, an 
understanding of the molecular mechanism of the disease to identify a therapeutic 
target and secondly a biological readout to monitor the beneficial effect preferentially 
with an easily accessible and measurable biomarker. There has been good progress in 
the understanding of the molecular players in the case of AD and PD over the last 
decades. However, monitoring the disease progression and identifying early signs 
clinically and biochemically has been an ongoing problem. For a long time, the only 
fully reliable diagnosis about the subtypes of many dementia variants was the post 
mortem analysis of the brain.  
The first identification of amyloid proteins in a human CSF was in 1992 showing 
the presence of Aβ [205]. CSF is accessible with the standard procedure of a lumbar 
puncture and proteins will be much more readily measurable than in blood as they do 
not have to cross the blood-brain barrier. It was also shown that αS was present in 
cerebrospinal fluid in PD patients with the potential as a biomarker [187,206].  
It was found in recent years for AD, that the three amyloid markers of total tau, 
phospho-tau and amyloid beta fragments (specifically 1-42) robustly correlate with 
MCI and dementia due to AD with sensitivity and specificity reaching 85–90% [207,208]. 
The three markers are used in combination and their diagnostic power can be 
explained in different ways. An increase in total tau correlates to AD pathology and 
can be linked to the release of tau by degenerating axons into the extracellular 
space [209]. High concentrations of total-tau are a sign of intense axonal degeneration 
that indicate fast disease progression [210,211]. The phospho-tau concentrations in CSF 
reflect the presence of neurofibrillary pathology [212,213]. 
CSF biomarkers in AD 
For Aβ the situation is reversed in the correlation between the CSF levels and 
disease progression. In 1992 Haass and colleagues first showed that Aβ is secreted to 
the CSF [205], but subsequent measurements of CSF Aβ could not show a clear change 
in AD [214,215]. This could be accounted for by the non-specific ELISA used. The 




relevant Aβ isoforms 1-40 and 1-42 were not distinguished and hence a change could 
not be observed [216]. 
It was then shown in 1995 that AD patients have reduced A42 [217]. This was 
explained by sequestration of Aβ42 in senile plaques [218] and possible oligomerisation 
and matrix effects, leading to the reduced levels [207]. This measure was improved by 
taking into account the Aβ40 to Aβ42 ratio as this allowed to determine the levels of 
Aβ42 in the background of the individual Aβ production [207,219]. Aβ40 production is 
about ten times higher than Aβ42 and does not change in AD but the 42:40 ratio 
reduces even more markedly than 42 alone [216,220]. These findings have been confirmed 
by ELISA methods [221], luminex [222], electrocheminoluminescence immunoassay [223], 
and other techniques [224,225]. Not only has the decrease been confirmed but also 
multiple large clinical studies have confirmed the link. Hansson and colleagues [226] 
conducted a large multicentre studies showing consistent results throughout and with 
an in depth meta-review by Olsson and colleagues [227].  
Overall around 90% of the MCI patients with pathological CSF biomarkers at 
baseline eventually progressed to AD dementia in these studies. Aβ42 levels decrease 
prior to onset of AD dementia by at least 10 years and prior later increase of tau and 
p-tau [209]. This suggests changes in Aβ precede the tau-related pathology. 
For the described CSF biomarkers, especially for Aβ, it was not so clear how the 
drop in Aβ42 could be explained. This could be due to decreased Aβ production, 
decreased Aβ clearance, aggregation and deposition of Aβ in brain tissue, with lower 
amounts diffusing to the extracellular space and CSF, increased proteolytic degradation 
of Aβ, and possibly more [216]. However, the most likely explanation is the increased 
rate of aggregation in the brain, as an inverse correlation was shown between CSF 
Aβ42 and plaque load in cortical regions [218]. 
 
Other diagnostic approaches in AD 
Another way of predicting and diagnosing AD uses the amyloid binding ThT-
derivative Pittsburgh B (PiB) as 11C-modified derivatives in positron emission 
tomography (PET). PiB interacts with the amyloid deposits in the brain showing 
increased ligand retention in cortical brain regions in AD compared to controls [228,229]. 
This concept has been expanded by the use of multiple 18F labelled tracers for amyloids 




which can have slightly different binding properties [230]. PET imaging shows good 
correlation with the CSF biomarkers and AD progression [229]. PiB and other amyloid 
beta ligands are targeting aggregated, beta-sheet structure containing protein deposits. 
This beta-sheet binding property leads to predominantly labelling of compact 
plaques and vascular deposits as shown in post-mortem tissue [231]. This means in turn 
that less closely packed aggregates and amorphous plaques are not getting picked up 
very well but the PET imaging shows good agreement with Aβ pathology regardless 
of the non-comprehensive labelling of all Aβ aggregates [232,233].  
Despite the fairly established biomarkers for AD, we still have not fully 
understood the molecular mechanisms of aggregation and pathology in the brain. With 
the secretion of Aβ into the CSF we have direct access to the resulting aggregate 
species before plaque formation. This can potentially allow us to examine structural 
properties of the former in the CSF. The biomarker approach described above selects 
for a sequence specific epitope on the protein. Alternatively, we can, orthogonal to 
mesoscopic PET imaging, use ThT to image the microscopic aggregates in the CSF [77]. 
Despite some potential diagnostic value, this could more importantly help us better 
understand the nature of the aggregates in the brain. 
Multiple anti- Aβ antibodies failed in phase III clinical trials recently. Most 
prominently bapineuzumab. There is a variety of explanations for this which I will 
discuss in more detail in the following chapter 4.2.3. It is important to understand 
however, the correct pathologic state of the neurotoxic protein. Otherwise potential 
non-harmful forms might be wrongly depleted and worsen the condition. There are 
two things I will examine in the following. Firstly, can we learn more about the number 
and structure of the aggregates in CSF by directly observing it via SAVE. Is the 
aggregate number and structure different between AD and HC in the CSF? This can 
potentially help translate some of these properties in to in vitro systems to study the 
correct aggregation states. Secondly, if we have a method of measuring aggregates in 
the CSF, can we inhibit their effects? This can help us evaluate e.g. antibodies in 
preclinical trials on human aggregates.  




CSF biomarkers in PD 
αS as a biomarker for PD cases is still not fully validated. The central role of αS in 
the role of pathogenicity and the correlation between the neurotoxicity and its levels 
make it an attractive biomarker candidate. There have been conflicting results as to 
whether the levels of total αS are linked to the disease progression and suitable as a 
biomarker [106,234-237]. The most recent results suggest no link for total CSF αS levels and 
PD. Some results also suggest a link between low levels of αS and tau in CSF [238]. All 
this however just shows even more the need to develop a prognostic and diagnostic 
marker for PD. Horrocks and colleagues were able to distinguish PD and HC CSF 
samples by the number of ThT active aggregates imaged with high-resolution TIRF 
microscopy [77]. This made the technique a promising candidate as diagnostic tool 
(Figure 10). Furthermore, it might help us understand the aggregates present in the 
brain. 
Figure 10  The SAVE method allowed to distinguish PD patients and HC patients by counting 
the number of ThT-active aggregates in the CSF. (A) shows an example image of a CSF patients 
CSF imaged with SAVE and the green circles show the counted aggregates. (B) and (C) show the 
direct comparison between the PD and HC samples as analysed with SAVE and an αS specific 
ELISA which does not show any difference between the samples in contrast to the SAVE method. 
Figure reprinted from Kundel at al. [37]. 
The following section will consist of two main parts. Firstly, the expansion of the 
SAVE method with various other extrinsically fluorescent dyes and the horizontal 
method transfer to AD CSF samples. Secondly, I will demonstrate how SAVE and 
other methods helped to understand why the antibody bapineuzumab might not have 
been successful in phase III clinical trials and how antibody effects differ between in 
vitro aggregated protein and aggregates in CSF.  
  





4.2.1 New Extrinsically Fluorescent Dyes to improve SAVE 
High resolution microscopy coupled with extrinsically fluorescent dyes can be 
used to visualise unlabelled single amyloid aggregates. In this chapter I show how 
parameters for the imaging of individual aggregates of αS can be optimised, using five 
different dyes. I will show that a dimer of Thioflavin T gives improved performance 
in this particular application. I will also show effects and how the sample handling can 
affect the outcome.   
The oligomeric states of αS were found to promote elevated levels of reactive 
oxygen species and Ca2+ in cells, membrane permeabilisation and play an important 
role in seeding and therefore elevated disease progression [239]. It is likely that absolute 
protein concentrations which are dominated by the monomer, often used in ELISA 
based diagnostic tests, might not be the best parameter for disease progression. Rather, 
a test which determines the relative concentrations of protein aggregates may be a 
better solution. Single amyloid visualisation through enhancement (SAVE) addresses 
this problem by measuring the individual aggregates (Figure 11) found in human 
CSF [77]. We explore if the technique can be improved or expanded with different beta-
sheet binding dyes to enhance its capabilities.  
Figure 11  Schematic of the SAVE method showing a simplified view of the single aggregate 
visualisation through enhancement with the sample deposited on a coated glass coverslip and 
imaging in TIRF mode after the addition of ThT and subsequent data acquisition and analysis. The 
scale bar is 10 µm showing αS aggregates. 
The SAVE method is particular useful for two reasons. Firstly, because it does 
not require a covalently attached fluorophore, which is not easily done in a biofluid. 
Secondly because it enables the size distribution of aggregates to be monitored within 
a single sample, which is not possible with an ensemble method. Despite the surge of 
oligomer specific ELISA tests, these still usually select positively for one epitope in the 
ensemble measurements. That means even with a specific epitope we will only be able 
to see one ensemble response to the overall presence of the structural binding sites. 




This means we would for example not be able to distinguish between many aggregates 
with little binding sites and little aggregates with many binding sites. 
I selected five dyes that have been shown previously to bind to beta-sheet 
structures present in amyloid aggregates. We compared ThT, a custom made PEG2 
linked Thioflavin Dimer (DiThT-PEG2), DCVJ, BTA-1 and Congo Red for testing 
(Figure 12). To the best of my knowledge, no other studies used extrinsically 
fluorescent dyes to image aggregates in biofluids. This makes the explorative nature of 
this work important.  
 
Figure 12  (A) shows the chemical structures of the extrinsically fluorescent dyes used to test 
for ThT alternatives. The dyes are ThT, Di-ThT-PEG2, BTA, DCVJ and CR. (B) The respective 
emission spectra of the tested dyes upon binding to αS aggregates is shown. All spectra are 
normalised for their intensity. 
The important properties of the dyes were tested for (1) the usability for SAVE 
with a sufficient signal to see individual aggregates (2) the optimal dye concentration 
to balance false positive and signal to noise with a constant protein concentration and 
(3) the most promising dyes, namely ThT and DiThT, were tested at various aggregate 
concentrations at their optimal imaging concentration.  




Figure 13  (A) The aggregate density measured with CR in the presence of aS aggregates with 
the SAVE method. We cannot see an increase in aggregate density until very high dye 
concentrations which have high error bars due to false positive background effects. (B) BTA-1 
doesn’t show any aggregates either. (C) An example of the lognormal fitted intensity distribution 
for BTA-1 has been plotted. As the overall number of detected spots is so low, the fits have big 
errors and doesn’t allow us to get conclusive results with either dye. Hence, they are not suited for 
the application. 
Where ThT, DiThT-PEG2 and DCVJ show good signal at various dye 
concentrations CR and BTA-1 show no signal (Figure 13). This has all been analysed 
using the methods described in chapter 3.3. In brief, we focus on all puncta signals 
above background to see if BTA-1 and CR are suitable. Even though they are known 
to bind beta-sheet structures, their photochemical properties are not sufficient to 
image single aggregates with the proposed method.  




Figure 14  The data of 3 technical repeats for each data point of ThT (green), Di-ThT (yellow) 
and DCVJ (orange) are shown. All graphs show the readout as a function of dye concentration. 
(A) shows the aggregate density without false positive correction. (B) shows the density of detected 
‘aggregate’ in the absence of protein, a measure of the false positive rate. (C) The mean SBR is 
calculated by fitting each cumulative histogram of each reapeat with a lognormal function as it bests 
represents the distribution. The SBR is calculated for each aggregate individually between the peak 
intensity and the surrounding pixels (D) The Intensities have also been fitted with a lognormal 
function as described for the SBR. At very low concentrations the fitting failed and is hence not 
displayed, as almost no aggregates were detected to start with. 
To compare binding affinities the binding curves have been normalised after 
fitting (Figure 15 A) with midpoint and saturation point. Fitted to a sigmoidal curve 
the half point is 1.1±0.3 μM, 0.1±86 μM and 6.3±0.4 μM for ThT, DiThT and DCVJ 
respectively. The higher binding affinity of the ThT-Dimer is probably due to its 
dimeric structure. DiThT shows the highest affinity to αS with ThT about 10-fold 
lower and DCVJ even lower. I distinguish two types of ‘background’: (1) SBR 
background as a function of signal strength to amorphous background noise which 




shows how sensitive the dye is, if an aggregate is present and (2) false positive 
background for dye molecules giving false positive signals, when no αS aggregates are 
present. The SBR is calculated locally for each fitted maximum and is hence not 
susceptible to changes in the overall illumination of the TIRF field. The false positive 
background for both ThT and DiThT does not increase at higher concentrations and 
stays consistently low over the whole range (Figure 14 B). However, the false positive 
background of DCVJ is significant above ~10 μM (Figure 14 B). There is an overall 
trend of increased SBR as function of aggregate density but there is no clear optimum 
(Figure 14 C). The optimal dye concentration for imaging is hence largely dominated 
by two factors. The low limit of the dye concentration is determined by the detection 
of the aggregates while the upper limit is determined by the increasing amounts of false 
positives. The mean intensity is fairly constant with an increase at higher dye 
concentrations with the high deviations make interpretation difficult. The exception 
here is DCVJ where the increase in false positives is matched by a decreased in 
intensity. This suggest that the false positives are bright enough to be above threshold 
but with overall low intensity and start dominating in presence over the aggregates. 
For above absolute signal intensity and the SBR ratio the histogram of the 
intensity for each set of data at a given concentration of dye was fitted to a lognormal 
distribution and is plotted in Figure 14 C, D. The photon count of the three lognormal 
fits was calculated using Equation 1 using values as stated in the Table 2 section.  
  




Figure 15  (The binding affinity for Di-ThT-PEG2 (yellow), ThT (green) and DCVJ (orange) 
fitted to a sigmoidal dose response normalised to its maximum density. Each point is the mean of 
at least three biological repeats each consisting of 27 recorded field of views (11x10³ μm²) with the 
standard deviation of each repeat as error. (B) The average density and as a function of protein 
concentration after 22h aggregation at fixed dye concentration of 10 µM ThT (yelow line) and 1 
µM Di-ThT-PEG2 (green line). Each density value is the average of 27 field of views. 
Representative image data for the various concentration is shown below. The square is a sample 
for a monomer concentration of 1E-4 µM and the triangle for 100 µM. The density is equal to the 
background density and therefore not included in the plot. 
Comparing the density of detected aggregates at the same protein concentration 
the saturation for ThT and DiThT is in the same regime indicating that neither detects 
more aggregates above its Kd. DCVJ though has a higher saturation density. This is 
due to increasing false positive events as shown in Figure 14 A, B. This could be caused 
by precipitation or micelle formation of the dye in the aqueous solution or unspecific 
binding to the PLL- coated surface. 
Changing the protein concentration over with fixed dye concentration can give us 
insight into relative detection limits. As shown in Horrocks et al. [77] with an enriched 
oligomer concentration the lower detection limit for these is 10 pM. In our case to 
compare ThT and DiThT I chose to aggregate αS to a mostly oligomeric state without 
specifying the oligomer concentration. Both dyes show a linear relation between the 
density and the protein concentration with DiThT appearing to be slightly more 
sensitive. At very high protein concentration the individual signals cannot be separated 
anymore. (Figure 15).  




Sample handling procedures 
I also tested the effect of the standardised spinning of the CSF samples post 
lumbar puncture and whether the freezing of the samples for storage has an effect on 
the outcome of our method. The centrifugation is a standard procedure to ensure no 
cells in the samples from piercing the skin before taking the sample.  
Prior to assay development a variety of controls were examined to exclude effects 
of the CSF sample preparation, processing and storage. CSF samples are obtained via 
lumbar puncture done by a trained clinician on the patient. In most cases the samples 
get subsequently centrifuged at 2000- 3000 g for 10-15 mins to remove cell debris and 
blood contamination. The samples get frozen on dry ice or flash frozen in liquid 
nitrogen and stored at –80°C. As the SAVE method is able to detect and distinguish 
different macromolecular structures and not only protein abundancies it was crucial 
for us to control for preservation of these. There has been evidence that freeze-thaw 
cycles can generate smaller size amyloid fibers and that storage conditions alter 
biomarker results [240-242]. To avoid biasing our results by generating smaller fibril 
fragments through freeze thaw cycles a fresh CSF sample (appr. 30min to 1h post 
spinal tap) was used to measure the effect. This was compared to the same sample 
frozen in liquid nitrogen and analysed later. No appreciable difference was observed 
in the oligomer count but the results show a small reduction of aggregates overall 
(Figure 16).  
Figure 16  SAVE imaging of a fresh and a frozen CSF sample. The mean of 27 field of views 
with the standard deviation as error shown. The overall aggregate count is reduced due to the freeze 
thaw cycle, but the change is overall small. It appears as if the non-diffraction limited fibrils are 
affected more strongly. 
This effect might be smaller than in an AD sample, as the sample was from a 
patient with no diagnosed AD or PD and is therefore probably not showing the same 
amount of oligomers and fibrils as it would in the case of a PD or AD patient. 




However, to allow for aliquoting samples for multiple repeats we kept one freeze-thaw 
step in any further sample handling and avoided subsequent freeze-thaw cycles.   




Figure 17  Comparison of different centrifuged and non-centrifuged CSF samples. (A) The 
normalised spot count is shown with the normalised mean of 3 repeats with 27 fov each with the 
standard deviation of as error. No depletion of one or the other species can be observed. (B) A 
histogram of the intensities shows now particular influence on large or small aggregates. The 
intensities from all three repeats are binned. (C) The aggregate density difference of a different set 
of deidentified patients. Each bar is the difference of centrifuged vs non-centrifuged of one repeat 
with 27 field of views with the error bar the higher standard deviation of the two values. Again, no 
clear influence of the centrifugation can be observed. 
To examine the influence of spinning, a frozen unspun sample from a single 
sample out of a PD cohort and a set of AD patient samples was used. The SAVE 
technique was applied, and results are shown in (Figure 17). There was no clear trend 
in the sample set of the AD cohort. All samples have been de-identified for research 
use and then divided into spun at 2000 g for 10 min at 4°C and unspun. The results 
are comparable for the PD sample with the speed slightly higher at 3000 g for 10 min 
at 20°C. A closer look at the intensity distribution to account for depletion of larger 
species did not give a difference either. The speed of the centrifugation seems to be 
low enough to not bias the results in our technique. These finding suggest that the 
sample procedure is not affecting the SAVE technique in its present form. Therefore, 
it is necessary to develop further parameters to get a better and predictive distinction 
of both PD and especially AD CSF samples.  
In both cases however it was not possible for us to access fresh and non-
centrifuged confirmed AD or PD CSF. It is conceivable that the presence of ThT-
positive aggregates was overall different in the tested CSF samples. Furthermore, as 




the patients required a spinal tap to analyse their CSF they are most probably in 
treatment for some form of neurological disorder which could potentially influence 
the outcome of the experiments. Nonetheless within the given circumstances it 
appears that neither the mild centrifugation nor the storage at -80°C affect the outcome 
of the SAVE measurements. 
  




4.2.2 SAVE to search for AD biomarkers in CSF 
After the SAVE method was used and assessed for αS we tried to establish if this 
method could be readily applied to CSF samples from AD patients. ThT is known to 
bind to Aβ protein as it exhibits the same extended beta-sheet structures that required 
for fluorescent enhancement of the dye. The hypothesis was that if there was a 
difference in the number of amyloid aggregates in the CSF we should be able to detect 
that difference. We measured a sample cohort of overall 37 samples with a clinical 
diagnosis of AD or as HC. All AD positive samples had protein levels of Aβ1-42 < 
600 ng/L, T-tau > 350 ng/L and P-tau181 > 80 ng/L according to Toledo et al. [243]. 
The details (protein levels, gender, age) of the cohort patients are listed in (Table 3). 
The SAVE analysis showed however no statistically significant difference between the 
two sample cohorts (Figure 18) in contrast to the results in PD (Figure 10) [77]. Neither 
the number of the aggregates nor their intensity changed significantly (Figure 18 A, 
Figure 19). I measured overall 37 samples with 18 in the AD cohort and 19 in the HC 
cohort. Even when comparing the mean number of aggregates in each sample the 
difference is not sufficiently significant.  
Figure 18  (A) Comparison between AD CSF samples (red) and HC CSF samples measured 
with the SAVE technique. The mean line is shown with 25 and 75 percentile and the error bar 
showing the SD of each cohort. ANOVA test shows no significance with p = 0.1237 between the 
18 and 19 samples in each cohort. (B) A ROC curve in green with the random chance line in grey 
is shown comparing the AD and HC cohort. The area under the curve is 0.635 which means the 
test is overall poor in discriminating AD from HC patients. 
ROC curves are frequently used to assess the diagnostic power of clinical test. Figure 
18 B shows the ROC curve for the AD and HC dataset. The further the line moves to 
the upper left the better the specificity and sensitivity of the test to distinguish AD 
from HC. In my case the curve deviates from the diagonal line which is equivalent to 
complete randomness only very little. This means the test is not suitable to distinguish 
samples in the cohorts. Horrocks et al. furthermore observed a shift in the intensities 




in the case of the αS aggregates [77]. The cumulative histogram of the intensities of all 
the detected aggregates shows a small deviation (Figure 19).  
Figure 19  The cumulative frequency histograms of the AD (red) and HC (green) cohort is 
shown as a function of Intensities. The shape of the curve is mostly very similar with only a small 
deviation in the mid region. 
To test whether this shift was sufficient to improve distinction between AD and 
HC improves I picked a randomly selected subset of samples with varying thresholds. 
(Figure 20 A) shows the box plot of all aggregate intensities of the ten-patient subset. 
The selected thresholds are indicated vertical bars. (Figure 20 B) shows the resulting 
mean intensities of the subsets selected via the indicated thresholds showing now 
improvement over the comparison of the number of aggregates. These findings 
however lead on to further studies in chapter 4.2.3. I go on to study structural 
properties of aggregates in human CSF under the effect of various antibodies and this 
is complemented by means of Ca2+ influx measurements. 
A possible explanation of the same level of detected ThT-active aggregates which 
I find in the AD and HC CSF could be the fact that AD has a mixture of aggregates 
present throughout the disease. It has been shown with ELISA that the levels of total 
Aβ42, Aβ40 and tau develop nonlinearly throughout the disease [207]. In this cohort the 
threshold for determining disease was defined by the results of the ELISA. These 
ELISA tests, even though they can predict disease progression, do not take into 
account clinical diagnosis and some of the HC cohort might still develop AD or other 
neurodegenerative diseases further down the line. The results could also be influenced 
by bias in protein levels due to e.g. tauopathies that clinically would not develop into  
 




Figure 20  (A) Box plot of individual peak intensities for a set of 5 sample each to specifically 
test various intensity thresholds to distinguish AD from HC. The box shows the 25 and 75% 
percentile with the mean line and standard deviation indicated by the bars. (B) Comparison between 
the indicated thresholds counting aggregates above the respective intensity thresholds. The box 
represents the mean between all 5 samples with the standard deviation as error and the result of 
the students t-test indicated above each comparison. 
AD but would still show increased tau levels. Together these factors could all 
contribute to the result that SAVE is not suitable as a tool to predict or diagnose AD. 
  




Table 3  Overview of all measured AD (red) and HC (green) CSF samples with the mean 
aggregate density and the standard deviation of all 27 field of views and the corresponding ELISA 




Std Dev Tau ng/L Aβ ng/L Ptau ng/L Age Gender 
AD/HC   >350 <600 >80   
390d 6.678 3.973 1180 290 117 77 M 
542b 14.357 8.578 984 556 88 75 F 
548b 10.285 8.995 1360 505 137 64 F 
554b 20.071 16.628 982 553 112 80 F 
557b 2.178 2.464 835 491 90 82 F 
708c 13.678 6.279 703 562 85 71 F 
715c 15.857 11.407 778 330 80 72 M 
720c 9.035 4.039 750 392 90 75 F 
722c 5.892 4.279 518 334 91 77 M 
731c 9.107 5.122 780 546 94 20 F 
734c 24.321 21.840 974 515 87 75 M 
757c 16.642 13.583 873 234 88 63 F 
788c 14.607 11.802 984 556 88 75 F 
800c 12.571 5.659 1310 532 143 82 M 
830c 7.285 5.450 826 591 167 52 F 
865c 12.892 11.902 720 508 104 72 F 
872c 15.250 8.420 768 522 102 85 F 
884c 4.357 4.638 1200 315 165 59 F 
883c 12.428 6.613 193 758 33 70 M 
537d 11.500 5.261 297 716 35 65 M 
547c 10.000 6.546 329 1250 53 78 M 
552c 15.107 11.505 264 617 50 68 F 
554c 9.428 6.945 324 809 43 69 M 
571c 17.642 17.489 332 678 46 62 M 
750c 18.928 8.119 283 1050 39 69 M 
768c 18.464 8.865 115 691 38 77 M 
777c 13.321 7.474 214 877 36 78 M 
809c 14.392 7.422 130 729 28 69 F 
812a 15.392 8.234 106 789 21 62 F 
815a 11.785 5.459 266 698 31 73 F 
820a 5.107 4.065 134 675 27 60 M 
821c 14.607 8.269 250 847 42 70 F 
823c 41.214 52.212 120 923 25 68 F 
842c 10.035 5.984 253 860 46 73 M 
847c 21.678 15.264 303 977 49 73 M 
870c 13.321 8.477 263 706 40 64 F 
879c 17.892 17.475 188 604 31 82 F 
  




Expansion of SAVE via a clusterin competition assay 
The extracellular chaperone clusterin binds to oligomeric Aβ42 aggregates with 
high affinity. Recent findings suggest that the molecular chaperon clusterin can help 
preventing cell toxic effects of Aβ aggregates [120]. Clusterin or Apolipoprotein J is a 
multifunctional disulfide linked heterodimeric glycoprotein composed of two 40 kDa 
subunits [244]. The CLU gene locus was associated to AD in genome wide studies [245,246]. 
It has been shown that the extracellular Clusterin sequesters oligomeric forms of the 
Aβ40 peptide in long lived stable complexes suppressing Aβ40 aggregation with a 
similar binding occurring for Aβ42 [247]. Furthermore clinical studies confirmed a 
potentially important role for clusterin in the earliest stages of the AD 
neurodegenerative process and suggest independent effects of clusterin and p-tau on 
Aβ-associated atrophy rate of the entorhinal cortex and hippocampus [248].  
The underlying rationale for the competition assay is the observation, that 
clusterin binds to oligomeric amyloid proteins such as αS oligomers [249]. It bound to 
αS aggregate already at sub-stochiometric ratios. At low clusterin: substrate ratios the 
amyloid formation was increased while high clusterin: substrate inhibited amyloid 
formation [249].The following in vitro data suggest a possibility of the use of fluorescently 
labelled clusterin in a competition assay as a probe to explore αS - clusterin interactions 
in CSF. To test this hypothesis, I used αS oligomers and pre-incubated them with 
varying concentrations of clusterin. I then added a fixed concentration of 1.5 nM 
Figure 1  Co-localisation competition with fluorescently labelled Clusterin and unlabelled 
Clusterin binding to αS Oligomers. The left graph shows the percentage co-localisation based on 
ThT with the concentration of the pre-incubated Clusterin given on the x-axis. Each point is the 
mean of three experiments each with 27 field of views and the error is the standard deviation of 
the mean. The data is fitted to a sigmoidal dose response function with an EC50 of 3.21 x 10-6 ± 
0.40 x 10-6 μM with an r2 of 0.91 for the fit. The right hand shows the dashed area with same data 
on a logarithmic scale.  




AF647 labelled clusterin and analysed the colocalisation with the ThT active 
aggregates.  
The difference in co-localisation could be used in addition to the density of the 
ThT active oligomers to improve diagnostics. Figure 21 shows the differences of co-
localisation dependent on the added amount of unlabelled wild-type clusterin with 
unchanged amount of labelled clusterin. The translation of this principle into CSF 
could potentially distinguish differences yet undetected by the current method by 
adding an additional parameter. CSF clusterin has been associated with PD, but the 
results are unclear to how they are linked [250-254]. With the proposed method I could 
detect if in the PD case more clusterin was associated with the oligomers and vice versa 
even if the overall aggregate yield was equal depending on the co-localisation rate. The 
combination of SAVE and clusterin colocalisation can help understand aggregates in 
our PD and HC CSF samples and possibly improve diagnostics. This system has not 
been further explored however as I have focused my efforts on detailing more of the 
structure of the Ca2+ inducing aggregates in human CSF of AD patients as described 
in the following chapter.   




4.2.3 Structural Effects of Antibodies on Aβ42 aggregates 
The development of new therapeutic antibodies led to the prominent and 
promising candidate Bapineuzumab developed by MedImmune which failed in Phase 
III clinical trials [255,256]. One of key questions was, why an antibody against Aβ 
aggregates which are linked to the disease was not successful. A therapeutic strategy in 
AD is to target the small soluble protein aggregates, in particular in the case of Aβ42, 
to reduce their toxic effect. A lack of understanding of the precise composition and 
structure of the aggregates in vivo makes this however a challenging task. We suggest 
that the combination of a single vesicle and single cell based ultrasensitive 
measurement of calcium influx and single aggregate imaging can help preclinical tests 
with aggregates that resemble more closely the in vivo situation. I will describe the assays 
we use briefly. Importantly all assays use very little sample volume (<10 ul) which 
makes it possible to measure, compare and screen with the precious resource of the 
human CSF. This all makes it as suitable approach to characterise potential therapeutic 
agents in CSF.  
A discussed earlier the small soluble aggregates are a potential target for treatment. 
Especially aggregates for human sources are of interest. Isolated aggregates from 
human sources such as the soluble fraction of brain homogenates have been used [29,257]. 
The preparative steps involved however could alter the properties of the notoriously 
transient aggregates. The suggested methods do not involve preparative steps but use 
the CSF directly in the assay. There have been few other experiments involving CSF 
without further preparative steps, namely by Klyubin and Walsh showing that 
aggregates in CSF can induce long-term potentiation deficits in brain slices which can 
be suppressed by antibody addition [257,258]. CSF is suitable as a representation of the 
extracellular processes in the brain as it freely exchanges in with interstitial fluid 
surrounding the brain. It has also been shown that AD CSF can cause cell death, which 
was reduced by the addition of extracellular chaperones [259].  
We have shown that picomolar levels of Aβ oligomers can induce Ca2+ influx into 
neuronal cells by local dosing via a nanopipette and via a quantitatively measuring the 
Ca2+ influx into vesicles [260]. As I showed previously we can image single aggregates of 
amyloid beta with the SAVE method. With these methods I will characterise the 
protein aggregates present in the CSF of AD patients and control individuals. I 




furthermore test the effectiveness of a single chain nanobody raised against amyloid 
beta Nb3, clusterin and the antibody bapineuzumab and their effects on the aggregates. 
The structural characterisation was done in parallel with a high-throughput Ca2+ 
influx assay and a single cell Ca2+ influx assay. I will include the results of the two assays 
as part of the integrated research to complete the story but will focus on my own work. 
regarding the structural changes. 
Figure 22  (A) Schematic of the vesice assay to measure Ca2+ influx due to AD and HC CSF. 
POPC vesicle filled with the calcium sensitive dye Cal-520 are tethered to the surface of a glass 
coverslide. Upon addition of addition of the sample (Aβ or CSF) the increase in fluorescence can 
be observed due to the Ca2+ in the surrounding buffer solution entering the vesicle. The addition 
of an ionophore allows the normalisation of each individual vesicle signal and hence a quantitative 
measurement. (B) No significant difference in the Ca2+ influx due to AD and HC CSF is observed. 
Full statistical details can be found in Table 4. 
The starting point was the measurement of Ca2+ influx with the high throughput 
vesicle assay induced by AD CSF and HC CSF. There was no significant difference 
between the samples (Figure 22). The ultrasensitive measurement of calcium into 
vesicles is achieved by tethering POPC vesicles filled with the Ca2+ sensitive dye Cal-
520 via a biotin-neutravidin interaction to a glass surface. These are spaced in a way 
that each vesicle can be detected individually on a high resolution TIRF microscope. 
The surrounding medium contains Ca2+ which can be detected when membrane 
disruption or perturbation due to amyloid aggregates leads to Ca2+ influx. After 
addition of an ionophore the maximum intensity of each fluorescence signal in each 
vesicle is determined to allow for a quantitative measure of the Ca2+ influx. This 
method allows detection of aggregates at very low concentration with the use of 
minimal amount of sample per measurement (<10 ul) [92].  
 




Figure 23  Comparison of the number of aggregates found in the AD CSF patients and HC 
CSF patients used in the vesicle and Ca2+ assay. The difference in the number of aggregates is not 
significant. The mean line with the standard deviation as error is shown. 5 of the AD CSF samples 
of this cohort were measured by Dr. D. Whiten. 
Secondly, the SAVE imaging with ThT showed no difference in the number of 
ThT-active aggregates (Figure 23). This is consistent with the findings described in 
chapter 4.2.2. These findings suggest that a similar number of aggregates in AD and 
HC CSF cause the Ca2+ influx. The results are also consistent with previous findings 
with aggregate specific ELISA-based detection. These neither detected a clear 
difference between AD CSF and control CSF [136,261].  
Figure 24  (A) Schematic of the SICM experiment to measure Ca2+ influx into astrocytes with 
the Ca2+ sensitive dye Fluo-4 and the use of a nanopipette to deliver the aggregates locally (Aβ or 
CSF). The astrocytes are filled with the Ca2+ sensitive dye Fluo-4 and surrounded by a Ca2+ 
containing bath solution. Upon delivery of the sample the increase in fluorescence is measured 
with a highly sensitive TIRF microscope. (B) The total integrated Ca2+ signal after addition of both 
AD and HC CSF does not show a significant difference in the cell assay. Full statistical details can 
be found in Table 5 
A SICM setup with a nanopipette dispensing the CSF onto single cells was used 
to measure the calcium influx into astrocytes as described previously [260] (Figure 24 A). 
In this technique local dosing reduces the diffusion time to the cell surface, leading to 
detectable Ca2+ influx at low picomolar concentration. For the directed delivery of the 
CSF onto cells we use a nanopipette setup as described before [260]. A SICM setup is 
used to control the distance of a nanopipette over the surface of a cell (Figure 24 A). 




The delivery of the reagents has previously been measured and modelled [262]. The 
sample is delivered to a surface area of about 1 µm2 with a distance of the pipette of 
about 300 nm above the cell. The cells are filled with the Ca2+ reporter dye fluo-4 and 
the bath solution is filled with Ca2+, to report any Ca2+ influx. This method allows the 
aggregates and CSF respectively to be delivered on small surface area, but the small 
cell to tip distance also reduces the diffusion distance for the aggregates before they 
reach the cells. This increases the local flux of the aggregates. This setup allows us to 
very sensitively measure the Ca2+ influx, in this case in to astrocytes, which reflect a 
realistic cell membrane in comparison to the POPC vesicles. Again, we did not see a 
significant difference in AD and HC but in both cases Ca2+ influx was observed (Figure 
24 B).  
After establishing the baseline for the Ca2+ influx the techniques helped to 
characterise the nature of the aggregates present in CSF. We tested the effectiveness 
of a single chain nanobody against Aβ, the extracellular chaperon clusterin and 
bapineuzumab.  
I tested bapineuzumab biochemically for binding to Aβ aggregates with a dot-blot 
and a labelled anti-human secondary antibody (Figure 25). This confirms that the 
antibody used are all native and binding to the aggregates. The Nb3 testing is not 
shown as this was done by Erwin DeGenst and clusterin binding was confirmed in 
previous studies of the same batch. 




Figure 25  Dot-blot of bapineuzumab and the control IgG antibody compared at increasing 
concentrations of Aβ42 aggregates with the monomer concentration shown. There is a clear 
concertation dependent increase in the known binder bapineuzumab, whereas the control antibody 
is not binding to the Aβ42 aggregates. The control is an empty buffer only control. 
As described earlier, there was no difference in the Ca2+ influx between the 
different CSF samples and no difference in the number of ThT-active species (Figure 
23). This is in agreement with aggregate specific ELISA-based detections [136,261]. This 
suggests that the number of aggregates causing the Ca2+ influx is comparable. 
To identify if there is a qualitative difference in the aggregates we added the 
extracellular chaperon clusterin to the CSF prior to our measurements. The 
extracellular chaperones that can reduce the toxicity of CSF and has been shown to 
bind to misfolded and aggregated proteins. As described earlier clusterin has been 
shown to bind Aβ42 oligomers at sub-stochiometric concentrations [249,259]. Clusterin 
can bind to oligomers in multiples and it can decrease the Ca2+ influx into single 
vesicles [92,118,247]. The affinity of clusterin for the oligomers of Aβ is very high as only 
100 pM of clusterin halved the Ca2+ influx in the vesicle assay [92].  
Clusterin suppressed the Ca2+ influx in both the vesicle assay and the cell assay. 
This suggests that the influx is indeed caused by protein aggregates. Clusterin is already 
present in the CSF with concentrations of about 90 nM both in HC and AD [263]. This 
implies that the concentration of clusterin is not high enough in the CSF which agrees 
with reports of toxicity reducing effects of high clusterin concentration [259].  




The next step was to use a Aβ42 specific single-chain nanobody Nb3 to see if we 
could reduce the effect Aβ specific. This nanobody was raised against the Aβ peptide 
binding to the epitope 17-28 with a measured dissociation constant to the monomer 
of 13 nM. The CSF samples were pre-incubated with 150 nM Nb3 for 15 min prior to 
the experiment. For recombinant Aβ42 oligomers approximately 18 nM was needed 
to half Ca2+ influx [92]. The same Ca2+ reducing effect with synthetic Aβ42 aggregates 
was found in the cell assay [260].  
Figure 26  Assessing the structural changes of the ThT-active aggregates with SAVE upon 
addition of bapineuzumab and Nb3 on synthetic Aβ42 and AD CSF. An aggregated solution of 
1 µM total Aβ42 monomer concentration was incubated with 150 nM of each antibody for 15 min 
and aggregates were counted as described previously. Each bar represents the mean of 3 slides with 
27 field of views overall imaging a 3 x 106 μm2 area. Error bars represent the standard error of the 
mean of all 27 field of views (B) The effect of the antibodies on the number of ThT positive 
aggregates in human CSF. The mean of 4 samples with 27 field of views each with the error bars 
representing the standard error of the mean of all samples. Full statistical details are in Table 6. 
 
  




After testing the effects of clusterin and Nb3 I went on to test the efficacy of 
bapineuzumab. The bivalent humanised antibody that was tested to bind soluble Aβ 
monomer and oligomers at the N-terminus [264]. However, the phase 3 trials did not 
show any clinical outcome in AD patients [255,256,265]. There are many possible 
explanations why the trials might have failed. One of the most agreed ones are, that 
the passive immunisation might have occurred to late in the disease, that the effective 
doses were to low and that the disease relevant species might not have been targeted 
adequately. Especially the two last points are the ones that we will investigate further 
with our proposed methods. 
150 nM bapineuzumab caused a relative decrease of 70% in Ca2+ influx and 1 µM 
reduced it completely with recombinant Aβ oligomers. It was also effective in 
preventing the Ca2+ influx in the cell assay. The concentration of bapineuzumab did 
not detectably alter the number of ThT-active species with recombinant Aβ oligomers 
(Figure 26 A) or with AD CSF (Figure 26 B). This indicates no significant change in 
the number of β-sheet containing species within the timescale of our experiments. 
When AD CSF samples instead of recombinant Aβ oligomers were used with an 
antibody concentration of 150 nM the Ca2+ influx was decreased insignificantly by 
~12% for both AD and HC (Table 4). An increase of the bapineuzumab concentration 
to 1 µM caused a relative decrease of ~75% in the vesicle assay (Table 4), but no 
significant reduction in the cell assay at either antibody concentration. Bapineuzumabs 
lack of reduction, even at high concentrations, could be explained by different affinities 
or interactions between the cell membrane and the oligomers in contrast to the POPC 
vesicle. The results show that higher bapineuzumab concentrations are needed to 
reduce the extent of Ca2+ influx caused by human CSF compared to synthetic Aβ42 
oligomers in buffer solution. 
In addition to the SAVE technique, I also tested bapineuzumab and Nb3 in a 
smFRET experiment to see if the antibodies potentially change features of the 
aggregates that are undetected with SAVE. According to the previous tests I 
aggregated dual-labelled co-aggregates and incubated them for 24 h and 48 h with a 
humanised IgG, bapineuzumab, Nb3 and no antibody and measured before addition 
and at both timepoints. The first aspect tested with this method was, whether the 
fraction of the aggregates goes down over time as a function of the presence of the 
antibodies. The smFRET technique is more sensitive towards small aggregates and 




hence might show differences in the non ThT active populations. Despite the 
increased sensitivity no significant difference was in the number of aggregates due to 
the presence of the antibodies (Figure 27 B). The consistent number of donors shows 
that no effect is masked by depletion of aggregates out of the mixture (Figure 27 A). 
This was further confirmed with the fraction of oligomers not changing either, 
meaning the equilibrium is not shifted (Figure 27 C). Again, if we normalise the 
aggregates and look at the fold reduction between the time intervals there is no 
significant reduction (Figure 27 D). Finally, there is no difference in the aggregate 
reduction comparing Nb3 and bapineuzumab to IgG. 
Figure 27  The effect of various antibodies on dual-labelled co-aggregates tested with 
smFRET at 24 h and 48 h after addition is shown. As indicated in (A) all three independent repeats 
are shown with the 25 and 75 percentiles as box, the median line and mean as small squares and 
the standard deviation of the mean as error. (A) The effect of the antibodies on the donor count is 
shown and to show that no donor depletion is causing any effects. In red (mock) only buffer is 
added to the aggregates; in blue the addition of a humanised anti IgG control antibody is plotted; 
in yellow bapineuzumab and in green Nb3. (B) The aggregate count of all FRET positive oligomers 
is plotted. (C) The percentage of oligomers as a function of FRET positive aggregates over the 
number of donor events is shown. (D) The fold reduction of FRET active aggregates over the first 
and second 24 h interval is shown. The reduction in aggregates is not significant, neither within the 
individual samples, nor compared to the IgG control. 




Even though I am not detecting changes in the number of aggregates with the 
smFRET method I can still get insight into the FRET efficiencies within the aggregates 
and hence look for structural changes. To analyse the structural changes upon addition 
of the antibodies I used the FRET efficiencies measured and compared them between 
the various incubation periods and antibodies.  
The FRET histograms of one repeat is plotted as an example for the underlying 
data for the subsequent fitting (Figure 28). All histograms were fitted, with all r2 below 
0.9 and are plotted (Figure 29). There is no significant change in the FRET efficiency 
and hence the structure of the aggregates under these conditions. 
Figure 28  Example histograms of the FRET efficiency change over time for the various 
antibodies. The FRET efficiencies are shown as a function of time: before incubation with antibody 
(grey), after 24h (red) and after 48h (blue) with (A) the mock buffer only, (B) 1 µM of an unspecific 
human backbone anti-IgG antibody, (C) 1 µM bapineuzumab and (D) 1 µM Nb3. 
I can therefore conclude, that any beneficial effects are due to binding to the 
aggregates and subsequently masking any potential harmful surfaces of the aggregates.  




Figure 29  The mean FRET efficiencies as fitted to the histograms. (A) The result of the 
gaussian fitting of the histograms with all three repeats shown as data-points (B) FWHM to show 
the homogeneity of the population. 
Possible explanations for the reduced effectiveness of the inhibition of the Ca2+ 
influx caused by human CSF include (1) reduction in the effectiveness of binding of 
the antibody to the oligomer due to molecular crowding and non-specific binding; (2) 
morphological changes between Aβ oligomer in CSF to the synthetic ones used in the 
in vitro case; (3) post-translational modification could be present in Aβ oligomers in the 
CSF, rendering them inaccessible or not recognisable to the antibody while still causing 
Ca2+ influx. Any combination of these effects could cause the observed effects and 
hence bapineuzumab is less effective in human CSF. 
Finally, I used an IP setup with Nb3 and BSA as control attached to magnetic 
beads to probe for the specificity of the Ca2+ influx effect. The depletion of Aβ42 due 
to the interaction with Nb3 should lead to a decrease in the number of ThT-active 
species and to a drop in the Ca2+ influx in our vesicle assay. This assumes the epitope 
is readily accessible and the Nb3 binding surface is available after binding to the 
oligomers. The magnetic beads with the streptavidin-biotin linker should allow for 
sufficient accessibility of the Nb3 epitope. After an incubation time equivalent to the 
previous experiments I removed the beads out of the CSF solution. The resulting 
SAVE and vesicle assay measurements are shown (Figure 30) 




Figure 30  IP pull-down test to test the specific depletion of aggregates with the Aβ42 specific 
Nb3 and BSA as control immobilised on Dynabeads. (A) SAVE imaging of two CSF samples (CSF 
6, CSF 7) before the IP procedure after incubation with Nb3 and BSA coated beads respectively. 
The datapoints show the aggregate counts per field of view for 27 imaged. The box shows the 25 
and 75% percentile, the mean line and the error bar is the standard deviation. (B) The Ca2+ influx 
of the same samples was measured with the vesicle assay showing the mean Ca2+ influx with 
standard error as error bars.  
With the SAVE imaging I observe a slight drop in the number of aggregates in 
the CSF after the IP step. This is consistent with a drop of toxicity in the vesicle assay. 
However, the difference between the Nb3 coated and BSA coated beads is not 
significant highlighting a common problem with these experiments. I believe that the 
observation might be a result of the unspecific binding of the aggregates to the bead, 
due to the hydrophobic nature of the aggregates. That means the aggregates are 
depleted out of solution by either the bead surface or hydrophobic interaction with 
BSA. I can confirm a decrease in toxicity due to the incubation suggesting it is indeed 
the Aβ42 aggregates. The reduction by adding antibodies in solution shows that they 
are Aβ42 containing.  




Table 4  Full statistical details of the single vesicle assay presented in the indicated figures above. 
Single Vesicle Assay 
Figure Sample Number Number of p Value 
  of vesicles CSF samples  
Figure 
22 B 
AD 4906 5 
0.44 
HC 4602 5 
 
Table 5 Full statistical details of the cell assay presented in the indicated figures above 
Cell Assay 
Figure Sample Areas  Number of p Value 
  per sample CSF samples  
 B 
AD 33 6 
0.30 
HC 65 9 
 
Table 6  Full statistical details of the single aggregate imaging presented in the indicated figures 
above 
Single Aggregate Imaging 
Figure Sample Areas  Number of p Value 
  per sample CSF samples  
Figure 
23 B 
AD 27 19 
0.49 
HC 27 12 
Figure 
26 A 
Aβ42 27 N/A 
0.70 
Aβ42 + BAPI 27 N/A 
Figure 
26 A 
Aβ42 27 N/A 
0.07 
Aβ42 + Nb3 27 N/A 
Figure 
26 B 
CSF 27 4 
0.62 
CSF + 150 nM BAPI 27 4 
Figure 
26 B 
CSF 27 4 





CSF 27 4 
0.73 
CSF + 150 nM Nb3 27 4 
  




4.3 Outlook and Discussion on methods using CSF  
I demonstrated that above assays, both the SAVE and the vesicle assay, can be 
useful to understand the molecular mechanisms of PD and AD. The SAVE technique 
has some obvious limitations, most importantly it only binds to beta-sheet structures. 
This is obviously specific for amyloid aggregates, but it is not specific to subtypes of 
aggregates made from different monomers such as Aβ42 or αS. This also means we 
cannot measure non-ß-sheet containing aggregates which might be more neurotoxic. 
SAVE can however still complement other techniques. Especially in the case of PD 
there seems to be a better relation between the number of aggregates in the CSF and 
with disease progression. It is imaginable that multiplexing with e.g. various 
extrinsically fluorescent dyes with specific binding sites or a combination of ThT or 
ThT-like dyes and antibodies could help expand the information content we could gain 
from imaging aggregates in CSF. 
Similarly, techniques that use other targeting molecules such as clusterin and 
explore competition or other interactions of amyloid aggregates on single molecule 
level could help in deciphering the molecular mechanisms of the neurotoxicity. This 
has been briefly explored and has potential to be developed into a high-throughput 
method. This would ideally be paired with a second parameter as clusterin, as a 
chaperone, is not sequence specific for e.g. Aβ42 or αS. 
The presented research lets me conclude that SAVE can be a useful tool in 
studying PD and AD alike. I have optimised the conditions for SAVE imaging showing 
that can be extended to other dyes such as DCVJ and DiThT which has a higher 
affinity for the aS aggregates. All this provides useful knowledge to select adequate 
dyes and concentrations in SAVE imaging. However, SAVE was not readily 
transferable to AD in the sense that the difference seen in PD patients was not 
observed in AD. Despite this limitation the technique is still useful in understanding 
aggregates in CSF. It allows us to specifically and compare effects of other proteins 
towards the aggregates in CSF. Crucially the exact composition and interaction of these 
amyloid aggregates, be it in PD or AD, might be different from the in vitro aggregates. 
This is where ongoing efforts towards IP procedures coupled with mass spectrometry 
come into play. The use of immobilised bait structures using the same binding 
properties as ThT and DiThT should allow to decipher these structures. The specificity 
to the ß-sheet structure motif and not a sequence specific motif could help understand 




the composition of the ThT active aggregates detected in SAVE and potentially 
improve the method. 
Optical methods have been developed too, to further improve the SAVE based 
toolbox. Namely the optical structural analysis of individual α‐Synuclein oligomers 
developed by Varela and colleagues [266]. This method utilises the polarisation direction 
of the light to decipher the structural properties if the binding entity. Beta-sheet 
structures are highly ordered a in consequence their binding sites for ThT too. 
Oligomers in contrast are amorphous and hence have not the same properties. This 
allows for an optical distinction of the emission light via the polarisation of the emitted 
fluorescence. This can then be applied to both in vitro and in situ samples such as PD 
CSF. 
With the right assays we might not be able to check for distinct biomarkers 
immediately, but we might be able to show the effectiveness of antibodies to various 
targets. This in turn helps us understand antibody binding better leading to a positive 
feedback loop. The above presented techniques are, as suggested, very useful in testing 
potential antibodies directly in human CSF too. Especially the vesicle assay can be used 
as a high-throughput method to readily assess capabilities of antibodies. It can also be 
used for the direct comparison of such as it is possible to generate binding affinity 
values for oligomers.  
With the mechanisms by which amyloid aggregates cause toxic effects and 
neuronal cell death still under investigation, above methods are even more powerful. 
Especially in the light of the proposed route of the permeabilisation of membranes, 
leading to altered calcium homeostasis and ultimately cell death. Our experiments 
explore this particular branch of proposed mechanisms and shows that that human 
CSF can induce Ca2+ influx in our assays using both single vesicles and astrocytes. This 
can be counteracted by the addition of clusterin, Nb3 and bapineuzumab. It is 
important to stress that this effect was much less in AD CSF than in the synthetic 
counterpart with Aβ42 oligomers in buffer. This suggests the Ca2+ influx causing 
oligomers differ in their structure and composition making and that Nb3, 
bapineuzumab and clusterin interact with other components in the CSF making them 
less available. This might explain why bapineuzumab is only effective in reducing the 
Ca2+ influx in CSF at 100-fold higher concentrations than used in the clinical trial [267] 
If the effects that we observe in CSF reflect those within the brain, this suggests that 




high concentrations of the antibody (or perhaps higher affinity and more selective 
antibodies) are required to sequester fully the potentially toxic aggregates.   




5 Size dependent Structure and Effects of Aβ42 
5.1 Introduction 
One of the most challenging aspects of studying Aβ42 in vitro is the heterogeneity 
of the species throughout the aggregation. The aggregates are also very low in 
concentration in comparison to the monomer concentration. These issues arise from 
the kinetics of aggregate formation in solution. 
The aggregation of Aβ42 happens at comparable fast reaction speeds when the 
critical aggregation concentration is reached. Most aggregation reactions are done at 
concentrations between 0.5- 10 µM monomer concentration in order to observe a lag 
phase. At these concentrations the lag phase is in the regime of tens of minutes to 
hours. However, this lag phase decreases as the monomer concentration increases. 
This short time window makes the study of very early aggregates very challenging.  
Figure 31  Kinetic scheme of a classic aggregation reaction. The fibril mass increases as a 
function of time. The arrows indicate possible situations at the different time points. Even though 
the fibril mass increases on average, smaller protofilaments or oligomers can be present at later 
times.  
Furthermore, the kinetics of the aggregation of Aβ42 are difficult to keep 
consistent and reproducible. This results from problems in the purification of pure 
monomer solutions and from impurities in preparations of solid-phase synthesised 
Aβ42. In addition, most preparative steps require time frames that are as long as or 




longer than the lag-phase. This results in aggregation during these steps, to varying 
degrees, and also often generates irregular lag-phases. However, by  generating MAβ42 
(Methionine- Aβ42) and Aβ42 recombinantly in E. coli the issues with the 
reproducibility of the kinetics can be overcome [199,268,269]. This enables the kinetics to 
be modelled to the mathematical models described earlier [132]. It was also shown that 
recombinant Aβ42 aggregates faster and is more neurotoxic than synthetic Aβ42 [270]. 
Another challenge in the analysis of protein aggregation with certain fluorescent 
techniques is the inherent need for a fluorescent dye. Especially the use of covalently 
attached fluorescent dyes. Due to the high dilutions needed in single molecule 
experiments, the use of antibodies is not always feasible. Very high Kd values for the 
binding are required to guarantee the binding at nM to pM concentrations. Covalently 
attached fluorescent dyes however can potentially alter the aggregation kinetics and 
can interfere with commonly used techniques, such as ThT curves, to measure the 
aggregation. This is often caused by fluorescence quenching effects. Thus, if we want 
to benefit from the detection advantages of the fluorescently labelled proteins, but still 
compare labelled and unlabelled protein, we need to find a way to bypass kinetic 
preparations of the aggregates. This would be possible by using a purification 
technique that separates species based on structural properties.  
In this chapter I will show how I used gradient ultracentrifugation to sample a 
wide range of amyloid aggregates allowing me to directly compare labelled and 
unlabelled protein. Furthermore, by using this technique I prepared aggregates of 
multiple sizes within a single experiment under the same preparation conditions. I then 
directly compared aggregates in respect to their structural properties and their effects 
on biological models 
Figure 32  Schematic representation of the ultracentrifugation workflow. Aβ42 monomers, 
either synthetic labelled co-aggregates or recombinant MAβ42, are aggregated. Usually a 
combination of time points is combined to sample all species (shown as coloured triangles on the 
graph) and then loaded onto a sucrose step-gradient. The gradient is divided into five fractions and 
subsequently measured. 




Gradient ultracentrifugation is a commonly used preparative technique for large 
molecular and macromolecular proteins such as organelles, molecular machines and 
others. The underlying principle uses the varying hydrodynamic radius (which I will 
refer to as size of the aggregates from here on) coupled with a gradient increasing in 
density to differentiate molecules of different sizes. As the centrifugal force is applied 
the different lengths/sizes migrate with different velocities according to their 
sedimentation coefficient. The sedimentation coefficient is determined by both the 
density of the aggregates and their physical shape. That means the relation between 
mass and sedimentation coefficient is only linear for equally shaped objects. In the case 
where amorphous oligomers and small fibrils are present simultaneously different 
shapes and different masses could provide similar sedimentation coefficients. 
However, we will be able to distinguish these situations with the single molecule 
methods if they arise. 
Analytical ultracentrifugation has been used before to study properties of amyloid 
aggregates of Aβ42 before [271]. These methods were the starting point for the 
purification of the Aβ42 aggregates. Gradient centrifugation has also been used to 
study Aβ40 aggregates and AD brain extracts [272,273]. However, gradient density 
centrifugation has not been used as a tool to compare amyloid aggregates on a single 
aggregate level structurally and biologically. As discussed, current research suggests 
that the small soluble oligomeric forms of aggregates are the most neurotoxic [86,274]. 
Hence oligomers would be an attractive target for treatment and/or prevention. 
However, as discussed previously, these forms are challenging to study in vitro. 
Gradient ultracentrifugation is one method that allows to access wide range of 
aggregate sizes in a single experiment [273,275,276]. Thus, the isolated sizes will be 
unchanged and consistent, independent of the kinetics of the aggregation.  
In addition, the wider array of isolated species will allow us to observe trends 
rather than differences between two extremes. We can also avoid the pitfalls that occur 
in other size separation methods, such as size-exclusion chromatography (SEC), which 
are problematic for fast aggregating proteins. For example, in SEC a high local 
concentration of protein may occur on the column which could facilitate aggregation 
resulting in the loss of the small oligomers.  




However, it is important to note that this experiment cannot take into account 
possible polymorphs within the same aggregate size. These have been implicated in 
amyloid fibrils but it is unclear what role they play for oligomers in vivo [115,277].  
The role of microglia and neuroinflammation in AD 
Neuroinflammation has also been suggested to play a role in the development of 
AD [278]. In particular, small soluble oligomers have been linked to neurotoxicity. This 
has led to studies of their structure, molecular interactions and biological mechanisms. 
As described in chapter 1.3 multiple variants of small soluble oligomers have been 
purified, structurally characterised and tested for their biological mechanism. However, 
to this day no atomic or molecular structure of non-β sheet containing Aβ42 oligomer 
exists. Furthermore, the molecular mechanism that leads from a presence of 
monomers to oligomers to neurotoxicity, and ultimately the specific clinical effects of 
AD, is also unknown. That does not mean, however, that the neurotoxic link has not 
been confirmed [16].  
The role of neuroinflammation in AD is a concept that increasingly gained 
traction more recently. The findings that microglia respond to injury paired with the 
observation of increased microglial activation in AD patients have lead to the 
hypothesis that the microglia cells are involved in the disease mechanism [279]. Microglia 
cells themselves are abundant in the brain and are linked to maintenance and plasticity 
of neuronal circuits and contribute to the protection and remodelling of 
synapses [278,280]. In the case of AD, microglia have been found to bind Aβ via cell 
surface receptors (SCARA1, CD36, CD14, α6β1 integrin, CD47) and Toll-like 
receptors (e.g. TLR2, TLR4, TLR6, and TLR9) [281-284]. This is thought to be an 
important part of the inflammatory reaction in AD. CD36, TLR4 and TLR6 result in 
the pro-inflammatory activation of microglia, while genetic deletion of these receptors 
reduces Aβ-induced cytokine production [283,285,286] 
The link between microglial activity and AD was backed up by the findings that 
pro-inflammatory cytokine levels in the AD brain such as interleukin (IL)-1β, TNFα 
and IL-6 were increased and in vitro studies showed that these pro-inflammatory 
cytokines led to neuronal toxicity and death [287]. TNFα in particular was shown to be 
elevated in AD serum, CSF, cortex and glial cell cultures after exposure to Aβ [278]. 
TNF-α stimulates NF-κB, a transcription factor for pro-inflammatory factors such as 
complement and cyclooxygenase (COX) [288,289], as well as survival factors such as 




calbindin, manganese-superoxide dismutase, and Bcl-2 [287]. The pathophysiological 
role for TNFα in AD however is not entirely clear. It has been both reported to kill 
human cortical neurons [290] but also to be trophic to rat hippocampal neurons [291]. It 
was also found to protect against glutamate, free radicals and Aβ toxicity in primary 
neuron cultures [292]. More specifically in AD, the risk for conversion from mild 
cognitive impairment to dementia is increased in patients with elevated concentrations 
of TNFα and lower concentrations of the anti-inflammatory TGF-β in the CSF [293]. 
Protofilament of Aβ42 in particular have been shown to stimulate microglia more 
robustly than mature fibrils or oligomers while leading to increased TNFα levels [294]. 
Other contributing factors to neuroinflammation such as complement, chemokines, 
caspases and others are reviewed extensively by Heneka and colleagues [278]. 
One system I used is a simplified cell membrane model and a technique to 
ultrasensitively measure oligomers through calcium influx into POPC vesicles. The 
other model is the measurement of TNFα production in mouse microglia cells in 
response to the aggregates 
To sum up, in the following chapter I will show how I addressed the problem of 
studying aggregation independent of kinetic effects. I will furthermore show how I 
examined if intermediate states of aggregation induce calcium influx and an 
inflammatory response and how this could potentially be applied to more complex 
biological questions. I will show that Aβ42 oligomers induced the highest Ca2+ influx 
in the single vesicle assay while protofilaments led to the biggest inflammatory 
response in mouse microglia cells. The single molecule measurements gave me a 
measurement of the relative aggregate concentration, I hence can be confident that the 
effects are proportional to the amount of aggregates present.  





5.2.1 Structural Characterisation 
It is essential to have structural information on protein aggregates to make 
insightful conclusions on molecular mechanisms and biological effects. In the 
following I will show how the size of the aggregates affects the toxicity of Aβ42 
aggregates. This will be a two-step process: (1) I used gradient ultracentrifugation to 
prepare sized aggregates which I characterised with single molecule methods to, (2) 
test the influence of size on the permeability of artificial membranes and on the 
inflammatory response.  
I will firstly describe how I developed a protocol for the sucrose ultracentrifugation 
method with the Aβ42 aggregates. This focuses particularly on the aspects of the 
structural characterisation via fluorescence and other methods. I characterised the 
kinetics of the aggregation itself with TIRF microscopy. This is important to help with 
the selection of aggregation timepoints to later on use as input for the gradient 
centrifugation, as I wanted to assure that the majority of possible aggregation states is 
present as a starting point for the preparation. Furthermore, this gives an indication 
and reference on where the sized aggregates would occur within the aggregation 
reaction.  
Figure 33  (A) Plate reader aggregation with ThT fluorescence as measure of the fibril mass 
of unlabelled Aβ42. The fluorescence traces of three parallel technical repeats are shown (B) Dual 
labelled co-aggregation of Aβ42 in TIRF mode. The number of detected aggregates is shown as a 
function of time with the bars representing the mean with the standard deviation as error and the 
blue line the median. Each dot represents one field of view. There is a clear increase in the number 
of detected spots after about 60 minutes. This measurement was done at constant dilution of the 
sample. The increase in aggregates corresponds well with ThT measurements for recombinant 
proteins but the lag phase appears to be longer. We also have to take into consideration, that this 
was optimised for the later time points in respect to dilution, with the dilution kept consistent 
throughout. I will discuss this in more detail in the text. 




I measured an aggregation of a 2 µM dual-labelled co-aggregation on the TIRF 
microscope to establish a starting point for the subsequent preparation. As shown in 
(Figure 33) the number of aggregates clearly increases after about 60 minutes. 
However, the TIRF method in this case was optimised for higher aggregate levels 
which means the threshold in terms of detection is skewed towards the bigger, brighter 
aggregates. Also, the number of the aggregates is not the ideal metric for an increase 
in size and/or aggregate mass, as in later stages the number of aggregates decreases 
with more and more monomers bound in large fibrils. Rather representative images 
(Figure 34 A) and histograms of the intensities (Figure 34 B) are a much better 
indication for an increase in size and/or aggregate mass. 
Figure 34  (A) Representative TIRF FRET images of various time-points of the aggregation 
are shown. The scale bar is 10 μm. (B) Intensity histograms of the dual-labelled co-aggregation of 
Aβ42. The histograms for all time points are shown as marked. Each histogram is the sum of 27 
field of views measured in three technical repeats of a single aggregation.  
The aggregation was also monitored with ThT in a plate reader for the unlabelled 
aggregation which I used later in the vesicle assay and for AFM experiments. I show a 
ThT aggregation of synthetic Aβ42 as used for the AFM and similar to the one used 
for the vesicle assay experiments (Figure 33 A). In the vesicle assay experiments these 
ThT reference measurements were done with recombinantly expressed MAβ42 (not 
shown). The purification and preparation for above Aβ42 was different to the one 




used in the vesicle assay, this leads to a slightly shorter lag-phase. This is not a problem 
as we have the centrifugation step to correct for any variability. 
The fluorescence labels for the co-aggregates interfere with ThT measurements, hence 
I could not measure the equivalent ThT curve for the dual-labelled aggregates. This 
does not pose a problem, as the smTIRF data is sufficient to select timepoints with 
the required distribution of sizes. I started testing the gradient with a mid to late 
aggregation timepoint at about 1 h 30 min, to include fibrillar species in the mix. For 
experiments with the vesicle assay, I started 3 aggregations in intervals starting 40 min 
1 h 20 min and 3 h before mixing and centrifugation. Both a single timepoint and 
mixed timepoint are viable as the analysis with single molecule methods shows the 
exact distribution of species and number of aggregates needed for further analysis. 
Furthermore, both the single timepoint and the mixed timepoint showed an abundance 
of species of all sizes with somewhat different distributions, which is accounted for by 
the SM measurements.  
  




Aggregate Structures as measured with dual-labelled co-aggregates 
I first used TIRF microscopy to observe the aggregates in FRET-mode using the 
dual-labelled co-aggregates. This gives very fast and accurate insight into the sizes and 
morphologies occurring as results of the preparation.  
The high-resolution TIRF microscopy allows me to measure on a length scale 
from the diffraction limit (~200nm) up to a few hundreds of µm in length in a single 
field of view. This has a few advantages: (1) we are not limited by large sizes in fractions 
that contain large fibrils in contrast to a confocal volume; (2) we can immediately see 
morphological differences through the images we record, mainly fibril shapes and 
structures; (3) the measurement is high throughput due to the comparably short 
measuring intervals (~10-15 mins per sample in triplicates). However, one notable 
limitation is the highest resolution we can achieve, as we need to measure structures at 
sub 200nm length-scales for small aggregates. TIRF microscopy is also a surface-based 
technique which might lead to preferential binding of some species to the coated 
surface or alter properties of the aggregates upon binding. The latter seems unlikely 
but cannot be fully excluded. I then complemented the TIRF data by measuring 
unlabelled protein with extrinsically fluorescent dyes such as ThT and pFTAA [77,295].  
The steps described below were directly used to assess the quality of the gradient 
centrifugation in its ability to cross-sectionally separate aggregates. I used sucrose as 
the gradient reagent as it did not have any measurable impact on the aggregates. 
Although sucrose has been found to impact the aggregation reaction in some cases of 
amyloid aggregation [296], this was not a concern for my experiment as the aggregation 
occurred in absence of sucrose. Aggregation that occurs during the centrifugation does 
not impact the results as the centrifugal force is constantly present throughout. To 
avoid any further aggregation during the time of measurements, the reactions were 
kept on ice immediately after the centrifugation and not used longer than a day, which 
was sufficient for all tests and assays. The sucrose used as gradient reagent was 
prepared matching the aggregation buffers for labelled and unlabelled protein 
respectively which should not affect the aggregates adversely. I also explored the 
possibility to cross-link the aggregates using GraFix [297]. The results were inconsistent 
and for the selected structural methods not strictly necessary. This could be a pathway 
to molecular structure determination though, taking into account the limitations of 
crosslinking proteins. 




The TIRF-monitored aggregation reaction guided the selection of suitable 
timepoints for subsequent experiments with the gradient ultracentrifugation. Using the 
TIRF microscopy with labelled co-aggregates I find that the mean size, as 
approximated by the intensity, increases. We can justify this approximation by the fact 
that all monomers contain a fluorescent dye and hence, the increase in intensity 
correlates with the increase in aggregate size. This is especially useful for sub-
diffraction sized aggregates as, even though they appear to have the same diameter, 
their intensity will still differ. I can see morphological different aggregates in the large 
fractions changing from diffraction limited puncta to elongated fibrils (Figure 35 A). 
The histograms for fractions are shown in (Figure 35 B).  
Figure 35  TIRF FRET images and analysis of the gradient centrifugation. (A) Images of three 
fractions are shown to represent the sizes detected with TIRF microscopy and are representative 
of the indicated fractions. The scale bar is 10 µm. (B) The FRET histograms of the fractions show 
a clear shift from a very narrow, dim distribution in the smaller fractions to a marked increase in 
the higher fractions and in the pellet. Each Histogram is the sum of aggregates of 27 field of views 
measured in three technical repeats of a single gradient ultracentrifugation preparation. 
In the smFRET method I used co-aggregates of 1:1 molar ratios of FRET-donor 
and FRET-acceptor labelled Aβ42 monomers. These monomers have been HPLC 
purified previously to avoid possible contamination products. There have been studies 
that suggest low percentage racemisation in some amino acids during solid phase 
synthesis which cannot be separated [269]. However, with no N-terminally, fully labelled 




recombinantly expressed Aβ42 available, this is for now the best approach to generate 
fluorescently labelled Aβ42 aggregates. Futhermore, these aggregates have been shown 
to be morphologically similar to unlabelled aggregates [298].  
The smFRET system allowed me to measure the relative aggregate size and their 
FRET efficiencies as described previously [56,121,122]. I could furthermore calculate a 
relative percentage of aggregates as function of monomer population in each individual 
sample, a number which I used to correct the biological effects we observe.  
Figure 36  FRET analysis of the dual-labelled co-aggregates as measured with the smFRET. 
The FRET efficiency is plotted against the apparent oligomer size inferred from the intensity. The 
aggregates increase in size and the FRET efficiency shifts to higher values. The FRET histograms 
are representative of the gradient centrifugation fractions and show all aggregates plotted of a single 
measurement. A single measurement of each fraction contains usually more than 10 000 aggregates, 
if not the concentrations were adjusted to do so. 
The apparent aggregate size plotted against the FRET efficiency (Figure 36) of all 
measured aggregates shows the shift from bottom left to upper right. This means a 




size increase and compaction. As with the TIRF microscopy measurements, the 
intensity is used as an approximation of the aggregate size. The apparent sizes in lower 
sized fractions stay consistently low while the increase can be clearly seen moving 
through the fractions to ultimately the pellet which shows large, high intensity, high 
FRET aggregate fibrils (Figure 36).  
Figure 37  Comparison of the FRET efficiencies as measured in the fractions used for the 
TNFα measurements. (A) The cumulative frequency histograms show the increase in higher FRET 
efficiency species with the curve shifting to the right. The Histograms contain all aggregates of the 
measured fractions (B) shows the normalised FRET efficiency histograms for all fractions. In the 
10 % fraction the peak is clearly shifted to the left and then increases over time. These histograms 
were the basis for fitting two populations (low and high FRET). The fit was done with the 10 % 
and pellet peak values as fixed values (low: 0.45 and high: 0.62) for the two populations. The 
resulting fits are shown in Figure 38. This is the result of one representative measurement of one 
preparation.  
The shift to higher FRET efficiency could suggest some form of compaction, but 
we do not observe distinct structural populations so we cannot definitely determine if 
there is a structural conversion as seen e.g. for αS oligomers [186,196].  
Lastly, the single aggregate measurement allowed me to determine a relative 
number of aggregates (Table 8). I used this number to normalise the biological assays 
to a relative aggregate concentration rather than absolute protein concentration.  




Figure 38  Fitted peak heights of the low (10%) and high (pellet) FRET populations to show 
the change in the structure more clearly. The fit error is shown as error. As it is apparent from 
above histograms, the transition is continuous. It needs to be noted that for the fitting the peak of 
the lowest and highest FRET distributions were used as forced peak positions (0.45 and 0.62 
respectively). This can explain the inversion in the 30 percent as the flanks of the peaks are not 
particularly well suited to fitting. 
 
Sizing aggregates without fluorescent labels  
For the single vesicle calcium influx assay it is not possible to use the FRET co-
aggregates as spectral overlap would interfere with the measurement of the vesicles. 
To overcome this problem I used the extrinsically fluorescent dye pFTAA which has 
similar properties to ThT (in that it binds amyloid structures) [128]. I used pFTAA to 
determine the relative aggregate concentration difference between the sucrose gradient 
fractions. This is somewhat limiting in comparison to the FRET methods, as I can 
only extract the absolute number of pFTAA active aggregates but not the fraction in 
respect to the total protein. I found that the trend for the intensities of the pFTAA 
active aggregates is similar to the smFRET. However, the lower fractions (10 % and 
20 %) have substantially less aggregates detected overall, which means that the 
histograms are only sparsely populated (Figure 41 C).  
The corresponding TIRF experiments were also carried out with unlabelled 
protein aggregates using the amyloid reporter dye pFTAA [128](Figure 39). This was to 
(1) get insights into the binding properties of ThT and pFTAA to oligomeric 
aggregates and, (2) as preparation for the TIRF and smFRET experiments done in 
conjunction with the vesicle assay as the used fluorescence excitation and emission 
wavelengths permitted the use of co-labelled aggregates.  




Figure 39  Representative TIRF images recorded with pFTAA of the increasingly larger 
fractions from 10 % through to 50 %. All images are adjusted for contrast. Especially in the 50% 
the fibrils are very apparent. The scale bar is 10 µm. 
Measuring pFTAA and ThT positive aggregates throughout the isolated sizes 
show that, below a certain size, no aggregates are detected with the extrinsically 
fluorescent dyes (Figure 40). I was not able to detect any aggregates in the 10% fraction 
and only a small number in the 20%. The 20% fraction contains the most oligomers 
as I will show later. I can readily detect aggregates in the bigger fractions. The decrease 
of aggregate number in the 50% and pellet can be explained by the presence of large 
fibrils containing most of the aggregate mass.  
In direct comparison pFTAA appears slightly more sensitive and is hence used 
for the following single molecule confocal experiments. The morphological changes 
cannot be seen as clearly as with the labelled protein, and the exact relation between 
fluorescence intensity and aggregate structure is not known. That means the estimate 
of size is not as accurate. There is still a correlation between fluorescence intensity and 
increase in size however (Figure 41 C). This correlation is better matched with pFTAA 
Figure 41B) than with ThT (Figure 41 A). Furthermore, it is entirely possible that the 
binding properties to the surface for small soluble oligomers is different to the binding 
properties of mature fibrils and protofibrils. This could lead to a lower representation 
as aggregate numbers in the lower fractions. The use of confocal measurements in 
solution using a method similar to the smFRET but with the pFTAA dye instead 
would avoid this problem.  




Figure 40  The aggregate count detected with the SAVE technique using (A) ThT and (B) 
pFTAA. (A) The aggregates per fov of 27 different areas as detected with ThT are shown as a 
function of the fractions (10-50 %) and the blank, input (before centrifugation), supernatant (SN) 
and pellet. (B) The same samples as imaged with pFTAA are shown. The overall aggregate count 
in the input is shown but cannot be compared quantitatively as the dilution due to the subsequent 
centrifugation has to be taken into account. The results show us however, the extent to which we 
can detect oligomers with ThT and pFTAA especially in the 20% fraction. We can however readily 
detect protofilaments and fibrils with both methods. The decrease in numbers in the pellet and the 
50% fraction is probably due to less abundant but larger aggregates. 
After assessing pFTAA on a TIRF setup I went on to use it in conjunction with 
the smFRET setup. In this case I can only observe the fluorescence directly from the 
dye and no FRET as in the following experiments. I could show that the increase in 
size correlates with an increase in mean intensity (Figure 41) when measured in the 
smFRET setup. This is consistent with the other measurements and allows us to use 
it together with the calcium influx assay. 
  




Figure 41  Cumulative Frequency histograms of the sucrose fractions as measured in TIRF 
with (A) ThT and (B) pFTAA. (A) The increase in intensity towards higher fractions is not as 
clearly defined especially for the 30% fraction which seems to be fairly low intensity in comparison 
to the 20% fraction. (B) The increase in intensity towards higher fractions is very apparent. 10% is 
not displayed as not enough aggregates were detected to display a meaningful histogram. All 
histograms are the cumulative relative intensities of the aggregates of 3 technical repeats with 9 fov 
each of one preparation. (C) Cumulative frequency histograms of the pFTAA intensities observed 
with the fractions used for the single vesicle assay as measured with the confocal SM technque. 
The lower shape of the curves of the 40 % and 50 % fractions clearly confirms the shift to bigger 
aggregates while the 10 % fraction shows the smallest ones. 
  




DNA-PAINT and AFM for nanoscopic sizes and structures  
The TIRF microscopy methods do not allow us to see any morphology 
differences below the diffraction limit. In principle it is possible to observe peptide 
monomers with both TIRF microscopy and the confocal smFRET if they have an 
attached fluorescence label, but neither of the techniques gives us a clear picture of the 
sub-diffraction morphology. Thus, I used AFM as a complementary technique to 
examine the morphology of the sub-diffraction aggregates (Figure 42).  
The AFM measurements showed a statistically significant increase in the height 
of the aggregates. The height can be measured very precisely with the AFM cantilever 
tip even down to the smallest sized aggregates and can distinguish monomers from 
aggregates. The height and width characteristics of the lower fraction matched with 
the properties of soluble oligomers. The 30% fraction which gave the highest increase 
in TNFα have a diameter and morphology that matches protofibrils with a mean length 
of ~ 80 nm and a single fibril chain width. The higher percentage fractions are all of 
fibrillar nature with heights and widths of mature fibrils. That means the AFM 
measurements confirmed the fluorescence data by showing oligomeric, round shaped 
aggregates up to the 20% fraction with a transition to more protofilaments, which is 
hidden in the TIRF below the diffraction limit, and fibrils in increasing size from there 
onwards. AFM however has its own limitations. This includes attachment to the mica-
substrate and the fact that the samples have to be dried which both can introduce 
artefacts.  
Therefore, I attempted to use DNA-PAINT, a technique that allows SR imaging 
of aggregates, with the sized aggregates. This fluorescence method would have some 
advantages over AFM, (1) it is a solution-based technique, as mentioned, (2) it could 
be more easily transferred into fixed and potentially live cells which I will demonstrate 
in chapter 5.2, (3) in principle it is possible to multiplex with various probes are 
available. One current limitation for DNA-PAINT technique I use in based on the use 
of an amyloid specific aptamer. This aptamer was developed for αS and not specifically 
for Aβ42. We validated that the aptamer binds Aβ42 via Aβ42-657 labelled aggregates 
co-localising with the super resolved reconstructed DNA-PAINT image. This was 
done in fixed cells however, as this was a primary interest. This is discussed in more 
detail in chapter 5.2. The application of DNA-PAINT has some limitations, mainly 
due to the fact that the surface coating usually used for AB42 imaging, namely PLL,   




Figure 42  Representative AFM images of the fractionated Aβ42 aggregates. (a)- (e) show a 
representative overview of the AFM image, a magnified view and a representative cross-section of 
a single aggregate. The height (f) and the deconvoluted diameter (g) Aβ42 aggregates is shown. The 
30% fraction (c) is the only one that shows characteristic cross-sectional width of the 
protofilaments while 10% (a) and 20% (b) have the cross-sectional width of oligomers and 40% 
(d) and 50% (e) are fibrils. The images and analysis have been kindly provided by Dr. Simone 
Ruggeri.  




is not compatible with DNA-PAINT. This means I had to use aspartic acid which was 
used previously with αS. I was not able to detect the fractionated AB42 aggregates with 
DNA-PAINT. This could have two explanations. The Aptamer recognises fibrillar 
structures much better, hence that it was not suited to resolve the smallest aggregates, 
but even larger ones were not clearly visible which was surprising, as I was able to 
detect aggregates with said aptamer in cells. It could be a surface effect, as I was not 
able to validate, that the unlabelled protein readily binds to aspartic acid. Altogether 
this does not mean it is not possible to do DNA-PAINT with Aβ42 aggregates, but it 
needs refinement with both surfaces and maybe aptamer alternatives.  
  




5.2.2 Biological effects 
The structural study of the Aβ42 aggregates is important but I was afurthermore 
interested in the biological implications of the structural changes. As stated before, it 
is thought that both the Ca2+ homeostasis is adversely affected in AD and also that 
neuroinflammation could play a role. Thus, these are the two biological consequences 
that I analysed.   
To examine the effects of aggregate size on Ca2+  influx through membranes I used 
the ultrasensitive measurement of Ca2+ influx into vesicles as described by Flagmeier 
and De et al. [92]. This allowed me to quantitatively and sensitively detect the presence 
of Aβ42 oligomers. But more importantly, in comparison to kinetic experiments, I 
could quantitate the relative amount of aggregates in the samples and used this 
information to normalise the response from the assay. I saw the biggest increase in 
Ca2+ influx, which is the measure of Aβ42 oligomers, in the smallest fractions (Figure 
43 B). The absolute numbers of pFTAA active aggregates to calculate the response per 
aggregate are shown in Table 7. The results are consistent with the increase measured 
during a time-course of an Aβ42 aggregation.  
Table 7  Confocal pFTAA aggregate count used to correct the Ca2+ assay as shown below. 
Sample Aggregate Count 
10 % 457100 
20 % 89200 
30 % 15420 
40 % 15300 
50 % 39760 
 
This increase becomes exaggerated if we normalise for the relative abundance of 
amyloid aggregates (as measured with pFTAA in solution). This means that the 
oligomer fractions induced the greatest calcium influx into single vesicles. The 
molecular mechanism of this Ca2+ influx however is unclear but may be some form of 
membrane perturbation or facilitated permeability. Arguably the vesicle membrane is 
far less complex and devoid of receptors in comparison to the cell membrane of e.g. 
the microglia cells. The increased calcium influx into vesicles through membrane 
perturbation seems not to be the same mechanism as the inflammatory response 




through the microglia cells as the peaks appear at different sizes of aggregates. This 
lends itself to speculate that oligomers of Aβ42 aggregates are distinct from the 
aggregates causing neuroinflammation which I will discuss in the following section.  
Figure 43  Ultrasensitive measurement of calcium influx of Aβ42 oligomers. (A) The calcium 
influx per detected pFTAA active aggregate percentage for the various sizes is shown. The mean 
is shown with error bars as standard deviation. (B) The uncorrected calcium influx data directly 
from the assay. The mean of three repeats each of all measured vesicles with standard deviation as 
error bars is shown.  
I have not used the equivalent smFRET measurements to normalise the response 
of the Ca2+ influx as the experimental protocol for the aggregation differed. In the case 
of the smFRET experiments I used a single timepoint as basis for the gradient 
centrifugation whereas in the unlabelled experiments I used multiple aggregation 
timepoints and pre-mixed them. The rationale behind this is, that the methods used to 
measure the unlabelled aggregates are not as sensitive as the smFRET, so more 
aggregates overall in each fraction are needed to get a good sampling. As the timepoints 
and hence the underlying relative proportions of aggregates can be different between 
labelled and unlabelled a different approach is needed. The selection of compatible 
dyes between the smFRET and the Ca2+ influx measurement could help resolve that 
problem.  
  




Aβ42 induced Pro-Inflammatory Response of Microglia Cells 
To evaluate the neuroinflammatory potential I used mouse microglia cells and 
measured their TNFα release upon addition of the Aβ42 aggregates (which are found 
mostly in the extracellular space) [86]. We did not only examine the effects of the size 
of the aggregates on membrane perturbation, but I also measured the TNFα 
production of mouse microglia cells per aggregate. The dual-labelled co-aggregates are 
diluted into the medium at nanomolar concentrations and the TNFα release is 
measured 24 h and 48 h post addition. Neither the remaining sucrose nor the labelled 
Aβ42 monomer gives any appreciable response (Figure 44). The aggregates were 
measured with the smFRET technique on the day of application onto the cells. 
The ELISA showed a maximum TNFα response with the aggregates of the 30% 
fraction after being corrected for the per aggregate response as measured with confocal 
FRET. This suggests that different size aggregates have different effects. TNFα levels 
reduce again after 48h of incubation of the cells in the 30% and 40% fractions, close 
to levels of the very large aggregates. The 10% and 20% fraction aggregates lead to an 
increase and unchanged release of TNFα after 48h. This could be explained by a 
continuation of the aggregation and hence conversion to larger aggregates. This is 
particular apparent in the consistent increase in TNFα over the 24 h in the 10 % and 
the opposite effect very strongly in the 30 % and then still present in the 40 % and 
50 % fractions. 




Figure 44  Three full biological repeats of the TNFα ELISA tested after 24 h and 48 h after 
addition of the aggregates. Each bar represents the mean of 3 measurements with the standard 
deviation as error. I prepared and provided the aggregates and Dr. Craig Hughes measured the 
TNFα in the mouse microglia 
In the lowest fraction I found a much higher number of donor events compared 
to the other fractions. This is a result of a highly concentrated monomer and hence 
small-mer solution in the supernatant which is partially found in the 10 % fraction. 
Hence the small-mers contribute to the much-increased number of FRET events from 
the input solution. I could not find any TNFα increase with pure monomer. Hence, I 
assumed that I could use the aggregate number directly. The fraction of aggregates is 
comparable to the other samples too (Table 8). The aggregate number was then used 
directly to give a semi-quantitative method to interpret the increase in TNFα. The 
detailed numbers of the FRET numbers that were used to correct the below ELISA 
are given in Table 8.  
  




Table 8  No. of FRET events, donor events and the fraction of aggregates used correct the 
TNFα assay. The values are the mean and standard deviation of three full technical repeats 
including aggregation and centrifugation step. The individual measurements of the according 
preparation was used to correct the respective TNFα assay. 
Sample 
No. of FRET 
aggregates (x 103) 
No. of donor 
events (x 105) 
Percentage of 
aggregates 
10 % 168± 20 63.2± 850.1 0.007± 0.006 
20 % 33± 39 63.7± 84.2 0.013± 0.008 
30 % 10± 5 6.2± 8.0 0.099± 0.090 
40 % 9± 4 7.2± 9.4 0.091± 0.095 
50 % 14± 18 3.3± 4.5 0.109± 0.094 
 
The TNFα ELISA showed a maximum at the 30 % fraction, which was identified as 
containing protofilaments. This is apparent in the ELISA results (Figure 45 A) and 
gets exaggerated by the correction applied by the smFRET measurements (Figure 
45 B).  
Figure 45  The TNFα increase per aggregate after correction with the relative abundance of 
protein aggregate shows an increase towards medium sized aggregates and very little response to 
smaller aggregates. (N=3; one shown) (B) The absolute measured response of TNFα as determined 
with ELISA. All bars are the mean of three replicates with the error bare the standard deviation.  
  




5.3 Outlook on size dependent effects 
I have shown in this chapter that it is possible to study a cross-section of aggregate 
sizes in parallel. This has two advantages over kinetic studies. Firstly, it decouples the 
preparation from kinetic variability, which is still a major “headache” in many 
aggregation experiments. Secondly, it allows us to directly compare numerous stages 
at the same time with adequate aggregate numbers.  
Figure 46  Model for the different effects on cell membranes and microglia cells through Aβ42 
oligomers and protofilaments. (A) The graph shows a simplified view on the aggregation and their 
respective predominant species with the two important points marked with (1) where 
predominantly oligomers are present and (2) where protofilaments are present. These two points 
correlate with the maximum response in (1) Ca2+ influx and (2) a maximum pro-inflammatory 
response. (B) The schematic shows the possible underlying mechanisms of these two effects with 
Ca2+ influx  
Furthermore, I found that protofilaments, not oligomers or fibrils, induce a pro-
inflammatory response. To confirm that the observed effects were not artefacts of 
varying concentrations of aggregate types, it was corrected to the response per 
aggregate using smFRET. I also normalised the measurement of the calcium influx 
into vesicles (with the limitation of normalising to pFTAA positive aggregates). The 




maximum calcium influx was observed with the small oligomeric species which 
matches the findings of kinetic studies [92]. 
Continuing from the first part, it would be intriguing to see what effect the various 
species have on Ca2+ influx and pro-inflammatory response in a combined cell model. 
This could for example be a combination of a single cell assay and a parallel 
inflammatory response measurement. We could then use targeted/ designed 
antibodies to bind to subsets of these aggregates, now that we have methods to purify, 
measure and test them biologically. This all could ultimately help to understand the 
underlying molecular mechanisms of aggregates in the brain better. 
Interestingly, the fact that the protofilaments are most potent at inducing the 
inflammatory response suggests a molecular mechanism. The TLR3 receptor has a 
cavity that can bind elongated structures of about 1 nm in diameter as shown with 
bound RNA (Figure 47). Protofilaments also have the same elongated shape as the 
bound RNA with a similar diameter. 
Figure 47  (A) The crystallography structure of the ectodomain of the TLR3 receptor bound 
to RNA (accession number 3CIY) according to [299] is shown in a top (top) and side view along the 
RNA, filament and fibril axis respectively (bottom). (B) The structure of a cross-beta filament is 
superimposed (accession number 2M5N [300]) where the RNA would usually bind. The cleft would 
have the correct diameter to accommodate this structure in contrast to (C) where the structure of 
an Aβ42 fibril is superimposed (accession number 5OQV  [116]). The cleft is clearly too narrow to 






6 Future Work 
The combination of single molecule techniques in studying human aggregates in 
CSF bears a variety of advantages but is still at the very beginning. Before further 
extending on the use of various dyes as diagnostic tool in PD or AD, I think the results 
of the AD SAVE application demand for more groundwork. Most crucially we need 
to identify what the exact composition the aggregates we detect. This includes (A) the 
aggregates itself, whether they consist of Aβ42 only, various different cleavage 
products, co-aggregates and/ or other aggregates and (B) any possible interaction 
partners, most notably chaperones such as clusterin or various heat-shock proteins.  
One possible way to better understand the aggregates is the extension of the 
competition assay with clusterin into the CSF. This would give insights into possible 
clearance mechanisms and interactions. There is also an option of the use of antibodies 
and eventually multiplexing while imaging single aggregates. This has already been 
explored by Zhang et al. [125]. But rather than focusing solely the diagnostic side, I think 
it these tools help understand the molecular nature of the human aggregates and their 
interactions in the extracellular space. 
A different approach to investigate the molecular nature of the aggregates is by 
IP. I described an IP experiment we used to demonstrate, that the Ca2+ influx in the 
vesicle assay is can be decreased by IP with Aβ42 specific antibodies. However, 
ultimately it would be intriguing to identify amyloid aggregates more general, e.g. with 
immobilised ß-sheet binding entities such as ThT and derivatives. These could then be 
analysed by e.g. mass spectrometry to explore their molecular composition. This would 
be an antibody unbiased view that could also give us insight into the strengths and 
weaknesses of the SAVE method. 
The conclusions about the oligomers and protofilaments in chapter 5 are 
interesting in the light of the aggregates in human CSF. The implications of 
protofilaments present in the CSF and the brain would have implications for treatment 
and could help understand some of the molecular and cellular consequences in the 
brain. I will discuss two ways of connecting the work I have presented.  
We could use the gradient centrifugation to purify aggregates from human CSF to 





detection methods we have at hand. A handful of improvements would be beneficial. 
As CSF samples are very low in volume and the number of aggregates is very low, a 
downscaling of the gradient would be ideal. We could use more sophisticated gradient 
mixes e.g. linear gradients and better sample collecting techniques to either focus on 
one particular species or get a finer sampling.  
The other way to connect the findings from this thesis would be to specifically 
look for species in the CSF we already identified. Especially protofilaments could be 
of interest, to see how abundant they are in the CSF. We could use AFM to detect the 
protofilaments. This comes with the problem of a very diverse mix of proteins in the 
CSF that would potentially be detected. However, pre-treatment with Proteinase K 
could help to digest most non-fibrillar and non-filamentous proteins and probe for the 
presence of protofilaments in the CSF. 
Figure 48  SAVE imaging of a CSF sample to test the decrease in ThT active aggregates after 
incubation with PK in preparation for AFM imaging experiments. Time course of the aggregate 
count (A) without PK and (B) with PK of three technical repeats. The aggregates of all three times 
the 12 fov are shown with box and error bars as indicated. (C) shows the direct comparison of the 
aggregate count per fov and the decrease after 30 min and 90 min. 
To explore this option, I performed some preliminary experiments. These showed 





incubation with 0.1 µM Proteinase K (Figure 48). This could be a suitable pre-
treatment to AFM to probe for the presence of protofilaments. 
Super- resolution imaging of Aβ with a “brain in a dish” 
In addition to above cell-biological and biophysical characterisation I explored 
options of imaging the pre-separated aggregates in vivo. Importantly for this experiment 
we need a resolution beyond the diffraction limit, as the differences between the 
oligomers are mostly below 200nm. I was interested if we could see a distinct 
difference in uptake, spreading and effect on human cortical neurons in a microfluidic 
device (Figure 49). This device is constructed to separate the compartments of the cell 
bodies with only the neurons in the central channel. The different fluid levels assure a 
pressure difference, so any agents added to one side of the chamber can only go across 
via active transport and not diffusion. 
Figure 49  Schematic of the microfluidic device to study spreading of Aβ aggregates. (A) The 
microfluidic chamber consists of two compartments divided with a central channel connected via 
fine channels. The cell bodies are added on one side the neuronal axons will grow through the 
central channel. The higher fluid in the central compartment avoids any diffusion through the 
channels. All aggregates crossing from one side to the other can only do so by active transport/ 
spreading by the cells along the axons. (B) Wide-field images of the microfluidic device stained 
with various neuronal and axonal markers to demonstrate the presence of axons in absence of cell 
bodies in the central chamber. This schematic was kindly provided by Dr. M. Horrocks. 
Firstly, we confirmed the suitability of DNA-PAINT for imaging of Aβ 
aggregates [201]. I used fluorescently labelled Aβ aggregates to confirm coincidence 
between the aggregates in the cell and the localisations detected via DNA-PAINT. 
DNA-PAINT uses a DNA Aptamer specific for amyloid aggregates as binding entity 
with a short complementary DNA-strand extension. This extension transiently binds 





prolonged time without any of the disadvantages of photochemical blinking of the dye 
itself. 
Figure 50  DNA-PAINT experiment to show imaging capabilities of DNA-PAINT to image 
Aβ42 aggregates in fixed neuronal cells. (A) The principle of DNA-PAINT is based on the PAINT 
technique as described with a docking strand attached to a DNA-aptamer which binds amyloid 
structures. A complementary imaging strand with a fluorophore attached is then usesd for PAINT 
in the cells. (B) The number of aggregates as detected with the fluorophore is displayed compared 
to an empty control (C) Representative widefield, TIRF and DNA-PAINT images are shown. The 
inset on the right shows the increase in resolution in the reconstructed image. This schematic was 
kindly provided by Dr. M. Horrocks. 
I first confirmed that the Aptamer co-localises with covalently labelled Aβ42-647 
in our cell model. I can clearly see an increase in resolution (Figure 50 C) 
We tried to show the spreading of Aβ42-647 along the axons from one cell body 
into another by adding high nanomolar concentrations of predominantly oligomeric 
aggregates. This was done without any size separation steps to maintain high protein 
concentrations and as a proof of principle experiment. 
Ultimately the goal is not only to study spreading in these devices but also the 





culture inserts would have added oligodendrocytes in the central chamber. Myelination 
and white matter lesions have been implicated in AD but not much is known about 
the process so far [301]. The described technique could help to get a controlled model 
that we could image on SR level and with the DNA-PAINT technique further down 
the line even multiplex. This would help to get insights into the interactions of the 







7 Concluding Remarks 
In the presented body of work, I have demonstrated that the study of amyloid 
aggregates in CSF can give us valuable insights into the nature of human aggregates. 
This question is particularly suited to the strengths of the biophysical methods. I have 
shown how the SAVE technique can be used with other dyes than ThT and that a 
dimeric variant of the ThT molecule is the most viable of the tested dyes. 
I have shown that SAVE is limited in its application as diagnostic tool in AD 
cases. It can however help to understand the effects of external factors on aggregates 
such as antibodies and nanobodies. I showed that, despite having an effect on Ca2+ 
Influx the antibody and nanobody did not change the structure of the aggregates.  
Finally, I showed the structure-function relationship for Ca2+ influx into vesicles 
and the inflammatory response of microglial cells. With the help of gradient 
ultracentrifugation and in-depth structural characterisation I showed that oligomers 
are the main inducers of Ca2+ influx whereas protofilaments are most potent in 







{ Size-dependent Structure and Effect of Aβ42 aggregates. De S†, Wirthensohn 
DC†, Flagmeier P†, Hughes C†, Aprile FA, Ruggeri FS, Whiten DR, Emin D, Sormani 
P, Knowles TPJ, Dobson CM, Bryant C, Vendruscolo M, Klenerman D Nature 
Structural and Molecular Biology (preparing submission) †contributed equally } 
Nanoscopic characterization of individual protein aggregates in human neuronal 
cells. Whiten DR†, Zuo Y†, Calo L, Choi M-L, De S, Flagmeier P, Wirthensohn DC, 
Kundel F, Lee SF, Dobson CM, Gandhi S, Spillantini M-G, Klenerman D, Horrocks 
MH, Chemical Sciences (under review) †contributed equally  
Shedding light on aberrant interactions: A review of modern tools for studying 
protein aggregates. Kundel F†, Tosatto L†, Whiten DR†, Wirthensohn DC†, 
Horrocks MH, Klenerman D FEBS Journal 2018 Mar 4, doi:10.1111/febs.14409. 
†contributed equally 
Inhibiting Ca2+ influx induced by aggregates in human CSF, Drews A†, De S†, 
Flagmeier P†, Wirthensohn DC†, Chen WH, Whiten DR, Vincke C, Mulydermans S, 
Paterson RW, Slattery CF, Fox NC, Schott JM, Zetterberg H, Dobson CM, Gandhi S, 
Klenerman D., Cell Reports 2017 Dec 12, 21 (11), p3310–3316. †contributed 
equally 
Ultrasensitive Measurement of Ca2+ Influx into Lipid Vesicles Induced by Protein 
Aggregates. Flagmeier P, De S, Wirthensohn DC, Lee SF, Vincke C, Muyldermans S, 
Knowles TPJ, Gandhi S, Dobson CM, Klenerman D. Angewandte Chemie Int Ed 
Engl. 2017 Jun 26;56(27):7750-7754. 
Multi-dimensional super-resolution imaging enables surface hydrophobicity 
mapping. Bongiovanni MN, Godet J, Horrocks MH, Tosatto L, Carr AR, 
Wirthensohn DC, Ranasinghe RT, Lee JE, Ponjavic A, Fritz JV, Dobson CM, 
Klenerman D, Lee SF. Nature Communications. 2016 Dec 8;7:13544.  
Individual aggregates of amyloid beta induce temporary calcium influx through the 
cell membrane of neuronal cells, Drews A, Flint J, Shivji N, Jönsson P, Wirthensohn 
D, De Genst E, Vincke C, Muyldermans S, Dobson C, Klenerman D. Scientific 






[1] 2016 WHO, 2018, 1–6. 
[2] A. Alzheimer, Allg. Z. Psychiatr. Psych. Med. 1907, 64, 146–148. 
[3] J. Parkinson, J. Neuropsychiatry Clin. Neurosci. 2002, 14, 223–236; discussion 222. 
[4] M. Goedert, M. G. Spillantini, K. Del Tredici, H. Braak, Nat. Rev. Neurol. 2013, 9, 13–
24. 
[5] C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald, K. 
Beyreuther, Proc. Natl. Acad. Sci.  1985, 82, 4245–4249. 
[6] J. P. Brion, A. M. Couck, E. Passareiro, J. Flament-Durand, J. Submicrosc. Cytol. 1985, 
17, 89–96. 
[7] I. Grundke-Iqbal, K. Iqbal, M. Quinlan, Y. C. Tung, M. S. Zaidi, H. M. Wisniewski, J. 
Biol. Chem. 1986, 261, 6084–9. 
[8] N. J. Pollock, S. S. Mirra, L. I. Binder, L. A. Hansen, J. G. Wood, Lancet (London, 
England) 1986, 2, 1211. 
[9] M. Goedert, C. M. Wischik, R. A. Crowther, J. E. Walker, A. Klug, Proc. Natl. Acad. Sci. 
U. S. A. 1988, 85, 4051–4055. 
[10] M. G. Spillantini, M. L. Schmidt, V. M.-Y. Lee, J. Q. Trojanowski, R. Jakes, M. Goedert, 
1997, 388, 839–840. 
[11] M. Goedert, Science 2015, 349, 1255555. 
[12] T. Crowther, M. Goedert, C. M. Wischik, Ann. Med. 1989, 21, 127–32. 
[13] C. Duyckaerts, Rev. Neurol. (Paris). 2013, 169, 825–833. 
[14] M. Goedert, B. Ghetti, M. G. Spillantini, Cold Spring Harb. Perspect. Med. 2012, 2, 
a006254. 
[15] F. Chiti, C. M. Dobson, Annu. Rev. Biochem. 2006, 75, 333–366. 
[16] F. Chiti, C. M. Dobson, Annu. Rev. Biochem. 2017, 86, 27–68. 






[18] C. M. Dobson, Nature 2003, 426, 884–890. 
[19] S. I. A. Cohen, S. Linse, L. M. Luheshi, E. Hellstrand, D. A. White, L. Rajah, D. E. 
Otzen, M. Vendruscolo, C. M. Dobson, T. P. J. Knowles, Proc. Natl. Acad. Sci. U. S. A. 
2013, 110, 9758–63. 
[20] A. K. Buell, C. Galvagnion, R. Gaspar, E. Sparr, M. Vendruscolo, T. P. J. Knowles, S. 
Linse, C. M. Dobson, Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 7671–7676. 
[21] S. Linse, Biophys. Rev. 2017, DOI 10.1007/s12551-017-0289-z. 
[22] J. L. Tomic, A. Pensalfini, E. Head, C. G. Glabe, Neurobiol. Dis. 2009, 35, 352–358. 
[23] C. A. Lasagna-Reeves, D. L. Castillo-Carranza, M. J. Guerrero-Muoz, G. R. Jackson, 
R. Kayed, Biochemistry 2010, 49, 10039–10041. 
[24] C. A. Lasagna-Reeves, D. L. Castillo-Carranza, U. Sengupta, A. L. Clos, G. R. Jackson, 
R. Kayed, Mol. Neurodegener. 2011, 6, 39. 
[25] K. Flach, I. Hilbrich, A. Schiffmann, U. Gärtner, M. Krüger, M. Leonhardt, H. 
Waschipky, L. Wick, T. Arendt, M. Holzer, J. Biol. Chem. 2012, 287, 43223–43233. 
[26] R. M. Koffie, M. Meyer-Luehmann, T. Hashimoto, K. W. Adams, M. L. Mielke, M. 
Garcia-Alloza, K. D. Micheva, S. J. Smith, M. L. Kim, V. M. Lee, et al., Proc. Natl. Acad. 
Sci. 2009, 106, 4012–4017. 
[27] M. P. Lambert, A. K. Barlow, B. A. Chromy, C. Edwards, R. Freed, M. Liosatos, T. E. 
Morgan, I. Rozovsky, B. Trommer, K. L. Viola, et al., Proc. Natl. Acad. Sci. 1998, 95, 
6448–6453. 
[28] S. Li, S. Hong, N. E. Shepardson, D. M. Walsh, G. M. Shankar, D. Selkoe, Neuron 2009, 
62, 788–801. 
[29] G. M. Shankar, S. Li, T. H. Mehta, A. Garcia-Munoz, N. E. Shepardson, I. Smith, F. 
M. Brett, M. A. Farrell, M. J. Rowan, C. A. Lemere, et al., Nat. Med. 2008, 14, 837–842. 
[30] M. Ahn, C. L. Hagan, A. Bernardo-Gancedo, E. De Genst, F. N. Newby, J. 
Christodoulou, A. Dhulesia, M. Dumoulin, C. V. Robinson, C. M. Dobson, et al., 
Biophys. J. n.d., 111, 2358–2367. 
[31] K. A. Conway, S. J. Lee, J. C. Rochet, T. T. Ding, R. E. Williamson, P. T. Lansbury, 
Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 571–576. 





[33] F. J. B. Bäuerlein, I. Saha, A. Mishra, M. Kalemanov, A. Martínez-Sánchez, R. Klein, I. 
Dudanova, M. S. Hipp, F. U. Hartl, W. Baumeister, et al., Cell 2017, 171, 179–187.e10. 
[34] K. A. Conway, J. D. Harper, P. T. Lansbury, Biochemistry 2000, 39, 2552–2563. 
[35] P. Arosio, T. P. J. Knowles, S. Linse, Phys. Chem. Chem. Phys. PCCP 2015, 17, 7606–
7618. 
[36] T. Shirahama, A. S. Cohen, Nature 1965, 206, 737–738. 
[37] F. Kundel, L. Tosatto, D. R. Whiten, D. C. Wirthensohn, M. H. Horrocks, D. 
Klenerman, FEBS J. 2018, DOI 10.1111/febs.14409. 
[38] B. Winner, R. Jappelli, S. K. Maji, P. A. Desplats, L. Boyer, S. Aigner, C. Hetzer, T. 
Loher, M. Vilar, S. Campioni, et al., Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 4194–4199. 
[39] E. Rockenstein, S. Nuber, C. R. Overk, K. Ubhi, M. Mante, C. Patrick, A. Adame, M. 
Trejo-Morales, J. Gerez, P. Picotti, et al., Brain 2014, 137, 1496–1513. 
[40] N. Cremades, S. I. A. I. A. Cohen, E. Deas, A. Y. Y. Abramov, A. Y. Y. Chen, A. Orte, 
M. Sandal, R. W. W. Clarke, P. Dunne, F. A. A. Aprile, et al., Cell 2012, 149, 1048–59. 
[41] T. F. Outeiro, P. Putcha, J. E. Tetzlaff, R. Spoelgen, M. Koker, F. Carvalho, B. T. 
Hyman, P. J. McLean, PLoS One 2008, 3, e1867. 
[42] D. P. Karpinar, M. B. G. Balija, S. Kügler, F. Opazo, N. Rezaei-Ghaleh, N. Wender, 
H.-Y. Kim, G. Taschenberger, B. H. Falkenburger, H. Heise, et al., EMBO J. 2009, 28, 
3256–3268. 
[43] E. S. Luth, I. G. Stavrovskaya, T. Bartels, B. S. Kristal, D. J. Selkoe, J. Biol. Chem. 2014, 
289, 21490–21507. 
[44] T. Fagerqvist, T. Näsström, E. Ihse, V. Lindström, C. Sahlin, S. M. F. Tucker, A. 
Kasaryan, M. Karlsson, F. Nikolajeff, H. Schell, et al., Amyloid Int. J. Exp. Clin. Investig. 
Off. J. Int. Soc. Amyloidosis 2013, 20, 233–244. 
[45] Z. S. Martin, V. Neugebauer, K. T. Dineley, R. Kayed, W. Zhang, L. C. Reese, G. 
Taglialatela, J. Neurochem. 2012, 120, 440–452. 
[46] T. J. Kaufmann, P. M. Harrison, M. J. E. Richardson, T. J. T. Pinheiro, M. J. Wall, J. 
Physiol. 2016, 594, 2751–2772. 





[48] A. I. Sulatskaya, A. A. Maskevich, I. M. Kuznetsova, V. N. Uversky, K. K. Turoverov, 
PLoS One 2010, 5, e15385. 
[49] T. P. J. Knowles, C. A. Waudby, G. L. Devlin, S. I. A. Cohen, A. Aguzzi, M. 
Vendruscolo, E. M. Terentjev, M. E. Welland, C. M. Dobson, Science 2009, 326, 1533–
1537. 
[50] S. I. A. A. Cohen, M. Vendruscolo, C. M. Dobson, T. P. J. J. Knowles, J. Mol. Biol. 
2012, 421, 160–171. 
[51] H. Naiki, K. Higuchi, K. Nakakuki, T. Takeda, Lab. Invest. 1991, 65, 104–110. 
[52] J. Brelstaff, M. G. Spillantini, A. M. Tolkovsky, Neural Regen. Res. 2015, 10, 1746–1747. 
[53] H. Tong, Y. Hong, Y. Dong, M. Häußler, J. W. Y. Lam, Z. Li, Z. Guo, Z. Guo, B. 
Zhong Tang, Chem. Commun. 2006, 0, 3705–3707. 
[54] Y. Li, V. Lubchenko, P. G. Vekilov, Rev. Sci. Instrum. 2011, 82, 053106. 
[55] P. Juszczyk, A. S. Kołodziejczyk, Z. Grzonka, Acta Biochim. Pol. 2005, 52, 425–431. 
[56] A. Orte, N. R. Birkett, R. W. Clarke, G. L. Devlin, C. M. Dobson, D. Klenerman, Proc. 
Natl. Acad. Sci. U. S. A. 2008, 105, 14424–14429. 
[57] J. Bieschke, A. Giese, W. Schulz-Schaeffer, I. Zerr, S. Poser, M. Eigen, H. Kretzschmar, 
Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 5468–5473. 
[58] A. Giese, B. Bader, J. Bieschke, G. Schaffar, S. Odoy, P. J. Kahle, C. Haass, H. 
Kretzschmar, Biochem. Biophys. Res. Commun. 2005, 333, 1202–1210. 
[59] M. H. Horrocks, L. Rajah, P. Jönsson, M. Kjaergaard, M. Vendruscolo, T. P. J. 
Knowles, D. Klenerman, Anal. Chem. 2013, 85, 6855–6859. 
[60] M. H. Horrocks, L. Tosatto, A. J. Dear, G. A. Garcia, M. Iljina, N. Cremades, M. Dalla 
Serra, T. P. J. Knowles, C. M. Dobson, D. Klenerman, Anal. Chem. 2015, 87, 8818–
8826. 
[61] L. Tosatto, M. H. Horrocks, A. J. Dear, T. P. J. Knowles, M. Dalla Serra, N. Cremades, 
C. M. Dobson, D. Klenerman, Sci. Rep. 2015, 5, 16696. 
[62] E. Haustein, P. Schwille, Curr. Opin. Struct. Biol. 2004, 14, 531–540. 
[63] D. Magde, E. Elson, W. W. Webb, Phys. Rev. Lett. 1972, 29, 705–708. 





[65] N. Zijlstra, C. Blum, I. M. J. Segers-Nolten, M. M. A. E. Claessens, V. Subramaniam, 
Angew. Chem. Int. Ed. Engl. 2012, 51, 8821–8824. 
[66] E. Betzig, G. H. Patterson, R. Sougrat, O. W. Lindwasser, S. Olenych, J. S. Bonifacino, 
M. W. Davidson, J. Lippincott-Schwartz, H. F. Hess, Science (80-. ). 2006, 313, 1642–
1645. 
[67] M. J. Rust, M. Bates, X. Zhuang, Nat. Methods 2006, 3, 793–795. 
[68] S. W. Hell, J. Wichmann, Opt. Lett. 1994, 19, 780–782. 
[69] A. Szymborska, A. de Marco, N. Daigle, V. C. Cordes, J. A. G. Briggs, J. Ellenberg, 
Science 2013, 341, 655–658. 
[70] A. Sharonov, R. M. Hochstrasser, Proc. Natl. Acad. Sci. 2006, 103, 18911–18916. 
[71] G. Giannone, E. Hosy, F. Levet, A. Constals, K. Schulze, A. I. Sobolevsky, M. P. 
Rosconi, E. Gouaux, R. Tampé, D. Choquet, et al., Biophys. J. 2010, 99, 1303–1310. 
[72] R. Jungmann, C. Steinhauer, M. Scheible, A. Kuzyk, P. Tinnefeld, F. C. Simmel, Nano 
Lett. 2010, 10, 4756–4761. 
[73] R. Jungmann, M. S. Avendaño, J. B. Woehrstein, M. Dai, W. M. Shih, P. Yin, Nat. 
Methods 2014, 11, 313–318. 
[74] M. N. Bongiovanni, J. Godet, M. H. Horrocks, L. Tosatto, A. R. Carr, D. C. 
Wirthensohn, R. T. Ranasinghe, J.-E. Lee, A. Ponjavic, J. V. Fritz, et al., Nat. Commun. 
2016, 7, ncomms13544. 
[75] V. L. Anderson, W. W. Webb, BMC Biotechnol. 2011, 11, 125. 
[76] K. P. R. Nilsson, FEBS Lett. 2009, 583, 2593–2599. 
[77] M. H. Horrocks, S. F. Lee, S. Gandhi, N. K. Magdalinou, S. W. Chen, M. J. Devine, L. 
Tosatto, M. Kjaergaard, J. S. Beckwith, H. Zetterberg, et al., ACS Chem. Neurosci. 2016, 
DOI 10.1021/acschemneuro.5b00324. 
[78] D. A. White, A. K. Buell, T. P. J. Knowles, M. E. Welland, C. M. Dobson, J. Am. Chem. 
Soc. 2010, 132, 5170–5175. 
[79] R. Henderson, P. N. Unwin, Nature 1975, 257, 28–32. 
[80] R. Henderson, J. M. Baldwin, T. A. Ceska, F. Zemlin, E. Beckmann, K. H. Downing, 





[81] S. W. Chen, S. Drakulic, E. Deas, M. Ouberai, F. A. Aprile, R. Arranz, S. Ness, C. 
Roodveldt, T. Guilliams, E. J. De-Genst, et al., Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 
E1994-2003. 
[82] A. W. P. Fitzpatrick, B. Falcon, S. He, A. G. Murzin, G. Murshudov, H. J. Garringer, 
R. A. Crowther, B. Ghetti, M. Goedert, S. H. W. Scheres, Nature 2017, 547, 185–190. 
[83] M. Schmidt, A. Rohou, K. Lasker, J. K. Yadav, C. Schiene-Fischer, M. Fändrich, N. 
Grigorieff, Proc. Natl. Acad. Sci. 2015, 112, 11858–11863. 
[84] P. K. Hansma, V. B. Elings, O. Marti, C. E. Bracker, Science (80-. ). 1988, 242, 209–216. 
[85] C. Canale, B. Torre, D. Ricci, P. C. Braga, in At. Force Microsc. Biomed. Res., Humana 
Press, 2011, pp. 31–43. 
[86] C. Haass, D. J. Selkoe, Nat. Rev. Mol. Cell Biol. 2007, 8, 101–112. 
[87] D. J. Selkoe, Trends Cell Biol. 1998, 8, 447–53. 
[88] R. J. O’Brien, P. C. Wong, Annu. Rev. Neurosci. 2011, 34, 185–204. 
[89] H. A. Pearson, C. Peers, J. Physiol. 2006, 575, 5–10. 
[90] M. Sakono, T. Zako, FEBS J. 2010, 277, 1348–1358. 
[91] A. N. Santos, M. Ewers, L. Minthon, A. Simm, R.-E. Silber, K. Blennow, D. Prvulovic, 
O. Hansson, H. Hampel, J. Alzheimer’s Dis. JAD 2012, 29, 171–176. 
[92] P. Flagmeier, S. De, D. C. Wirthensohn, S. F. Lee, C. Vincke, S. Muyldermans, T. P. J. 
J. Knowles, S. Gandhi, C. M. Dobson, D. Klenerman, Angew. Chemie Int. Ed. 2017, 56, 
7750–7754. 
[93] K. Pauwels, T. L. Williams, K. L. Morris, W. Jonckheere, A. Vandersteen, G. Kelly, J. 
Schymkowitz, F. Rousseau, A. Pastore, L. C. Serpell, et al., J. Biol. Chem. 2012, 287, 
5650–5660. 
[94] G. M. Shankar, D. M. Walsh, D. Walsh, M. Rowan, H. Schoemaker, A. Draguhn, K. 
Wicke, V. Nimmrich, R. Bitner, J. Harlan, et al., Mol. Neurodegener. 2009, 4, 48. 
[95] D. M. Walsh, A. Lomakin, G. B. Benedek, M. M. Condron, D. B. Teplow, J. Biol. Chem. 
1997, 272, 22364–22372. 
[96] D. M. Walsh, D. M. Hartley, Y. Kusumoto, Y. Fezoui, M. M. Condron, A. Lomakin, 





[97] R. W. Hepler, K. M. Grimm, D. D. Nahas, R. Breese, E. C. Dodson, P. Acton, P. M. 
Keller, M. Yeager, H. Wang, P. Shughrue, et al., Biochemistry 2006, 45, 15157–15167. 
[98] J. Laurén, D. A. Gimbel, H. B. Nygaard, J. W. Gilbert, S. M. Strittmatter, Nature 2009, 
457, 1128–1132. 
[99] L. Yu, R. Edalji, J. E. Harlan, T. F. Holzman, A. P. Lopez, B. Labkovsky, H. Hillen, S. 
Barghorn, U. Ebert, P. L. Richardson, et al., Biochemistry 2009, 48, 1870–1877. 
[100] M. Hoshi, M. Sato, S. Matsumoto, A. Noguchi, K. Yasutake, N. Yoshida, K. Sato, Proc. 
Natl. Acad. Sci. 2003, 100, 6370–6375. 
[101] A. Noguchi, S. Matsumura, M. Dezawa, M. Tada, M. Yanazawa, A. Ito, M. Akioka, S. 
Kikuchi, M. Sato, S. Ideno, et al., J. Biol. Chem. 2009, 284, 32895–32905. 
[102] D. M. Walsh, M. Townsend, M. B. Podlisny, G. M. Shankar, J. V Fadeeva, O. El Agnaf, 
D. M. Hartley, D. J. Selkoe, J. Neurosci. 2005, 25, 2455–2462. 
[103] M. B. Podlisny, B. L. Ostaszewski, S. L. Squazzo, E. H. Koo, R. E. Rydell, D. B. 
Teplow, D. J. Selkoe, J. Biol. Chem. 1995, 270, 9564–9570. 
[104] S. Lesné, M. T. Koh, L. Kotilinek, R. Kayed, C. G. Glabe, A. Yang, M. Gallagher, K. 
H. Ashe, Nature 2006, 440, 352–357. 
[105] J. C. Stroud, C. Liu, P. K. Teng, D. Eisenberg, Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 
7717–7722. 
[106] M. Ahmed, J. Davis, D. Aucoin, T. Sato, S. Ahuja, S. Aimoto, J. I. Elliott, W. E. Van 
Nostrand, S. O. Smith, Nat. Struct. Mol. Biol. 2010, 17, 561–7. 
[107] J. D. Harper, C. M. Lieber, P. T. Lansbury  Jr., Chem. Biol. 1997, 4, 951–959. 
[108] A. Parbhu, H. Lin, J. Thimm, R. Lal, Peptides 2002, 23, 1265–1270. 
[109] M. Bartolini, M. Naldi, J. Fiori, F. Valle, F. Biscarini, D. V. Nicolau, V. Andrisano, 
Anal. Biochem. 2011, 414, 215–225. 
[110] E. A. Yates, E. M. Cucco, J. Legleiter, ACS Chem. Neurosci. 2011, 2, 294–307. 
[111] F. S. Ruggeri, J. Adamcik, J. S. Jeong, H. A. Lashuel, R. Mezzenga, G. Dietler, Angew. 
Chemie Int. Ed. 2015, 54, 2462–2466. 






[113] M. T. Colvin, R. Silvers, Q. Z. Ni, T. V. Can, I. Sergeyev, M. Rosay, K. J. Donovan, B. 
Michael, J. Wall, S. Linse, et al., J. Am. Chem. Soc. 2016, 138, 9663–9674. 
[114] W. Qiang, W.-M. Yau, J.-X. Lu, J. Collinge, R. Tycko, Nature 2017, 541, 217–221. 
[115] D. Eisenberg, M. Jucker, Cell 2012, 148, 1188–1203. 
[116] L. Gremer, D. Schölzel, C. Schenk, E. Reinartz, J. Labahn, R. B. G. Ravelli, M. Tusche, 
C. Lopez-Iglesias, W. Hoyer, H. Heise, et al., Science (80-. ). 2017, 358, 116–119. 
[117] H. Ding, P. T. Wong, E. L. Lee, A. Gafni, D. G. Steel, Biophys. J. 2009, 97, 912–21. 
[118] P. Narayan, S. Meehan, J. A. Carver, M. R. Wilson, C. M. Dobson, D. Klenerman, 
Biochemistry 2012, 51, 9270–9276. 
[119] P. Narayan, A. Orte, R. W. Clarke, B. Bolognesi, S. Hook, K. A. Ganzinger, S. Meehan, 
M. R. Wilson, C. M. Dobson, D. Klenerman, Nat. Struct. Mol. Biol. 2012, 19, 79–83. 
[120] P. Narayan, K. M. Holmström, D.-H. Kim, D. J. Whitcomb, M. R. Wilson, P. St. 
George-Hyslop, N. W. Wood, C. M. Dobson, K. Cho, A. Y. Abramov, et al., 
Biochemistry 2014, 53, 2442–2453. 
[121] P. Narayan, K. A. Ganzinger, J. McColl, L. Weimann, S. Meehan, S. Qamar, J. A. 
Carver, M. R. Wilson, P. St. George-Hyslop, C. M. Dobson, et al., J. Am. Chem. Soc. 
2013, 135, 1491–1498. 
[122] M. Iljina, G. A. Garcia, A. J. Dear, J. Flint, P. Narayan, T. C. T. Michaels, C. M. Dobson, 
D. Frenkel, T. P. J. Knowles, D. Klenerman, Sci. Rep. 2016, 6, 28658. 
[123] R. R. Murphy, G. Danezis, M. H. Horrocks, S. E. Jackson, D. Klenerman, Anal. Chem. 
2014, 86, 8603–8612. 
[124] G. S. Kaminski Schierle, S. van de Linde, M. Erdelyi, E. K. Esbjo ̈rner, T. Klein, E. 
Rees, C. W. Bertoncini, C. M. Dobson, M. Sauer, C. F. Kaminski, J. Am. Chem. Soc. 
2011, 133, 12902–12905. 
[125] W. I. Zhang, G. Antonios, A. Rabano, T. A. Bayer, A. Schneider, S. O. Rizzoli, J. 
Alzheimers. Dis. 2015, 46, 1007–1020. 
[126] S. Fritschi, F. Langer, S. Kaeser, L. Maia, E. Portelius, D. Pinotsi, D. Winkler, W. 
Maetzler, K. Keyvani, P. Spitzer, et al., Brain 2014, DOI 10.1093/brain/awu255. 
[127] J. Brelstaff, B. Ossola, J. J. Neher, T. T. Klingstedt, K. P. R. Nilsson, M. Goedert, M. 





[128] A. Aslund, C. J. Sigurdson, T. Klingstedt, S. Grathwohl, T. Bolmont, D. L. Dickstein, 
E. Glimsdal, S. Prokop, M. Lindgren, P. Konradsson, et al., ACS Chem. Biol. 2009, 4, 
673–84. 
[129] T. Klingstedt, A. Aslund, R. A. Simon, L. B. G. Johansson, J. J. Mason, S. Nyström, P. 
Hammarström, K. P. R. Nilsson, Org. Biomol. Chem. 2011, 9, 8356–70. 
[130] T. Klingstedt, H. Shirani, K. O. Andreas, N. J. Cairns, C. J. Sigurdson, M. Goedert, K. 
P. R. Nilsson, 2013, 10179–10192. 
[131] E. Hellstrand, B. Boland, D. M. Walsh, S. Linse, ACS Chem. Neurosci. 2010, 1, 13–18. 
[132] G. Meisl, J. B. Kirkegaard, P. Arosio, T. C. T. Michaels, M. Vendruscolo, C. M. 
Dobson, S. Linse, T. P. J. Knowles, Nat. Protoc. 2016, 11, 252–272. 
[133] G. Meisl, X. Yang, B. Frohm, T. P. J. Knowles, S. Linse, G. G. Glenner, C. W. Wong, 
J. Hardy, D. Allsop, T. P. J. Knowles, et al., Sci. Rep. 2016, 6, 18728. 
[134] P. Arosio, T. C. T. Michaels, S. Linse, C. Månsson, C. Emanuelsson, J. Presto, J. 
Johansson, M. Vendruscolo, C. M. Dobson, T. P. J. Knowles, Nat. Commun. 2016, 7, 
10948. 
[135] A. Munke, J. Persson, T. Weiffert, E. De Genst, G. Meisl, P. Arosio, A. Carnerup, C. 
M. Dobson, M. Vendruscolo, T. P. J. Knowles, et al., Proc. Natl. Acad. Sci. U. S. A. 
2017, 114, 6444–6449. 
[136] M. J. Savage, J. Kalinina, A. Wolfe, K. Tugusheva, R. Korn, T. Cash-Mason, J. W. 
Maxwell, N. G. Hatcher, S. J. Haugabook, G. Wu, et al., J. Neurosci. 2014, 34, 2884–
2897. 
[137] R. Jakes, M. G. Spillantini, M. Goedert, FEBS Lett. 1994, 345, 27–32. 
[138] M. G. Spillantini, M. L. Schmidt, V. M. Lee, J. Q. Trojanowski, R. Jakes, M. Goedert, 
Nature 1997, 388, 839–840. 
[139] M.-C. Chartier-Harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay, S. Lincoln, 
C. Levecque, L. Larvor, J. Andrieux, M. Hulihan, et al., Lancet 2004, 364, 1167–1169. 
[140] A. B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. 
Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, et al., Science 2003, 302, 841. 
[141] M. H. Polymeropoulos, C. Lavedan, E. Leroy, S. E. Ide, A. Dehejia, A. Dutra, B. Pike, 





[142] R. Krüger, W. Kuhn, T. Müller, D. Woitalla, M. Graeber, S. Kösel, H. Przuntek, J. T. 
Epplen, L. Schöls, O. Riess, Nat. Genet. 1998, 18, 106–108. 
[143] J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban, E. Lezcano, R. Ros, I. Ampuero, L. Vidal, 
J. Hoenicka, O. Rodriguez, B. Atarés, et al., Ann. Neurol. 2004, 55, 164–173. 
[144] C. Proukakis, C. G. Dudzik, T. Brier, D. S. MacKay, J. M. Cooper, G. L. Millhauser, 
H. Houlden, A. H. Schapira, Neurology 2013, 80, 1062–1064. 
[145] A. P. Kiely, Y. T. Asi, E. Kara, P. Limousin, H. Ling, P. Lewis, C. Proukakis, N. Quinn, 
A. J. Lees, J. Hardy, et al., Acta Neuropathol. 2013, 125, 753–769. 
[146] P. Pasanen, L. Myllykangas, M. Siitonen, A. Raunio, S. Kaakkola, J. Lyytinen, P. J. 
Tienari, M. Pöyhönen, A. Paetau, Neurobiol. Aging 2014, 35, 2180.e1-5. 
[147] D. Eliezer, E. Kutluay, R. Bussell, G. Browne, J. Mol. Biol. 2001, 307, 1061–1073. 
[148] R. Bussell, D. Eliezer, J. Mol. Biol. 2003, 329, 763–778. 
[149] H. Han, P. H. Weinreb, P. T. Lansbury, Chem. Biol. 1995, 2, 163–169. 
[150] B. I. Giasson, I. V Murray, J. Q. Trojanowski, V. M. Lee, J. Biol. Chem. 2001, 276, 2380–
2386. 
[151] W. Hoyer, D. Cherny, V. Subramaniam, T. M. Jovin, Biochemistry 2004, 43, 16233–
16242. 
[152] V. N. Uversky, J. Biomol. Struct. Dyn. 2003, 21, 211–234. 
[153] R. Bussell, D. Eliezer, J. Biol. Chem. 2001, 276, 45996–46003. 
[154] E. A. Greenbaum, C. L. Graves, A. J. Mishizen-Eberz, M. A. Lupoli, D. R. Lynch, S. 
W. Englander, P. H. Axelsen, B. I. Giasson, J. Biol. Chem. 2005, 280, 7800–7807. 
[155] J. Li, V. N. Uversky, A. L. Fink, Biochemistry 2001, 40, 11604–11613. 
[156] M.-B. Fares, N. Ait-Bouziad, I. Dikiy, M. K. Mbefo, A. Jovičić, A. Kiely, J. L. Holton, 
S.-J. Lee, A. D. Gitler, D. Eliezer, et al., Hum. Mol. Genet. 2014, 23, 4491–4509. 
[157] D. Ghosh, M. Mondal, G. M. Mohite, P. K. Singh, P. Ranjan, A. Anoop, S. Ghosh, N. 
N. Jha, A. Kumar, S. K. Maji, Biochemistry 2013, 52, 6925–6927. 
[158] D. Ghosh, S. Sahay, P. Ranjan, S. Salot, G. M. Mohite, P. K. Singh, S. Dwivedi, E. 





[159] H. A. Lashuel, B. M. Petre, J. Wall, M. Simon, R. J. Nowak, T. Walz, P. T. Lansbury, J. 
Mol. Biol. 2002, 322, 1089–1102. 
[160] L. Giehm, D. I. Svergun, D. E. Otzen, B. Vestergaard, Proc. Natl. Acad. Sci. U. S. A. 
2011, 108, 3246–3251. 
[161] N. Lorenzen, S. B. Nielsen, A. K. Buell, J. D. Kaspersen, P. Arosio, B. S. Vad, W. 
Paslawski, G. Christiansen, Z. Valnickova-Hansen, M. Andreasen, et al., J. Am. Chem. 
Soc. 2014, 136, 3859–3868. 
[162] B. D. van Rooijen, M. M. A. E. Claessens, V. Subramaniam, FEBS Lett. 2008, 582, 
3788–3792. 
[163] M. S. Celej, R. Sarroukh, E. Goormaghtigh, G. Fidelio, J.-M. Ruysschaert, V. Raussens, 
Biochem. J. 2012, DOI 10.1042/BJ20111924. 
[164] R. Cappai, S.-L. Leck, D. J. Tew, N. A. Williamson, D. P. Smith, D. Galatis, R. A. 
Sharples, C. C. Curtain, F. E. Ali, R. A. Cherny, et al., FASEB J. Off. Publ. Fed. Am. Soc. 
Exp. Biol. 2005, 19, 1377–1379. 
[165] L. Fonseca-Ornelas, C. Schmidt, A. R. Camacho-Zarco, C. O. Fernandez, S. Becker, 
M. Zweckstetter, Chemistry 2017, 23, 13010–13014. 
[166] D. E. Ehrnhoefer, J. Bieschke, A. Boeddrich, M. Herbst, L. Masino, R. Lurz, S. 
Engemann, A. Pastore, E. E. Wanker, Nat. Struct. Mol. Biol. n.d., 15, 558–566. 
[167] L. Pieri, K. Madiona, R. Melki, Sci. Rep. 2016, 6, 24526. 
[168] M. S. Planchard, S. E. Exley, S. E. Morgan, V. Rangachari, Protein Sci. A Publ. Protein 
Soc. 2014, 23, 1369–1379. 
[169] K. M. Danzer, D. Haasen, A. R. Karow, S. Moussaud, M. Habeck, A. Giese, H. 
Kretzschmar, B. Hengerer, M. Kostka, J. Neurosci. 2007, 27, 9220–9232. 
[170] N. Cremades, S. W. Chen, C. M. Dobson, in Int. Rev. Cell Mol. Biol. (Ed.: M. Sandal), 
Academic Press, 2017, pp. 79–143. 
[171] C. D. Borsarelli, L. J. Falomir-Lockhart, V. Ostatná, J. A. Fauerbach, H.-H. Hsiao, H. 
Urlaub, E. Paleček, E. A. Jares-Erijman, T. M. Jovin, Free Radic. Biol. Med. 2012, 53, 
1004–1015. 
[172] W. Ariesandi, C.-F. Chang, T.-E. Chen, Y.-R. Chen, PLoS One 2013, 8, e53487. 





[174] A. K. Frimpong, R. R. Abzalimov, V. N. Uversky, I. A. Kaltashov, Proteins 2010, 78, 
714–722. 
[175] E. Illes-Toth, M. R. Ramos, R. Cappai, C. Dalton, D. P. Smith, Biochem. J. 2015, 468, 
485–493. 
[176] A. S. Phillips, A. F. Gomes, J. M. D. Kalapothakis, J. E. Gillam, J. Gasparavicius, F. C. 
Gozzo, T. Kunath, C. MacPhee, P. E. Barran, Analyst 2015, 140, 3070–3081. 
[177] C. W. T. Leung, F. Guo, Y. Hong, E. Zhao, R. T. K. Kwok, N. L. C. Leung, S. Chen, 
N. N. Vaikath, O. M. El-Agnaf, Y. Tang, et al., Chem. Commun. (Camb). 2015, 51, 1866–
1869. 
[178] V. B. Kovalska, M. Y. Losytskyy, O. I. Tolmachev, Y. L. Slominskii, G. M. J. Segers-
Nolten, V. Subramaniam, S. M. Yarmoluk, J. Fluoresc. 2012, 22, 1441–1448. 
[179] J. I. Gallea, M. S. Celej, J. Biol. Chem. 2014, 289, 26733–26742. 
[180] S. Nath, J. Meuvis, J. J. Hendrix, S. A. Carl, Y. Engelborghs, Biophys. J. 2010, 98, 1302–
1311. 
[181] B. D. van Rooijen, K. A. van Leijenhorst-Groener, M. M. a. E. Claessens, V. 
Subramaniam, J. Mol. Biol. 2009, 394, 826–833. 
[182] M. Kostka, T. Högen, K. M. Danzer, J. Levin, M. Habeck, A. Wirth, R. Wagner, C. G. 
Glabe, S. Finger, U. Heinzelmann, et al., J. Biol. Chem. 2008, 283, 10992–11003. 
[183] J. Levin, T. Högen, A. S. Hillmer, B. Bader, F. Schmidt, F. Kamp, H. A. Kretzschmar, 
K. Bötzel, A. Giese, J. Parkinsons. Dis. 2011, 1, 205–216. 
[184] M. Caruana, T. Högen, J. Levin, A. Hillmer, A. Giese, N. Vassallo, FEBS Lett. 2011, 
585, 1113–1120. 
[185] E. Sierecki, N. Giles, Q. Bowden, M. E. Polinkovsky, J. Steinbeck, N. Arrioti, D. 
Rahman, A. Bhumkar, P. R. Nicovich, I. Ross, et al., Sci. Rep. 2016, 6, 37630. 
[186] M. Iljina, G. A. Garcia, M. H. Horrocks, L. Tosatto, M. L. Choi, K. A. Ganzinger, A. 
Y. Abramov, S. Gandhi, N. W. Wood, N. Cremades, et al., Proc. Natl. Acad. Sci. U. S. 
A. 2016, 113, E1206-15. 
[187] T. Tokuda, M. M. Qureshi, M. T. Ardah, S. Varghese, S. A. S. S. Shehab, T. Kasai, N. 






[188] X. Wang, S. Yu, F. Li, T. Feng, Neurosci. Lett. 2015, 599, 115–119. 
[189] K. M. Danzer, L. R. Kranich, W. P. Ruf, O. Cagsal-Getkin, A. R. Winslow, L. Zhu, C. 
R. Vanderburg, P. J. McLean, Mol. Neurodegener. 2012, 7, 42. 
[190] M. Delenclos, T. Trendafilova, D. R. Jones, S. Moussaud, A.-M. Baine, M. Yue, W. D. 
Hirst, P. J. McLean, Front. Neurosci. 2015, 9, 511. 
[191] H. Dimant, S. K. Kalia, L. V. Kalia, L. N. Zhu, L. Kibuuka, D. Ebrahimi-Fakhari, N. 
R. McFarland, Z. Fan, B. T. Hyman, P. J. McLean, Acta Neuropathol. Commun. 2013, 1, 
6. 
[192] K. Eckermann, S. Kügler, M. Bähr, Biochim. Biophys. Acta 2015, 1852, 1658–1664. 
[193] R. F. Roberts, R. Wade-Martins, J. Alegre-Abarrategui, Brain A J. Neurol. 2015, 138, 
1642–1657. 
[194] N. Plotegher, E. Gratton, L. Bubacco, Biochim. Biophys. Acta 2014, 1840, 2014–2024. 
[195] J. Levin, A. S. Hillmer, T. Högen, P. J. McLean, A. Giese, Biochem. Biophys. Res. Commun. 
2016, 477, 76–82. 
[196] N. Cremades, S. I. A. Cohen, E. Deas, A. Y. Abramov, A. Y. Chen, A. Orte, M. Sandal, 
R. W. Clarke, P. Dunne, F. A. Aprile, et al., Cell 2012, 149, 1048–59. 
[197] W. Hoyer, D. Cherny, V. Subramaniam, T. M. Jovin, J. Mol. Biol. 2004, 340, 127–139. 
[198] S. Thirunavukkuarasu, E. A. Jares-Erijman, T. M. Jovin, J. Mol. Biol. 2008, 378, 1064–
1073. 
[199] D. M. Walsh, E. Thulin, A. M. Minogue, N. Gustavsson, E. Pang, D. B. Teplow, S. 
Linse, FEBS J. 2009, 276, 1266–81. 
[200] S. L. Shammas, G. a. Garcia, S. Kumar, M. Kjaergaard, M. H. Horrocks, N. Shivji, E. 
Mandelkow, T. P. J. Knowles, E. Mandelkow, D. Klenerman, Nat. Commun. 2015, 6, 
7025. 
[201] J. Schnitzbauer, M. T. Strauss, T. Schlichthaerle, F. Schueder, R. Jungmann, Nat. Protoc. 
2017, 12, 1198–1228. 
[202] M. H. Horrocks, S. F. Lee, S. Gandhi, M. Iljina, L. Tosatto, C. M. Dobson, D. 
Klenerman, Biophys. J. 2014, 106, 268a. 





Jackson, C. M. Dobson, D. Klenerman, ACS Chem. Biol. 2018, 13, 636–646. 
[204] F. S. Ruggeri, S. Vieweg, U. Cendrowska, G. Longo, A. Chiki, H. A. Lashuel, G. Dietler, 
Sci. Rep. 2016, 6, DOI 10.1038/srep31155. 
[205] C. Haass, M. G. Schlossmacher, A. Y. Hung, C. Vigo-Pelfrey, A. Mellon, B. L. 
Ostaszewski, I. Lieberburg, E. H. Koo, D. Schenk, D. B. Teplow, Nature 1992, 359, 
322–5. 
[206] O. M. A. El-Agnaf, S. A. Salem, K. E. Paleologou, M. D. Curran, M. J. Gibson, J. a 
Court, M. G. Schlossmacher, D. Allsop, FASEB J. 2006, 20, 419–425. 
[207] K. Blennow, H. Hampel, M. Weiner, H. Zetterberg, Cerebrospinal Fluid and Plasma 
Biomarkers in Alzheimer Disease, Nature Publishing Group, 2010. 
[208] B. Olsson, R. Lautner, U. Andreasson, A. Öhrfelt, E. Portelius, M. Bjerke, M. Hölttä, 
C. Rosén, C. Olsson, G. Strobel, et al., Lancet Neurol. 2016, 15, 673–684. 
[209] H. Zetterberg, K. Blennow, J. Alzheimer’s Dis. 2013, 33, S361–S369. 
[210] K. Sämgård, H. Zetterberg, K. Blennow, O. Hansson, L. Minthon, E. Londos, Int. J. 
Geriatr. Psychiatry 2010, 25, 403–410. 
[211] Å. K. Wallin, K. Blennow, H. Zetterberg, E. Londos, L. Minthon, O. Hansson, 
Neurology 2010, 74, 1531–1537. 
[212] T. Tapiola, I. Alafuzoff, S. K. Herukka, L. Parkkinen, P. Hartikainen, H. Soininen, T. 
Pirttilä, Arch. Neurol. 2009, 66, 382–389. 
[213] K. Buerger, M. Ewers, T. Pirttilä, R. Zinkowski, I. Alafuzoff, S. J. Teipel, J. 
DeBernardis, D. Kerkman, C. McCulloch, H. Soininen, et al., Brain 2006, 129, 3035–
3041. 
[214] M. Tabaton, M. G. Nunzi, R. Xue, M. Usiak, L. Autilio-Gambetti, P. Gambetti, 
Biochem.Biophys.Res.Commun. 1994, 200, 1598–1603. 
[215] W. E. Van Nostrand, S. L. Wagner, W. R. Shankle, J. S. Farrow, M. Dick, J. M. 
Rozemuller, M. a Kuiper, E. C. Wolters, J. Zimmerman, C. W. Cotman, Proc. Natl. 
Acad. Sci. U. S. A. 1992, 89, 2551–2555. 
[216] K. Blennow, N. Mattsson, M. Schöll, O. Hansson, H. Zetterberg, Trends Pharmacol. Sci. 
2015, 36, 297–309. 





Galasko, L. Chang, B. Miller, C. Clark, R. Green, Ann. Neurol. 1995, 38, 643–648. 
[218] A. M. Fagan, M. A. Mintun, R. H. Mach, S. Y. Lee, C. S. Dence, A. R. Shah, G. N. 
LaRossa, M. L. Spinner, W. E. Klunk, C. A. Mathis, et al., Ann. Neurol. 2006, 59, 512–
519. 
[219] J. Dumurgier, S. Schraen, A. Gabelle, O. Vercruysse, S. Bombois, J.-L. Laplanche, K. 
Peoc’h, B. Sablonnière, K. V Kastanenka, C. Delaby, et al., Alzheimers. Res. Ther. 2015, 
7, 1–9. 
[220] P. Lewczuk, N. Lelental, P. Spitzer, J. M. Maler, J. Kornhuber, J. Alzheimer’s Dis. 2014, 
43, 183–191. 
[221] N. Andreasen, C. Hesse, P. Davidsson, L. Minthon,  a Wallin, B. Winblad, H. 
Vanderstichele, E. Vanmechelen, K. Blennow, Arch. Neurol. 1999, 56, 673–80. 
[222] A. Olsson, H. Vanderstichele, N. Andreasen, G. De Meyer, A. Wallin, B. Holmberg, 
L. Rosengren, E. Vanmechelen, K. Blennow, Clin. Chem. 2005, 51, 336–345. 
[223] H. Zetterberg, U. Andreasson, O. Hansson, G. Wu, S. Sankaranarayanan, M. E. 
Andersson, P. Buchhave, E. Londos, R. M. Umek, L. Minthon, et al., Arch. Neurol. 
2008, 65, 1102–1107. 
[224] J. Wiltfang, H. Esselmann, M. Bibl, A. Smirnov, M. Otto, S. Paul, B. Schmidt, H. W. 
Klafki, M. Maler, T. Dyrks, et al., J. Neurochem. 2002, 81, 481–496. 
[225] A. Leinenbach, J. Pannee, T. Dülffer, A. Huber, T. Bittner, U. Andreasson, J. Gobom, 
H. Zetterberg, U. Kobold, E. Portelius, et al., Clin. Chem. 2014, 60, 987–994. 
[226] O. Hansson, J. Seibyl, E. Stomrud, H. Zetterberg, J. Q. Trojanowski, T. Bittner, V. 
Lifke, V. Corradini, U. Eichenlaub, R. Batrla, et al., Alzheimer’s Dement. 2018, DOI 
10.1016/j.jalz.2018.01.010. 
[227] B. Olsson, R. Lautner, U. Andreasson, A. Öhrfelt, E. Portelius, M. Bjerke, M. Hölttä, 
C. Rosén, C. Olsson, G. Strobel, et al., Lancet Neurol. 2016, 15, 673–684. 
[228] W. E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D. P. Holt, M. 
Bergström, I. Savitcheva, G. F. Huang, S. Estrada, et al., Ann. Neurol. 2004, 55, 306–
319. 
[229] C. R. Jack, J. R. Barrio, V. Kepe, Acta Neuropathol. 2013, 126, 643–657. 





C. L. Masters, V. L. Villemagne, J. Nucl. Med. 2013, 54, 880–886. 
[231] B. J. Bacskai, M. P. Frosch, S. H. Freeman, S. B. Raymond, J. C. Augustinack, K. A. 
Johnson, M. C. Irizarry, W. E. Klunk, C. A. Mathis, S. T. DeKosky, et al., Arch. Neurol. 
2007, 64, 431–434. 
[232] A. Lockhart, J. R. Lamb, T. Osredkar, L. I. Sue, J. N. Joyce, L. Ye, V. Libri, D. Leppert, 
T. G. Beach, Brain 2007, 130, 2607–2615. 
[233] M. D. Ikonomovic, W. E. Klunk, E. E. Abrahamson, C. A. Mathis, J. C. Price, N. D. 
Tsopelas, B. J. Lopresti, S. Ziolko, W. Bi, W. R. Paljug, et al., Brain 2008, 131, 1630–
1645. 
[234] S. Hall, Y. Surova, A. Öhrfelt, K. Blennow, H. Zetterberg, O. Hansson, O. Hansson, 
Mov. Disord. 2016, 31, 898–905. 
[235] B. Mollenhauer, C. J. Caspell-Garcia, C. S. Coffey, P. Taylor, L. M. Shaw, J. Q. 
Trojanowski, A. Singleton, M. Frasier, K. Marek, D. Galasko, et al., Neurology 2017, 89, 
1959–1969. 
[236] N. K. Majbour, N. N. Vaikath, P. Eusebi, D. Chiasserini, M. Ardah, S. Varghese, M. 
E. Haque, T. Tokuda, P. Auinger, P. Calabresi, et al., Mov. Disord. 2016, 31, 1535–1542. 
[237] T. Stewart, C. Liu, C. Ginghina, K. C. Cain, P. Auinger, B. Cholerton, M. Shi, J. Zhang, 
Am. J. Pathol. 2014, 184, 966–975. 
[238] S. F. Moore, R. a. Barker, Park. Relat. Disord. 2014, 20, S104–S107. 
[239] M. Fändrich, J. Mol. Biol. 2012, 421, 427–440. 
[240] S. Ceru, S. J. Kokalj, S. Rabzelj, M. Skarabot, I. Gutierrez-Aguirre, N. Kopitar-Jerala, 
G. Anderluh, D. Turk, V. Turk, E. Zerovnik, Amyloid 2008, 15, 147–59. 
[241] N. Le Bastard, P. P. De Deyn, S. Engelborghs, Clin. Chem. 2015, 61, 734–43. 
[242] J. Klener, K. Hofbauerová, A. Bartoš, J. Ríčný, D. Rípová, V. Kopecký, Clin. Chem. 
Lab. Med. 2014, 52, 657–64. 
[243] J. B. Toledo, H. Zetterberg, A. C. van Harten, L. Glodzik, P. Martinez-Lage, L. 
Bocchio-Chiavetto, L. Rami, O. Hansson, R. Sperling, S. Engelborghs, et al., Brain 
2015, 138, awv199. 
[244] M. Calero, A. Rostagno, E. Matsubara, B. Zlokovic, B. Frangione, J. Ghiso, Microsc. 





[245] J.-C. Lambert, S. Heath, G. Even, D. Campion, K. Sleegers, M. Hiltunen, O. 
Combarros, D. Zelenika, M. J. Bullido, B. Tavernier, et al., Nat. Genet. 2009, 41, 1094–
1099. 
[246] D. Harold, R. Abraham, P. Hollingworth, R. Sims, A. Gerrish, M. L. Hamshere, J. S. 
Pahwa, V. Moskvina, K. Dowzell, A. Williams, et al., Nat. Genet. 2009, 41, 1088–93. 
[247] P. Narayan, A. Orte, R. W. Clarke, B. Bolognesi, S. Hook, K. a Ganzinger, S. Meehan, 
M. R. Wilson, C. M. Dobson, D. Klenerman, Nat. Struct. Mol. Biol. 2011, 19, 79–83. 
[248] R. S. Desikan, W. K. Thompson, D. Holland, C. P. Hess, J. B. Brewer, H. Zetterberg, 
K. Blennow, O. A. Andreassen, L. K. McEvoy, B. T. Hyman, et al., JAMA Neurol. 
2014, 71, 180–7. 
[249] J. J. Yerbury, S. Poon, S. Meehan, B. Thompson, J. R. Kumita, C. M. Dobson, M. R. 
Wilson, FASEB J. 2007, 21, 2312–2322. 
[250] K. D. Van Dijk, W. Jongbloed, J. A. Heijst, C. E. Teunissen, H. J. Groenewegen, H. 
W. Berendse, W. D. J. van de Berg, R. Veerhuis, Park. Relat. Disord. 2013, 19, 1079–
1083. 
[251] C. L. Maarouf, T. G. Beach, C. H. Adler, H. A. Shill, M. N. Sabbagh, T. Wu, D. G. 
Walker, T. A. Kokjohn, A. E. Roher, A. P. Consortium, Neurol. Res. 2012, 34, 669–676. 
[252] G. N. Yin, H. W. Lee, J. Y. Cho, K. Suk, Brain Res. 2009, 1265, 158–170. 
[253] A. M. Lidström, C. Hesse, L. Rosengren, P. Fredman, P. Davidsson, J. Alzheimer’s Dis. 
2001, 3, 435–442. 
[254] H. P. Vranová, J. Mareš, M. Nevrlý, D. Stejskal, J. Zapletalová, P. Hluštík, P. Kaňovský, 
J. Neural Transm. 2010, 117, 1177–1181. 
[255] S. Salloway, R. Sperling, N. C. Fox, K. Blennow, W. Klunk, M. Raskind, M. Sabbagh, 
L. S. Honig, A. P. Porsteinsson, S. Ferris, et al., N. Engl. J. Med. 2014, 370, 322–333. 
[256] R. Vandenberghe, J. O. Rinne, M. Boada, S. Katayama, P. Scheltens, B. Vellas, M. 
Tuchman, A. Gass, J. B. Fiebach, D. Hill, et al., Alzheimers. Res. Ther. 2016, 8, 18. 
[257] D. M. Walsh, I. Klyubin, J. V Fadeeva, W. K. Cullen, R. Anwyl, M. S. Wolfe, M. J. 
Rowan, D. J. Selkoe, Nature 2002, 416, 535–539. 
[258] I. Klyubin, V. Betts, A. T. Welzel, K. Blennow, H. Zetterberg, A. Wallin, C. A. Lemere, 





[259] J. J. Yerbury, M. R. Wilson, Cell Stress Chaperones 2010, 15, 115–121. 
[260] A. Drews, J. Flint, N. Shivji, P. Jönsson, D. Wirthensohn, E. De Genst, C. Vincke, S. 
Muyldermans, C. Dobson, D. Klenerman, Sci. Rep. 2016, 6, DOI 10.1038/srep31910. 
[261] T. Yang, T. T. O’Malley, D. Kanmert, J. Jerecic, L. R. Zieske, H. Zetterberg, B. T. 
Hyman, D. M. Walsh, D. J. Selkoe, Alzheimer’s Res. Ther. 2015, 7, DOI 10.1186/s13195-
015-0100-y. 
[262] B. Babakinejad, P. Jönsson, A. López Córdoba, P. Actis, P. Novak, Y. Takahashi, A. 
Shevchuk, U. Anand, P. Anand, A. Drews, et al., Anal. Chem. 2013, 85, 9333–9342. 
[263] H. P. Vranová, E. Hényková, M. Kaiserová, K. Menšíková, M. Vaštík, J. Mareš, P. 
Hluštík, J. Zapletalová, M. Strnad, D. Stejskal, et al., J. Neurol. Sci. 2014, 343, 120–124. 
[264] L. A. Miles, G. A. N. Crespi, L. Doughty, M. W. Parker, Sci. Rep. 2013, 3, DOI 
10.1038/srep01302. 
[265] E. Liu, M. E. Schmidt, R. Margolin, R. Sperling, R. Koeppe, N. S. Mason, W. E. Klunk, 
C. A. Mathis, S. Salloway, N. C. Fox, et al., Neurology 2015, 85, 692–700. 
[266] J. A. Varela, M. Rodrigues, S. De, P. Flagmeier, S. Gandhi, C. M. Dobson, D. 
Klenerman, S. F. Lee, Angew. Chemie Int. Ed. 2018, DOI 10.1002/anie.201710779. 
[267] W. F. Goure, G. A. Krafft, J. Jerecic, F. Hefti, Alzheimer’s Res. Ther. 2014, 6, DOI 
10.1186/alzrt272. 
[268] I. Nasir, S. Linse, C. Cabaleiro-Lago, ACS Chem. Neurosci. 2015, 6, 1436–1444. 
[269] R. Silvers, M. T. Colvin, K. K. Frederick, A. C. Jacavone, S. Lindquist, S. Linse, R. G. 
Griffin, Biochemistry 2017, 56, 4850–4859. 
[270] V. H. Finder, I. Vodopivec, R. M. Nitsch, R. Glockshuber, J. Mol. Biol. 2010, 396, 9–
18. 
[271] P. Arosio, T. Cedervall, T. P. J. Knowles, S. Linse, Anal. Biochem. 2016, 504, 7–13. 
[272] D. Sehlin, H. Englund, B. Simu, M. Karlsson, M. Ingelsson, F. Nikolajeff, L. Lannfelt, 
F. E. Pettersson, PLoS One 2012, 7, e32014. 
[273] R. V Ward, K. H. Jennings, R. Jepras, W. Neville, D. E. Owen, J. Hawkins, G. Christie, 
J. B. Davis, A. George, E. H. Karran, et al., Biochem. J. 2000, 348 Pt 1, 137–44. 





[275] P. Cizas, R. Budvytyte, R. Morkuniene, R. Moldovan, M. Broccio, M. Lösche, G. 
Niaura, G. Valincius, V. Borutaite, Arch. Biochem. Biophys. 2010, 496, 84–92. 
[276] S. Maeda, N. Sahara, Y. Saito, M. Murayama, Y. Yoshiike, H. Kim, T. Miyasaka, S. 
Murayama, A. Ikai, A. Takashima, Biochemistry 2007, 46, 3856–3861. 
[277] A. T. Petkova, R. D. Leapman, Z. Guo, W.-M. Yau, M. P. Mattson, R. Tycko, Science 
2005, 307, 262–5. 
[278] M. T. Heneka, M. J. Carson, J. El Khoury, G. E. Landreth, F. Brosseron, D. L. 
Feinstein, A. H. Jacobs, T. Wyss-Coray, J. Vitorica, R. M. Ransohoff, et al., Lancet 
Neurol. 2015, 14, 388–405. 
[279] C. H. Latta, H. M. Brothers, D. M. Wilcock, Neuroscience 2015, 302, 103–111. 
[280] K. Ji, G. Akgul, L. P. Wollmuth, S. E. Tsirka, PLoS One 2013, 8, e56293. 
[281] M. E. Bamberger, M. E. Harris, D. R. McDonald, J. Husemann, G. E. Landreth, J. 
Neurosci. 2003, 23, 2665–2674. 
[282] D. M. Paresce, R. N. Ghosh, F. R. Maxfield, Neuron 1996, 17, 553–65. 
[283] C. R. Stewart, L. M. Stuart, K. Wilkinson, J. M. Van Gils, J. Deng, A. Halle, K. J. 
Rayner, L. Boyer, R. Zhong, W. A. Frazier, et al., Nat. Immunol. 2010, 11, 155–161. 
[284] Y. Liu, S. Walter, M. Stagi, D. Cherny, M. Letiembre, W. Schulz-Schaeffer, H. Heine, 
B. Penke, H. Neumann, K. Fassbender, Brain 2005, 128, 1778–1789. 
[285] F. J. Sheedy, A. Grebe, K. J. Rayner, P. Kalantari, B. Ramkhelawon, S. B. Carpenter, 
C. E. Becker, H. N. Ediriweera, A. E. Mullick, D. T. Golenbock, et al., Nat. Immunol. 
2013, 14, 812–820. 
[286] J. B. El Khoury, K. J. Moore, T. K. Means, J. Leung, K. Terada, M. Toft, M. W. 
Freeman, A. D. Luster, J. Exp. Med. 2003, 197, 1657–1666. 
[287] H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G. M. Cole, N. R. Cooper, P. 
Eikelenboom, M. Emmerling, B. L. Fiebich, et al., Neurobiol. Aging 2000, 21, 383–421. 
[288] K. Yamamoto, T. Arakawa, N. Ueda, S. Yamamoto, J.Biol.Chem. 1995, 270, 31315–
31320. 
[289] J. R. Cardinaux, I. Allaman, P. J. Magistretti, Glia 2000, 29, 91–97. 





[291] S. W. Barger, A. D. Harmon, Nature 1997, 388, 878–881. 
[292] S. W. Barger, D. Horster, K. Furukawa, Y. Goodman, J. Krieglstein, M. P. Mattson, 
Proc. Natl. Acad. Sci. 1995, 92, 9328–9332. 
[293] E. Tarkowski, N. Andreasen, A. Tarkowski, K. Blennow, J. Neurol. Neurosurg. Psychiatry 
2003, 74, 1200–1205. 
[294] G. S. Paranjape, L. K. Gouwens, D. C. Osborn, M. R. Nichols, ACS Chem. Neurosci. 
2012, 3, 302–311. 
[295] A. Aslund, C. J. Sigurdson, T. Klingstedt, S. Grathwohl, T. Bolmont, D. L. Dickstein, 
E. Glimsdal, S. Prokop, M. Lindgren, P. Konradsson, et al., ACS Chem. Biol. 2009, 4, 
673–84. 
[296] W. Qi, A. Zhang, T. A. Good, E. J. Fernandez, Biochemistry 2009, 48, 8908–8919. 
[297] H. Stark, Methods Enzymol. 2010, 481, 109–126. 
[298] L. M. Jungbauer, C. Yu, K. J. Laxton, M. J. LaDu, J. Mol. Recognit. 2009, 22, 403–13. 
[299] S.-Y. Zhang, E. Jouanguy, S. Ugolini, A. Smahi, G. Elain, P. Romero, D. Segal, V. 
Sancho-Shimizu, L. Lorenzo, A. Puel, et al., Science 2007, 317, 1522–7. 
[300] A. W. P. Fitzpatrick, G. T. Debelouchina, M. J. Bayro, D. K. Clare, M. A. Caporini, V. 
S. Bajaj, C. P. Jaroniec, L. Wang, V. Ladizhansky, S. A. Müller, et al., Proc. Natl. Acad. 
Sci. U. S. A. 2013, 110, 5468–73. 
[301] S. E. Nasrabady, B. Rizvi, J. E. Goldman, A. M. Brickman, Acta Neuropathol. Commun. 
2018, 6, 22. 
 
  




10 Table of Tables 
Table 1  Overview over all used filters and dichroic mirrors. ................................................... 28 
Table 2  Values for calculation of Photons for SAVE experiments.  .......................................... 32 
Table 3  Overview of all measured AD (red) and HC (green) CSF samples. ................................ 53 
Table 4  Full statistical details of the single vesicle assay ......................................................... 67 
Table 5 Full statistical details of the cell assay ......................................................................... 67 
Table 6  Full statistical details of the single aggregate imaging ................................................ 67 
Table 7  Confocal pFTAA aggregate count used to correct the Ca2+ assay. ................................ 90 
Table 8  No. of FRET events, donor events and the fraction of aggregates . ............................. 94 
 
11 Table of Figures 
Figure 1 Histological and molecular representations of amyloid aggregates .............................. 3 
Figure 2 Commonly used bulk techniques to characterise protein aggregation .......................... 7 
Figure 3  Schematic of the working principle of a confocal microscope for smFRET and TCCD. ... 8 
Figure 4 TIRF setup for smFRET and SAVE measurements. ......................................................... 9 
Figure 5. TCCD and smFRET for the ultrasensitive detection of protein aggregates .................. 10 
Figure 6 High resolution fluorescence images and emission spectra of pFTAA bound to 
pathogenic hallmarks in AD. ........................................................................................... 18 
Figure 7 TEM images of oligomers.. ........................................................................................ 21 
Figure 8 Workflow of the data analysis for the TIRF imaging. .................................................. 31 
Figure 9 Threshold testing as a function of monomer concentration ....................................... 33 
Figure 10 The SAVE method to distinguish PD patients and HC patients .................................. 39 
Figure 11 Schematic of the SAVE method. ............................................................................... 40 
Figure 12 The chemical structures of the extrinsically fluorescent dyes used ........................... 41 
Figure 13 The aggregate density measured with CR in the presence of aS aggregates with the 
SAVE method. ................................................................................................................ 42 
Figure 14 ThT, Di-ThT and DCVJ comparison. .......................................................................... 43 
Figure 15 The binding affinity for Di-ThT-PEG2, ThT and DCVJ. ................................................ 45 
Figure 16 SAVE imaging of a fresh and a frozen CSF sample. .................................................... 46 
Figure 17 Comparison of different centrifuged and non-centrifuged CSF samples. ................... 48 
Figure 18 Comparison between AD CSF samplesand HC CSF samples measured with SAVE ...... 50 
Figure 19 The cumulative frequency histograms of the AD and HC cohort ............................... 51 
Figure 20 Box plot of individual peak intensities to test intensity thresholds ........................... 52 
Figure 21 Co-localisation competition Clusterin binding to αS Oligomers ................................ 54 
Figure 22 Schematic of the vesice assay to measure Ca2+ influx due to AD and HC CSF. ............ 57 




Figure 23 Comparison of the number of aggregates found in the AD CSF patients and HC CSF 
patients .......................................................................................................................... 58 
Figure 24  Schematic of the SICM experiment to measure Ca2+ influx into astrocytes .............. 58 
Figure 25 Dot-blot of bapineuzumab and the control IgG antibody .......................................... 60 
Figure 26 Assessing the structural changes of the ThT-active aggregates with SAVE ................. 61 
Figure 27 The effect of various antibodies on dual-labelled co-aggregates tested with smFRET 63 
Figure 28 Example histograms of the FRET efficiency change over time ................................... 64 
Figure 29 The mean FRET efficiencies as fitted to the histograms. ............................................ 65 
Figure 30 IP pull-down test to test the specific depletion of aggregates ................................... 66 
Figure 31 Kinetic scheme of a classic aggregation reaction. ...................................................... 71 
Figure 32 Schematic representation of the ultracentrifugation workflow. ................................ 72 
Figure 33 Aggregation with ThT fluorescence and dual labelled co-aggregation of Aβ42 in TIRF
 ...................................................................................................................................... 76 
Figure 34 Representative TIRF FRET images of various time-points of the aggregation. ............ 77 
Figure 35 TIRF FRET images and analysis of the gradient centrifugation. .................................. 80 
Figure 36 FRET analysis of the dual-labelled co-aggregates as measured with the smFRET. ...... 81 
Figure 37 Comparison of the FRET efficiencies as measured in the fractions used for the TNFα 
measurements.. ............................................................................................................. 82 
Figure 38 Fitted peak heights of the low (10%) and high (pellet) FRET populations. .................. 83 
Figure 39 Representative TIRF images recorded with pFTAA .................................................... 84 
Figure 40 The aggregate count detected with the SAVE technique using ThT and pFTAA. ......... 85 
Figure 41 Cumulative Frequency histograms o in TIRF and SM with ThT and pFTAA. ................ 86 
Figure 42 Representative AFM images of the fractionated Aβ42 aggregates. ........................... 88 
Figure 43 Ultrasensitive measurement of calcium influx of Aβ42 oligomers. ............................ 91 
Figure 44 Three full biological repeats of the TNFα ELISA ......................................................... 93 
Figure 45 The TNFα increase per aggregate after correction .................................................... 94 
Figure 46 Model for the different effects on cell membranes and microglia cells through Aβ42 
oligomers and protofilaments. ........................................................................................ 95 
Figure 47 The crystallography structure of the TLR3 receptor bound to RNA, filament and fibril.
 ...................................................................................................................................... 96 
Figure 48 SAVE imaging of a CSF sample to test the decrease in ThT active aggregates after 
incubation with PK in preparation for AFM imaging experiments. ................................... 98 
Figure 49 Schematic of the microfluidic device to study spreading of Aβ aggregates.. .............. 99 
Figure 50 DNA-PAINT experiment to show imaging capabilities of DNA-PAINT to image Aβ42 
aggregates in fixed neuronal cells.. ............................................................................... 100 
 
